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Abstract 
Biocompatible and biodegradable macromolecules have been intensively used in 
pharmaceutical industries in various formulation preparations to fulfill different 
requirements. In the last two decades, RNA interference (RNAi) gene regulation has 
attracted a lot of attention for its high potency in medical applications.  However, 
inadequate delivery of RNA molecules to intracellular target sites has become the 
bottleneck in both laboratory use and clinical therapy in the future. In general, the small 
interfering RNA molecules as well as other RNA molecules have poor pharmacokinetic 
profiles, can easily be hydrolyzed or degraded, cause serious immunogenic response and 
can be toxic to particular cell types and organs. To fulfill the demands, a variety of 
polymeric vehicles have been synthesized and investigated, and various chemical 
reactions have endowed the delivery systems with properties like high membrane 
permeability, low toxicity and tunable size and surface functionalities for anti-
aggregation, etc. In our research, we have explored the major parameters that influenced 
the efficiency of siRNA delivery based on the experiments using carbohydrate based 
cationic polymers as successful biocompatible polymer models. Structure-property 
relationship has been studied from many perspectives, including the carbohydrate units, 
length of the polymers, dose response, and topology of the polymer-siRNA polyplexes in 
this study.  
Herein, two series of carbohydrate-based polycations were synthesized and 
examined that varied in the degree of polymerization (n)—one containing trehalose 
[Tr4(n) series: Tr4(23), Tr4(55), Tr4(77)] and the other containing beta-cyclodextrin 
[CD4(n) series: CD4(10), CD4(26), CD4(39), CD4(143), CD4(239)]. In addition, two 
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monosaccharide models were examined for comparison that contains tartaramidoamine 
(T4) and galactaramidoamine (G4 or Glycofect) repeats. Delivery profiles for pDNA 
were compared with those obtained for siRNA delivery and reveal that efficacy differs 
significantly as a function of carbohydrate type, nucleic acid type and dose, polymer 
length, and presence of excess polymer in the formulation. The Tr4 polymers yielded 
higher efficacy for pDNA delivery, yet, the CD4 polymers achieved higher siRNA 
delivery and gene down regulation.   The T4 and Glycofect derivatives, while efficient 
for pDNA delivery, were completely ineffective for siRNA delivery.  A strong polymer 
length and dose dependence on target gene knockdown was observed for all polymers 
tested. Also, free polymer in solution (uncomplexed) was demonstrated to be a key factor 
in promoting siRNA uptake and gene down regulation.  
The carbohydrate family has been systematically studies in biochemistry. Inspired 
by the nature, carbohydrates have been a platform that polymer chemists have gained 
ideas from to improve stability and biocompatibility of nanosystems, for example, by 
incorporating them as degradable domains or using them as new coating materials. 
Herein, we have examined nanosystems that have been coated with synthetic 
polycarbohydrates: poly(glucose) and poly(trehalose), as coating materials aimed to 
improve the profile of siRNA delivery into brain cancer cells. The poly(trehalose) coated 
nanocomplexes were demonstrated to be substantially effective for quantitative siRNA 
delivery in presence of high salt concentrations and serum proteins. The ability of 
trehalose to lower phase transition energy associated with water freezing and protective 
properties have shown that poly(trehalose) has great promise to serve as an important 
component in formulation of effective nanomedicines.   
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In order to fulfill the requirement for tracking the nanoparticles, studying the 
intracellular unpacking mechanism as well as pharmacokinetic studies in future, we have 
also developed series of cationic polymers combining lanthanide ion chelating domains. 
To improve the biocompatibility and the performance of the polymers in facilitating the 
dissociation of the nanoparticles, we have incorporated the α,α-(D)-trehalose, a naturally 
abundant disaccharide into the polymer chains. The trehalose has been known for its 
potency in protecting biological materials from dehydration and aggregation. The so-
formed trehalose containing polymers have shown to be effective material to facilitate 
siRNA mediated target gene knockdown.  The complexation and dissociation with 
siRNA can also be monitored via FRET (Förster resonance energy transfer) by chelating 
the polymers with luminescent lanthanide ions (Eu3+ and Tb3+) and labeling the siRNA 
with organic dyes (Cy5 and TMR). On the other hand, compared with the currently 
commercially-available MRI contrast agent Magnevist, the polymers have achieved twice 
the relaxivity in two different magnetic fields. 
In summary, by combining the carbohydrate moieties and oligoamines, we have 
systematically examined the structure-property relationship of various well designed 
polymers on siRNA delivery profiles using glioblastoma cells as model. On the other 
hand, we have successfully incorporated the trehalose moieties into the lanthanide 
chelating polymers to increase the biocompatibility and performance of the polymers for 
both siRNA delivery and imaging. By incorporating different lanthanide ions, we can 
potentially use these well structured polymers as theranostic models in fundamental 
biological research.  
 
vi 
 
List of Content 
Acknowledgement--------------------------------------------------------------------------------i 
Abstract--------------------------------------------------------------------------------------------iii 
List of Content------------------------------------------------------------------------------------iv 
List of Figures-------------------------------------------------------------------------------------ix 
List of Tables--------------------------------------------------------------------------------------xii 
List of Schemes-----------------------------------------------------------------------------------xiii 
List of Abbreviations----------------------------------------------------------------------------xiv 
List of Publications---------------------------------------------------------------------------- -xvii 
Chapter 1: Introduction: Polymeric Materials for siRNA delivery and tracking----1 
1. Cellular mechanism and barriers for siRNA delivery---------------------------------------2 
2. Versatile synthetic strategies for siRNA delivery-------------------------------------------6 
3. Targeted delivery systems for siRNA---------------------------------------------------------21 
4. siRNA delivery tracking and theranostics development-----------------------------------31 
Chapter 2: Carbohydrate Based Cationic Polymers for siRNA Delivery-- Role of 
Polymer Length, Carbohydrate Size, and Nucleic Acid Type--------------------------44 
 1. Background--------------------------------------------------------------------------------------45 
 2. Introduction---------------------------------------------------------------------------------------45 
 3. Experimental section----------------------------------------------------------------------------50 
  Materials and methods-------------------------------------------------------------------50 
Synthesis and characterization of the carbohydrate-containing monomers and 
Polymers-----------------------------------------------------------------------------------51 
  Polymer siRNA binding studies via gel electrophoresis shift assays-------------55 
  Polyplex formation and analysis via dynamic light scattering (DLS)-------------56 
  Cell culture studies-----------------------------------------------------------------------56 
  Luciferase assay and protein assay-----------------------------------------------------57 
  Cellular uptake measurement by flow cytometry------------------------------------58 
  MTT assay---------------------------------------------------------------------------------59 
vii 
 
 4. Results--------------------------------------------------------------------------------------------60 
  Preparation and characterization of polymer vehicles-------------------------------60 
  Gel electrophoresis study of polymer-siRNA complexation-----------------------63 
  Dynamic light scattering (DLS) study-------------------------------------------------66 
  Effect of polyplex formulation on siRNA delivery to cultured glioblastoma cells 
                                           ---------------------------------------------------------------------------------69 
Promotion of siRNA-mediated gene down regulation by addition of free 
Polymers-----------------------------------------------------------------------------------72 
  Influence of polymer length on polyplex uptake and efficacy---------------------75 
  Comparison of pDNA and siRNA delivery profiles---------------------------------77 
  MTT assay to evaluate the cytotoxicity-----------------------------------------------79 
 5. Discussion----------------------------------------------------------------------------------------80 
Chapter 3. Promotion and stabilization effect of poly carbohydrates coating for 
nanosystems in siRNA delivery into cancer cells.-----------------------------------------94 
 1. Background--------------------------------------------------------------------------------------95 
 2. Introduction--------------------------------------------------------------------------------------96 
 3. Materials----------------------------------------------------------------------------------------100 
 4. Polymer Synthesis-----------------------------------------------------------------------------102 
 5. Material preparation and properties study--------------------------------------------------115 
  Polyplex formulation of diblock copolymer with siRNA--------------------------115 
  Polyplex lyophilization-----------------------------------------------------------------116 
  Gel electrophoresis of polyplexes-----------------------------------------------------116 
  Dynamic light scattering measurements---------------------------------------------117 
  Evaluation of phase transitions of the polytrehalose and trehalose solutions with 
differential scanning calorimetry (DSC)---------------------------------------------118 
6. Biological studies to evaluate the copolymers on siRNA delivery----------------------120 
Cell culture experiments----------------------------------------------------------------120 
Cellular uptake measurement by flow cytometry-----------------------------------121 
Cellular uptake study via cell confocal microscopy--------------------------------126 
viii 
 
Luciferase assay and protein assay----------------------------------------------------128 
Assessment of toxicity via MTT assay-----------------------------------------------135 
7. Discussion and conclusion--------------------------------------------------------------------136 
Chapter 4. Trehalose containing lanthanide click polycations for siRNA delivery 
and tracking ------------------------------------------------------------------------------------141 
1. Background-------------------------------------------------------------------------------------142 
2. Introduction-------------------------------------------------------------------------------------143 
3. Experiments and results-----------------------------------------------------------------------147
 Materials----------------------------------------------------------------------------------147 
Synthesis of monomers and polymers------------------------------------------------150 
Investigation on properties of polymers----------------------------------------------161 
Determination of the number of water coordinate sites------------------161 
Inductively coupled plasma optical emission spectroscopy-------------162 
Polymer siRNA binding assay-----------------------------------------------163 
Relaxivity of Gd chelated polymers-----------------------------------------164 
Dynamic light scattering study----------------------------------------------166 
Stability of polyplexes upon addition of heparin-------------------------167 
FRET(Fluorescence resonance energy transfer) of polymer/siRNA 
complexation-------------------------------------------------------------------168 
Cellular uptake of polyplexes and target gene knockdown in brain  
cancer cells-------------------------------------------------------------------------------172 
Cellular uptake for polyplexes via flowcytometry------------------------172 
Luciferase assay for siRNA mediated gene knockdown-----------------173 
Cytotoxicity study via MTT assay------------------------------------------175 
4. Conclusion--------------------------------------------------------------------------------------177 
Chapter 5. Conclusions-------------------------------------------------------------------------183 
Reference------------------------------------------------------------------------------------------189 
 
ix 
 
List of Figures 
Chapter 1 
Figure 1. (a). Structure of siRNA (b). The exogenous dsRNA induced gene silencing pathway.--4 
Figure 2. Common sites of chemical modification on siRNA backbones------------------------------7 
Figure 3. A. Aptamer-conjugated siRNA B. cholesterol-conjugated siRNA.-------------------------8 
Figure 4. Lac-PEG-siRNA conjugates.---------------------------------------------------------------------8 
Figure 5. Stable nucleic acid-lipid particles (SNALPs).-------------------------------------------------11 
Figure 6. Structure of PEI.-----------------------------------------------------------------------------------12 
Figure 7: A. PEGylation of siRNA via SPDP linker. B.The formation of siRNA-PEG/PEI 
polyelectrolyte.------------------------------------------------------------------------------------------------13 
Figure 8: A. Synthetic scheme of graft copolymer of PEI and PEG.----------------------------------14 
Figure 9: The structure of chitosan, only the deacetylated units are shown in the figure.----------16 
Figure 10: A.The structure of bis-(guanidinium)-tetrakis-(β-cyclodextrin) dendrimeric tetrapod.17 
Figure 11: The self assembly of cyclodextrin linear polymer with adamantane terminated 
polymeric chains.---------------------------------------------------------------------------------------------18 
Figure 12: Structure of cyclodextrin linear click copolymers.------------------------------------------19 
Figure 13: Examples of PGAAs (Poly(glycoamidoamine)s).------------------------------------------19 
Figure 14: Structure of trehalose click copolymers.-----------------------------------------------------20 
Figure 15: The diagrammatic structure of IgG.-----------------------------------------------------------23 
Figure 16: The conjugation of antibodies to polymers.--------------------------------------------------24 
Figure 17: The synthetic route of conjugating RGD to PEI.--------------------------------------------26 
Figure 18: Sequence of the modified LHRH, structure of CPT and LHRH-PEG-CPT conjugate.27 
Figure 19: Synthesis of siRNA-PEG-LHRH conjugates and self assembly of polyelectrolyte.---28 
Figure 20:  The structure of folic acid and synthetic route of polymer.-------------------------------29 
Figure 21: Conjugating lactose to the block copolymer via reductive coupling.--------------------31 
Figure 22. Schematic representation of siRNA absorption and Dox loading onto L-amino acid β-
CD modified QDs.--------------------------------------------------------------------------------------------33 
Figure 23.  Structures of polycations containing lanthanide chelates.--------------------------------35 
Chapter 2 
Figure 1. Schematic structures of the carbohydrate-containing cationic polymers.-----------------47 
x 
 
Figure 2. Schematic showing the different delivery destination of siRNA (cytoplasm) and pDNA 
(nucleus).-------------------------------------------------------------------------------------------------------47 
Figure 3: 1H-NMR characterization of polymers Tr4 and CD4.---------------------------------------62 
Figure 4: SEC characterization for trehalose polymer Tr4(77).----------------------------------------63 
Figure 5. The binding of polymers with siRNA examined by agarose gel electrophoresis shift 
assays.---------------------------------------------------------------------------------------------------------64 
Figure 6. Dynamic light scattering study to monitor complexation of siRNA.----------------------67 
Figure 7.  Influence of siRNA concentration and N/P ratio on polyplex-induced target gene 
(luciferase) down-regulation.-------------------------------------------------------------------------------71 
Figure 8. Enhancement of siRNA delivery by polymer vehicles Tr4(77) and CD4(143).---------72 
Figure 9. siRNA-mediated gene down regulation with U87-luc2 cells as a function of polyplex 
type.------------------------------------------------------------------------------------------------------------75 
Figure 10. Comparison of pDNA and siRNA delivery efficiency.------------------------------------77 
Figure 11: MTT assay to measure the cytotoxicity of siRNA-containing complexes.--------------80 
Chapter 3. 
Figure 1. Schematic illustration of polyplexes formation from diblock copolymers complexed 
with siRNA.---------------------------------------------------------------------------------------------------99 
Figure 2. Characterization of the glycopolymers.------------------------------------------------------104 
Figure 3. Gel electrophoresis assay.----------------------------------------------------------------------117 
Figure 4 a. Hydrodynamic radii and ζ-potentials of polyplexes in water over the period of 4 h.118 
Figure 5. Physical properties of polytrehalose and polyplexes.---------------------------------------119 
Figure 6. (a) Cell viability by MTT assay of polytrehalose (b) Cellular uptake at siRNA 
concentration of 100 nM (c) Dependence of cellular uptake on siRNA concentration in (c) or (d) 
DMEM with 10% FBS (e) The rate of the uptake at 100 nm siRNA concentration in (e) 
OptiMEM or (f) DMEM with 10% FBS.---------------------------------------------------------------123 
Figure 7. Confocal microscopy of U-87 cells transfected with Cy5-labeled siRNA.--------------127 
Figure 8.  Luciferase gene expression and cell viability observed in HeLa cells.------------------129 
Figure 9. Luciferase gene knockdown in luciferase-expressing U-87 cells.------------------------131 
Figure 10 A-B. Confocal microscopy images obtained at various time points for cells transfected 
with polyplexes.---------------------------------------------------------------------------------------------134 
Figure 11.  MTT assay in U-87 cell line with various polyplex formulations.--------------------135 
 
 
xi 
 
Chapter 4. 
Figure 1. Structures of trehalose containing lanthanide click polycations and illustration of FRET 
for polymer and siRNA.-----------------------------------------------------------------------------------147 
Figure 2.  Structural determination of 2,3,4,2’,3’,4’-hexa-O-acetyl-6,6’-diazido-6,6’-dideoxyl-D-
trehalose.-----------------------------------------------------------------------------------------------------151 
Figure 3. ESI-MS characterization of compound 1-alkyne-6-carboxybenzyl-2,3,4,5-tetra (tert-
butyloxycarbonyl) pentaethylenetetraamine.  ----------------------------------------------------------155 
Figure 4. 1HNMR characterization of di-carboxylbenzyl-di-pentaethylenetetraamine click 
trehalose macromonomers.-------------------------------------------------------------------------------156 
Figure 5. 1HNMR characterization of DTPA-BA.----------------------------------------------------157 
Figure 6.  a). 1HNMR spectra of trehalose pentaethylene polymers with lanthanide chelation 
domain. b). The SEC analysis of the polymer.  -------------------------------------------------------159 
Figure 7.  Gel electrophoresis analysis of TrN4Ln(Ln=Eu, Gd, Tb).-------------------------------164 
Figure 8. Relaxivity measurement of TrN4Gd.--------------------------------------------------------165 
Figure 9. Dynamic light scattering study of polyplexes formed by lanthanide containing polymers 
with siRNA.-------------------------------------------------------------------------------------------------166 
Figure 10. Stability of polyplexes upon addition of heparin.-----------------------------------------167 
Figure 11. Illustration of monitoring polyplex formation via FRET.--------------------------------169 
Figure 12. FRET study on the TrN4Eu/Cy5-siRNA and TrN4Tb/TMR-siRNA complexation and 
heparin mediated dissociation.----------------------------------------------------------------------------170 
Figure 13. Cellular uptake and target gene knockdown studies of polyplexes formed from 
lanthanide polymers with siRNA.------------------------------------------------------------------------174 
Figure 14. Cytotoxicity examined via MTT assay.-----------------------------------------------------176 
 
 
 
 
 
 
 
 
 
xii 
 
List of Tables 
Chapter 2. 
Table 1. GPC characterization of the click polymers.---------------------------------------------------61 
Chapter 3. 
Table 1. Determining molecular weight and composition of diblock copolymers by aqueous size 
exclusion chromatography.--------------------------------------------------------------------------------103 
Chapter 4. 
Table 1. Determination of number of water coordination sites.--------------------------------------161 
Table 2. ICP-OES analysis of the lanthanide content of polymers TrN4Eu, TrN4Gd and TrN4Tb 
respectively. -------------------------------------------------------------------------------------------------162 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
List of Schemes 
Chapter 2. 
Scheme 1. Synthesis of trehalose pentaethylene click polymer and cyclodextrin pentaethylene 
click polymer.-------------------------------------------------------------------------------------------------55 
Chapter 3. 
Scheme 1. Synthesis of P(MAG46-b-AEMAx) via RAFT Polymerization.-----------------------102 
Scheme 2. Synthesis of 6-methacrylamido-6-deoxytrehalose (MAT).------------------------------105 
Scheme3. Polymer synthesis via RAFT polymerization. ---------------------------------------------105 
Chapter 4. 
Scheme 2: Synthesis the Trehalose Pentaethyleneamine click macromonomer.-------------------151 
Scheme 3. Synthetic scheme of diethylenetriaminepentaacetic acid bisanhydride.----------------157 
Scheme 4. Synthetic scheme of trehalose based lanthanide containing polymers.-----------------158 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiv 
 
List of Abbreviations 
Boc    tert-butoxylcarbonyls 
BSA    bovine serum albumin 
Cbz     carboxylbenzyl 
CD4    poly(β-cyclodextrin click pentaethylenetetraamine) 
Cy5    cyanine dye 5 
Đ (Mw/Mn):    polydispersity index. 
DCC     di cyclohexylcarbodiimide 
DCM    dichloromethane 
DEPC    Diethylpyrocarbonate 
DLS    Dynamic light scattering 
DMEM   Dulbecco’s modified eagle medium 
DMSO   dimethylsulfoxide 
D2O    deuterium oxide 
DTPA    diethylenetriaminepentaacetic acid 
DTPA-BA   diethylenetriaminepentaacetic acid bisanhydride 
FACS    fluorescent activated cell sorting 
FBS    fetal bovine serum 
FRET    Fluorescence resonance energy transfer 
G4    galactaramidoamine  
GPC    gel permeation chromatography 
xv 
 
HeLa    human cervix adenocarcinoma cells 
IR    infra red 
MHS    Mark-Houwink-Sakurada 
Mn    number average of molecular weight 
Mw    weight average of molecular weight 
mRNA   message ribonucleic acid 
MRI    Magnetic Resonance Imaging 
MTT    (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) 
n    degree of polymerization (number of repeating units) 
N4Gd             poly(pentaethyleneamine-amidodiethylenetriaminetriaacetic gadolium) 
N4Tb             poly(pentaethyleneamine-amidodiethylenetriaminetriaacetic terbium) 
NMR    Nuclear Magnetic Resonance Spectroscopy 
N/P    amines of polymer/phosphate on siRNA 
ICP-OES             Inductively coupled plasma optical emission spectroscopy 
Opti-MEM   reduced serum media 
pDNA    plasmid DNA 
PEI    Polyethylenimine 
RISC    RNA-induced silencing complex 
RNAi    RNA interference 
SEC    Size-exclusion chromatography 
siRNA    small interfering ribonucleic acid 
xvi 
 
T4    tartaramidoamine 
TAE    Tris-Acetate-EDTA buffer 
TEM    transmission electron microscopy 
TMR    tetramethyl rhodamine 
Tr4   poly(α,α-trehalose click pentaethylenetetraamine) 
U87   Human glioblastoma-astrocytoma, epithelial-like cell line 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xvii 
 
List of Publications 
Lian Xue 
2003.09-2007.07 
 
B.S. in Pharmacy.  
Peking University  
Bachelor thesis: Design and synthesis of non-peptidomietics 
β-secretase inhibitors. 
2008.08-2011.08 
2011.08-2014.7 
 
 
Ph.D. in Chemistry. 
University of Minnesota, TC. MN  
Advisor: Theresa M. Reineke  
Doctoral Thesis:Synthesis and Evaluation of Carbohydrate 
Based Cationic Polymers for siRNA Delivery and Tracking 
 
Publications and Presentations:  
1. A. E. Smith, A. Sizovs, G. Grandinetti, L. Xue, T. M. Reineke, “Diblock 
Glycopolymers Promote Colloidal Stability of Polyplexes and Effective pDNA 
and siRNA Delivery under Physiological Salt and Serum Conditions” 
Biomacromolecules, 2011, 12 ,3015–3022 
2. N. P. Ingle, L. Xue, T. M. Reineke, “Spatio-Temporal Cellular Imaging of 
Polymer-pDNA Nanocomplexes Affords In Situ Morphology and Trafficking 
Trends” Mol. Pharm., 2013, Article ASAP. 
3. L. Xue, N. Ingle, T. M. Reineke, “Highlighting the Role of Polymer Length, 
Carbohydrate Size, and Nucleic Acid Type in Potency of Glycopolycation 
Agents for pDNA and siRNA Delivery” Biomacromolecules, 2013, Article 
ASAP. 
4. A. Sizovs, L. Xue, Z. Tolstyka, N. Ingle, Y. Wu, M. Cortez, T. M. Reineke, 
“Poly(trehalose): Sugar-Coated Nanocomplexes Promote Stabilization and 
Effective Polyplex-Mediated siRNA Delivery” J. Am. Chem. Soc., 2013, 135, 
15417–15424. 
5. Sneha S. Kelkar, Lian Xue, S. Richard Turner and Theresa M. Reineke, 
Lanthanide-Containing Multi-functional Polymers for Monitoring Polyplex 
Dynamics via Lanthanide Resonance Energy Transfer. Manuscript submitted to 
Biomacromolecules. 
6.  Lian Xue, Sneha S. Kelkar, Theresa M. Reineke, Trehalose Containing 
Lanthanide Click Polycations for siRNA Delivery and Tracking . Manuscript in 
preparation. 
xviii 
 
7. Lian Xue, Theresa M. Reineke. Trehalose cationic polymers for siRNA delivery 
into glioblastoma cells.  8th National Graduate Research Polymer Conference, 
June 6 - 9, 2010. 
8. Lian Xue, Theresa M. Reineke. Structure-property relationship of click 
polycations for siRNA delivery. MII Technical Conference and Review of 
Virginia Tech, 2010. 
9. Lian Xue, Theresa M. Reineke. Carbohydrate-based click polycations for siRNA 
delivery. Oral presentation, 243rd ACS National Meeting & Exposition March 
25- 29 2012, San Diego, California. 
10. Lian Xue, Anliang Li. Chapter 14. Bioavailability—Targeted delivery and 
Prodrugs. 2008.02. ISBN: 978-122-01735-2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
Chapter 1 
 
Introduction: Polymeric Materials for siRNA delivery and tracking 
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Background 
RNA interference gene regulation has been investigated intensively in medical 
applications in last two decades. However, inadequate delivery of RNA molecules to 
intracellular target sites has become the bottleneck in both laboratory use and clinical 
therapy. Generally, the small interfering RNA molecules as well as other RNA molecules 
have poor pharmacokinetic profiles, can be hydrolyzed or degraded easily, cause serious 
immunogenic response and can be toxic to particular cell types as well. Several strategies 
have been developed to improve the pharmacokinetics of siRNA, including chemical 
modification, virus vectors, lipid and polymer complexation, etc. In order to achieve 
desirable properties with variations, developing biocompatible and biodegradable 
materials to successfully deliver siRNAs to targets has become a main strategy. In recent 
years, a variety of polymeric vehicles have been extensively synthesized and investigated; 
several of them have been developed from benchtop to bedside. The diversity of chemical 
reactions endows the delivery systems with various properties like high efficiency, low 
toxicity, and tunable sizes and surface properties for targeted delivery. Tracking the 
siRNA delivery becomes important as to understand the dynamic of the polyplexes, to 
elucidate the mechanism of interactions with cells, to provide a platform for potential 
theranostics development.  
1. Cellular mechanism and barriers for siRNA delivery 
1.1 Cellular mechanism of post-transcriptional gene regulation by siRNA 
It was a milestone that Fire and Mello P1 P discovered that mixing the sense and 
antisense strands of small RNAs achieved approximately tenfold more efficiency in gene 
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silencing than either strand alone. They named such double stranded RNA-induced gene 
down-regulation “RNA interference” or RNAi.    
RNA interference is an RNA-dependent gene regulation method to help control 
gene activity. In living cells, RNAi can play an important role in defense against parasitic 
genes to minimize viral infections, secure genome stability and repress protein synthesis 
to regulate the development of organisms. In research, it provides a powerful tool to 
study the function of specific genes and pathways, and this may revolutionize drug 
discovery in the future. 
In the classical view of the Central Dogma, genetic information is transcribed 
from DNA into RNA, and then translated from mRNA to proteins. Generally, there are 
two types of RNA molecules that are central to RNAi, and these are micro RNA (miRNA) 
and small interfering RNA (siRNA). In the exogenous dsRNA-initiated RNAi pathway 
(shown in Figure 1b), the ribonuclease III-like nuclease (so-called Dicer P2 P) in the 
cytoplasm is responsible for processing of exogenous dsRNA to short RNA. The short 
double-stranded nucleotide fragments are called small interfering RNAs (siRNA).  The 
siRNAs usually comprise 21-25 base pairs of double strand RNAs with 2-3 unpaired 
overhanging bases on each end P1 P. Then, they are bound to RNA-binding proteins and 
transferred to an RNA-Induced Silencing Complex (RISC). However, only one of the 
double strands, the antisense strand, can guide the gene silencing, and the other strand 
(antisense strand) will be degraded while the activation of RISCP3 P. Subsequently, the 
activated RISC complex binds to a messenger RNA (mRNA) molecule complementarily 
and induces the cleavage of the mRNA. In this manner, the translation to protein is 
inhibited due to diminishment of the templates. 
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Figure 1: This shows the (a). Structure of siRNA (b). The exogenous dsRNA induced 
gene silencing pathway. This image was copied from reference Dykxhoorn, D. M.; 
Novina, C. D.; Sharp, P. A. Nat Rev Mol Cell Biol 2003, 4, 457-467P4P. 
1.2 Barriers in systemic and local delivery of siRNA nanoparticles 
The potency of siRNA in therapeutic applications is versatile from central 
nervous systems therapeutics, antiviral and anticancer agents, inflammation to 
cardiovascular therapeutics. Theoretically, siRNA can act on target mRNAs and their 
correlated proteins are considered to be untreatable by small molecules or monoclonal 
antibodies. P5 P From 1989 to March 2014 (according 
to Uhttp://www.wiley.com/legacy/wileychi/genmed/clinical/ U), over 1996 gene therapy 
clinical trials have been completed or are in progress. Among these, 12 are for siRNA, 
most of the vectors used in these trials were viral-based. However, nonviral vectors are 
recognized as important components for oligonucleotide therapeutics.   
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Delivery strategies for siRNA nanoparticles depend on accessibility of the target 
sites. Typically for eyes, skin, mucus membranes, lung diseases as well as local tumors, 
local delivery will be sufficient. However, for most pathologic sites, systemic 
administration is still the major delivery route. Physiological barriers for siRNA delivery 
can be classified into instability in serum, poor permeability through vascular 
endothelium and extracellular matrix, unexpected lymphatic clearance, poor cellular 
uptake and endosome escape. Firstly, siRNAs have short half lives and low stability in 
serum.  They can easily undergo hydrolysis as compared to pDNA, and even cause 
immunogenic responses. Therefore, siRNAs are incorporated into nanoparticles for 
systemic delivery to improve the pharmacokinetic profiles. Post injection, the 
nanoparticles (NPs) must avoid filtration, phagocytosis and degradation in the blood 
stream. The survivability of the NPs depends on both size (5-250 nm) and surface 
characteristics. The surface properties and functionalities are also important to avoid 
aggregation and unwanted enzymatic degradation. P6 P 
Secondly, it is desirable for the NPs to cross the vascular endothelial cell barrier 
and avoid lymphatic clearance. There are certain tissues like solid tumors, the liver and 
spleen that allow entry of particles as large as 200 nm in diameter. In solid tumors, there 
is a enhanced permeability and retention (EPR) effect that allows relatively large 
nanoparticles to accumulate in tumor tissue. The EPR effect can be attributed to 
progressive angiogenesis and high vascular density, defective vascular structure, over 
excretion of different vascular dilators as well as impaired lymphatic clearance in solid 
tumorsP7 P.  Targeting solid tumors through the EPR effect is still a major design objective 
for nanosized delivery systems.  
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More importantly, naked natural siRNA is not readily taken up by cells. Therefore, 
compensating for the negative charge of siRNA or shielding the charge is crucial to 
facilitate the internalization process. Once taken up by the cells via endocytosis, the 
siRNA –vector complexes have to escape the endosome to reach the cytoplasm where the 
RISC machinery is located P8 P. The main hypothesis supporting cationic polymers for gene 
delivery is the “proton sponge” theory, which states that polycations can buffer acidic 
conditions by absorbing protons in the endosome. The drop in proton concentration in the 
endosome will trigger the influx of protons together with chloride, and this leads to 
osmotic influx of water to disrupt the endosomes and release the polyplexes into the 
cytoplasm. P9 P Lastly, the siRNA must be released from vectors or formulations to reach the 
RNAi machinery RISCs. 
2. Versatile synthetic strategies for siRNA delivery  
Generally, to improve the delivery efficacy of siRNA, these polynucleotides can 
be chemically modified or incorporated into non-viral vectors. Conjugating delivery 
materials with siRNA via covalent linkage is another approach to overcoming the 
delivery difficulties.    
2.1 Chemical modifications on siRNA backbones 
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Figure 2: Common sites of chemical modification on siRNA backbones 
Chemical modification of siRNA can improve the pharmacokinetic properties, 
activity and reduce side effects such as immunogenic responses and kidney toxicityP10 P. 
The plasma stability and in vitro potency can be dramatically improved by fully 
modifying the 2’-OH. A siRNA with 2’-OH alkylation and fluorine substitution in an 
alternating manner has shown >500-fold improvement in potency. P11 P Also 4’-thio-
modified siRNA exhibits improved activity and nuclease stability in some systems. P12 P  
2.2 siRNA conjugates 
Conjugating the siRNA sense strand to small molecules, peptides, aptamers (in 
Figure 3A) and polymers can increase the efficacy of siRNA to target specific cell types 
or to improve the stability and solubility in serum. Cholesterol-modified siRNA (in 
Figure 3B) can significantly facilitate the accumulation of siRNA in the liver and silence 
apolipoprotein B in mice liver and jejunum to reduce blood cholesterolP13 P. It was also 
reported that conjugating siRNA via a disulfide bond to penetratin or transportan, which 
are two kinds of peptide transduction domains (PTDs), can help siRNA penetrate into 
almost 100% of cell populations with 8% toxicityP14 P.   
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A                                                                      B 
 
Figure 3: A. Aptamer-conjugated siRNA B. cholesterol-conjugated siRNA. The sense 
strand and anti-sense strand are represented as blue and orange circles respectively. P14 P 
This figure was copied from reference “de Fougerolles, A.; Vornlocher, H. P.; 
Maraganore, J.; Lieberman, J. Nature Reviews Drug Discovery 2007, 6, 443-453”P14 P. 
It is noteworthy that a class of nanometer-scale covalent carriers of siRNA can be 
prepared through self-assembly of PEG-based block ionomers. One example is 
conjugation of siRNA with lactosylated PEG (shown in Figure 4) through acid-labile 
linkages, and followed by incorporated with cationic poly(L-lysine) to form micelles. The 
micelles were reported to remarkably enhance RNAi in cultured hepatoma cells P15 P.  
 
Figure 4: Lac-PEG-siRNA conjugates. This figure was copied from reference “Oishi, M.; 
Nagasaki, Y.; Itaka, K.; Nishiyama, N.; Kataoka, K. Journal of the American Chemical 
Society 2005, 127, 1624-1625”P15P. 
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2.3 Synthetic vehicles for siRNA delivery 
Common features of synthetic nanoparticlesP16 P 
Generally, delivery vectors are designed to facilitate the uptake of siRNA into the 
target cells. In systemic delivery, the vectors should also protect siRNA from enzymatic 
degradation and immune system recognition and also avoid non-specific delivery. By 
survey of the existing nanoparticles, there are several common features that are useful for 
successful nano system design. 
2.3.1 Surface properties 
In colloidal systems like those containing siRNA nanoparticles, zeta potentials are 
widely used for quantifying the magnitude of the electrical charge at the Debye layer, 
which is a few nanometers from the surfaces in water. A vehicle bearing positive charge 
can facilitate the cellular uptake process, but at the same time it can increase the 
probability for adsorption onto surfaces and aggregation with serum proteins which are 
usually negatively charged. For example, polyethyleneimine (PEI) which is cationic 
polymer not only neutralizes the intense negative charge of the nucleic acids, but also 
condenses the complexes into a much smaller particle to facilitate endocytosis, the major 
way of cellular internalizationP17 P. 
For in vivo siRNA delivery, coating the surface of the nanoparticles with 
hydrophilic blocks like poly(ethylene glycol) (PEG) allows formation of core-shell 
structures to increase the solubility of the particle, to shield the charge, and to prevent 
aggregation. This approach can also protect the particles against degradation and immune 
system recognition, and provide longer circulation times in the blood stream. PEG has 
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been extensively used in drug delivery, and it can be utilized to control and tune the 
particle sizeP18 P. 
2.3.2 Biodistribution and toxicity 
Systemic administration of synthetic nanoparticles will usually lead to 
accumulation in organs like the liver, spleen, kidneys, lungs and tumors. Excretion from 
the kidney is size dependent, and usually polymers with less than 50 kDa in molecular 
weight can easily be excreted through the kidneysP19 P. Also the enhanced permeability and 
retention effect as mentioned in 1.4 plays an important role in accumulating nanoparticles 
in solid tumors. 
Safety is a primary concern for design of siRNA delivery vehicles. For example, 
viral vectors, which were widely applied in gene delivery a decade ago, can induce lethal 
immune responses and infectionP20 P. Therefore, biodegradable and biocompatible synthetic 
materials have great potential to achieve lower toxicity with high transfection efficacy.    
2.3.3 Synthetic materials for siRNA delivery 
Non-viral vectors have many advantages for oligonucleotide delivery. They are 
relatively safe, offer tunable properties and one can incorporate a wide range of ligands 
with this approach. Nanosized siRNA vectors can range from lipid based materials, 
polycations, gold nanoparticles, functionalized carbon nanotubes and quantum dots. 
Among all these types of delivery vectors, lipid based and cationic polymers are 
predominant in various applications. 
2.3.3.1 Lipid based materials 
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Lipid based materials have been incorporated in many pharmaceutical 
formulations over the last two decades. Cationic lipid materials such as Lipofectamine 
2000 or its analogs have been used for in vitro pDNA or siRNA deliveryP21 P. The history of 
cationic lipid based gene vectors can be traced back to the discovery of the ability of 
DOTMA (N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride) (shown in 
Figure 5b) to delivery both DNA and RNA. P22 P   
In a recent study, siRNAs were incorporated into stable nucleic acid lipid particles 
(SNALP) (shown in Figure 5a) and intravenously administrated to non-human primates. 
Successful apo-B knock down was observed in 24 hours. P23  
         DOTMA  
 
                   
Figure 5: A. Stable nucleic acid-lipid particles (SNALPs) formed from cationic lipid, 
non cationic lipids and PEG chains. This figure was copied from reference” Whitehead, 
K. A.; Langer, R.; Anderson, D. G. Nature Reviews Drug Discovery 2009, 8, 516-516”.P16 P 
B. structure of DOTMA. 
Positively charged lipids incorporate with negatively charged siRNA to form 
"lipoplexes".  It has been reported that a stealth lipoplex can be taken up by the 
reticuloendothelial system (RES), where Kupffer cells in the liver could engulfed the 
lipoplexes which bound to blood proteinsP24 P.  This resulted in low transfection efficiency 
in vivo. Toxicities of cationic lipids are an issue that must be addressed. In response to 
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this issue, PEGylated liposomes were developed to overcome non-specific 
accumulationP25 P..   
2.3.3.2 Polymer based vehicles 
Cationic polymers, linear or branched, have been developed and used as efficient 
transfection agents in vitro and in vivo P26 P. Usually the cationic polymers can bind with 
nucleic acids through electrostatic interactions and hydrogen bonding to neutralize the 
negative charge and further condense the large nucleic acids into smaller sized stable 
nanoparticles.  Polyelectrolyte self-assembled nanoparticles (termed polyplexes) are the 
dominant type of polymeric delivery systems used for siRNA delivery. Usually the 
cationic polymer contains amine---including primary, secondary, tertiary and quaternary 
amines, as well as other positively charged groups like amidines and guanidinesP27 P. In 
physiological conditions, the cationic polymers can interact with the negatively charged 
phosphate groups on nucleic acid backbones, although the substructure of a polyplex is 
still under study. The charge ratio refers to the N:P ratio, which is often applied as a 
parameter to demonstrate the efficacy of the cationic polymer in transfection experiments.  
2.3.3.2.1 PEIs (polyethyleneimines)  
N
H n
Poly(ethyleneimine)  
Figure 6:  Structure of PEI 
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PEI has been extensively investigated in nuleotide delivery including DNA and siRNA. It 
has been reported the low molecular weight PEI can efficiently stabilize siRNAs and 
successfully deliver siRNA into tumors via systemic administration in a mouse model, 
resulting in a remarkable reduction of target receptor c-erbB2/neu (HER-2) expressionP28 P. 
The intraperitoneal administration of polyplexes formed with PEI and siRNA has 
successfully achieved knock down of the target, the NMDA (N-methyl-D-aspartate) 
receptor NR2B which is related to chronic painP29 P. To stabilize siRNA in the polyplex, 
PEGylated siRNA was also used for anti-angiogenic gene therapy (shown in Figure 7) P30P. 
The siRNA was covalently bound to PEG via cleavable disulfide bonds that were 
introduced by the crosslinking reagent N-succinimidyl 3-(2-pyridyldithio)propionate 
(SPDP). The siRNA-PEG conjugates interact with PEI to form polyelectrolyte complex 
micelles through self-assembly. 
 
Figure 7: A. PEGylation of siRNA via SPDP linker. B.The formation of siRNA-
PEG/PEI polyelectrolyte. This figure was copied from reference “Kim, S. H.; Jeong, J. H.; 
Lee, S. H.; Kim, S. W.; Park, T. G. Journal of Controlled Release 2008, 129, 107-116”P28P. 
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Although PEI is efficient for nucleic acid delivery, it has serious cytotoxicity 
which appears to be molecular weight and concentration dependent P31P. To improve its 
biocompatibility, hydrophilic PEG was incorporated, and this was expected to reduce the 
cytotoxicity and improve the water solubility of PEI/DNA complexes. Therefore different 
PEGylation chemistries/architectures were developed, such as block and graft 
copolymers of PEI and PEGP31 P (the synthetic schemes are shown in Figure 8).  
AP  
 
 
B 
 
 
 
Figure 8: A. Synthetic scheme of graft copolymer of PEI and PEG. This figure was 
copied from reference “Ahn, C.-H.; Chae, S. Y.; Bae, Y. H.; Kim, S. W. Journal of 
Controlled Release 2002, 80, 273-282.P”29P. B. Synthetic route of block copolymers of PEI 
and PEG. This figure was copied from reference “Petersen, H.; Martin, A. L.; Stolnik, S.; 
Roberts, C. J.; Davies, M. C.; Kissel, T. Macromolecules 2002, 35, 9854-9856”.P32P 
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It has also been reported that PEG-b-PEI diblock copolymers can enhance DNA 
condensation better than multi-PEGylated PEIs.P32 P Since siRNA and DNA behave quite 
differently in terms of their intracellular mechanisms of action, it is recommended that 
separate evaluations of the graft copolymers (PEG-g-PEI), which already have optimal 
molecular weight and N/P ratio for DNA, should be conducted.P33P     
To reduce the toxicity of long chain PEI and increase the gene transfection 
efficiency of low molecular weight PEI, various degradable links were incorporated into 
short chain PEI, such as amides, acetals, esters and disulfidesP34 P. Transfection efficiencies 
of disulfide crosslinked PEI have also been investigated, and it was found that these 
depended strongly on both the degree of crosslinking and the precursor molecular 
weightsP34 P. 
2.3.3.2.2 Carbohydrate-based delivery systems 
a. chitosan 
Chitosan (shown in Figure 9) is a linear polysaccharide derived from 
deacetylation of chitin which is fully acetylated β-(1-4)-linked poly(N-acetyl-D-
glucosamine). Chitosan consists of randomly distributed β-(1-4)-linked D-glucosamine 
(deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit), depending on the 
degree of deacetylation. It has been widely used in controlled release formulations 
because it is biocompatible and biodegradable at a slow rateP35P.  Chitosan also increases 
transcellular and paracellular transport across the muscosal epitheliumP36 P.  
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Figure 9: The structure of chitosan, only the deacetylated units are shown in the figure. 
Due to the cationic nature from the protonated primary amine, chitosan had been 
investigated for nucleic acid delivery. It has been used in oral delivery of DNA to 
intestinal epithelial cells to produce IgA and serum IgG2a which are two forms of 
antibodiesP37 P. The efficacy of chitosan/siRNA in gene silencing in vitro is strongly 
dependent on the molecular weight and degree of deacetylation. High MW and high 
degree of deacetylated chitosan perform better, but the effective N/P ratio was as high as 
50:1P38P. 
b. cyclodextrin based delivery systems   
There are three kinds of cyclodextrins (CD)- α, -β, and –γ, constituted by 6 to 8 
glucopyranoside units respectively. The three dimensional structure of β-CD endows it 
with proper ring size for optimal H-bonding, and due to the special cup like shape and 
relatively hydrophobic cavity, it can dramatically enhance the water solubility of 
hydrophobic moieties. Also the CDs are quite biocompatible and extremely water soluble, 
and can provide 6-8 reactive sites for easily performed chemical modifications. More 
interestingly, the adamantane has one of the highest binding affinity to β-CD (association 
constant on the order of 10 P4 P-10P5P MP-1 P for adamantane carboxylate) in aqueous solution, the 
property can be utilized for self assembly of macromolecules and design of biosensorsP39P .  
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Cyclodextrin itself does not have cationic center to complex with siRNA, 
therefore different cation containing cyclodextrin derivatives were synthesized for 
oligonucleotide delivery. In Marsura’s group, a bis-(guanidinium)-tetrakis-(β-
cyclodextrin) dendrimeric tetrapod (shown in Figure 10) has been synthesized and shown 
the potency in siRNA delivery to embryonic lung fibroblastsP40 P.  Also, a series of 
polycationic β-Cyclodextrin “Click Clusters” with monodispersity and size range of 80-
130nm were developed by Dr. Reineke’s group and from the preliminary study, the ones 
containing three to four secondary amine groups were most promising vehicles for DNA 
delivery, but the re evaluation of the vehicles for siRNA delivery is still required P41 P. 
A. B. 
Figure 10: A.The structure of bis-(guanidinium)-tetrakis-(β-cyclodextrin) dendrimeric 
tetrapod. The figure was copied from reference”P40 P”. B. Structure of β-Cyclodextrin “Click 
Clusters. The figure was copied from reference ”P41 P”. 
Dr. Davis’ group has performed extensive investigation on the CD containing 
polymers for drug and nucleic acid delivery for many years. And from the all 
investigations so far, the CD-containing polycations show low toxicities in vitro and in 
vivo, and they hadn’t been observed to enter the nucleus of cells, which is a feature 
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beneficial for siRNA deliveryP42 P.  The linear CD-containing polycations can be decorated 
by PEG by terminating the chain with adamantane, which can form inclusion complexes 
with cyclodextrin through self assemblyP42 P. The PEG moiety was terminated with 
adamantine, and a targeting moiety can be incorporated on the other end. And this kind of 
formulation has been brought from benchtop to bedside to achieve the first targeted 
delivery of siRNA in humanP43 P. In this formulation, the targeting component transferrin 
(Tf), which can specifically bind to transferrin receptors that are over expressed in tumor 
cells, was conjugated at the end of PEG chain opposite to adamantane.  The four 
components (siRNA, CDP, PEG-AD, Tf-PEG-AD) then formed nanoparticles via self 
assembly when mixed together P43P (shown in Figure 11).  
  
Figure 11: The self assembly of cyclodextrin linear polymer with adamantane terminated 
polymeric chains P43 P. 
The Reineke’s group has developed a series of cyclodextrin click copolymers 
(shown in Figure 12) with different oligoethyleneamines for pDNA delivery into HeLa 
cells P44 P. The cell viability was quite high through all the structures and the transfection 
efficiency depended on the number of amines in each repeating unit and the degree of 
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polymerization. Among them, Cd3R49R (with three amines in each unit and degree of 
polymerization is 49) and Cd4 R93R showed the most efficient reporter gene expression.   
 
Figure 12: Structure of cyclodextrin linear click copolymers with different 
oligoethyleneamine analogues. The figure was copied from reference “P44 P” 
c. poly(glycoamidoamine)s 
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Figure 13: Examples of PGAAs (Poly(glycoamidoamine)s). In this figure, the polymers 
contain four secondary amines and either two or four hydroxyl groups per repeat unit 
with differing stereochemistry. This figure was copied from reference “P45 P”. 
Inspired by the transfection agents PEI and chitosan, The Reineke’s group has 
explored the polymers with carbohydrate moieties along with linear amino backbone 
linked via amide groups. Initially, the synthesis of these polymers proceeds by 
polycondensation of carbohydrate diesters with diamines. They found out that both the 
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number and the stereochemistry of hydroxyl units remarkably affect the biological 
properties of the polymers. Interestingly, the galactarate-based polymers showed higher 
transfection efficiency despite the lower binding affinity to pDNA compared with 
tartarate polymers in HeLa cellsP45 P.  
In the later studies, they concluded that the higher number of amine groups in 
repeating units  would facilitate greater cellular uptake, and this may because the stronger 
interaction with cell surface proteoglyans as well as with endosomes. The carbohydrate 
components also affect gene expression level, and this could be attributed to the different 
buffering capacities. Also, the higher amine density (T series polymers have shorter 
molecular distance between oligoamines) could probably cause release via membrane 
defect formation. The different amine spacer could influence buffering capacity 
dramatically, but the decreased buffering capacity leads to an increase on gene expression, 
this finding also indicated the contradiction between the relation of buffering capacity 
and gene deliveryP46 P.   
 
Figure 14: Structure of trehalose click copolymers. The figure was copied from 
reference ”P47 P”. 
The trehalose based copolymers (shown in Figure 14), represent another series of 
promising transfection reagents were designed and synthesized in The Reineke group via 
copper(I) catalyzed alkyl-azide cycloaddition polymerization. The initial concern about 
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incorporating a trehalose unit was its potency of water retention and great water solubility, 
protein stabilization, anti-aggregation properties, and its own stability against hydrolysis 
benefiting from an anomeric effect, also the rigid concave shape of the molecules may 
facilitate the nanoparticle formation.  The click polymerization is an efficient way to 
synthesize polymers of high degree of polymerization in mild conditions. Surprisingly, 
the polymers can efficiently compact DNA at quite low N/P ratios and the one with three 
secondary amine groups in a repeating unit appears to reduce serum-mediated polyplex 
aggregationP47 P.  Later on, the effect of trehalose polymers’ length on the efficacy was 
studied by synthesis of polymers with different degree of polymerization. There were no 
apparent evidence observed of the length of the polymers affecting the pDNA binding 
affinity, cellular internalization and DNase resistance.  The degree of polymerization of 
the polymers does influence the serum stability and gene expressionP48 P.   
Although all the studies were based on pDNA, the low toxicity and high 
transfection efficiency of PGAAs shows great potency for siRNA delivery in the future.  
Apart from the polymers above, cationic peptides like cell membrane transduction 
peptides as well as other lysine rich and arginine rich polypeptides are utilized for 
transfection agents. The polymethacrylate with amine groups on side chains are also 
commonly used for oligonucleotide delivery.  In addition, a variety of nanoparticles like 
functionalized quantum dots, gold nanoparticles, carbon nanotubes can be applied both to 
deliver siRNA and track the intracellular events by imaging. 
3. Targeted delivery systems for siRNA  
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Ideally, if delivery of siRNA can be enhanced specifically to the tissue of interest, 
like liver, spleen or tumor tissues, infected cells, it can not only reduce the dose of siRNA 
but also lower the risk of toxicity and side effects caused by high concentrations of 
siRNA and off target effects. Although currently there are few reports on targeted 
delivery of siRNAs in vivo, the targeted delivery systems of other small drugs, ODNs and 
pDNAs can guide the rational design of targeted delivery systems for siRNA.  
In solid tumors, enhanced permeability and retention (EPR) effect can be applied 
to facilitate the passively targeted delivery of therapeutics to tumor cells. In systemic 
delivery, to exhibit EPR effect, the particles must circulate at least 6 hours in blood. 
Another paradigm is to incorporate endocytosis related ligands that can be selectively 
recognized by tumor cells. This approach depends on the specificity of the interaction and 
binding affinity between the ligands and tumor cells, the accessibility of the location of 
the interaction, and the density of the receptors compared to normal cells. 
In addition, tumor targeting via extracellular activation of nanocarriers is another 
paradigm that guides the design of targeted delivery systems. This strategy takes 
advantages of the special environment as a mean to trigger transformation of the stealth 
nanoparticles to a more active form of nanoparticles.  The unique environment of tumor 
cells like slightly acidic and hypoxia condition as well as abundant proteinases can be 
used as selective mechanisms for tumor tissue P49 P. Up to date, according to different 
targeting moieties used in delivery, the systems can be divided to several classes: 
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3.1 Antibody and antibody fragment mediated delivery 
Antibodies are immunoglobulins that can bind to unique part of antigens in a 
highly specific manner.  The huge diversity and availability of monoclonal antibodies 
endows them with the possibility as routine clinical treatment for cancer diseases and the 
potency for targeted delivery for therapeutics. 
 
Figure 15: The diagrammatic structure of IgG. This figure was copied from 
website: Uhttp://www.bmb.leeds.ac.uk/teaching/icu3/selfdir/immunol/index.htm 
Usually the antibodies, such IgGs (shown in Figure 15), are consisted of Fab 
fragments and Fc fragments, the later can be possibly recognized as antigen. In recent 
reports, fragment Fab and scFv have been used and more beneficial over the whole 
antibodies, because they are less bulky, easy to deal with and less immunogenicP50 P. To this 
end, the antibodies are still of high cost.   
It is challenging to conjugate antibodies or fragments to polymers, usually the 
glycosylated part has been considered as the ideal site for conjugation to maintain the 
activity of the antibodies, the schemes are shown as followsP51 P:  
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a. 
 
 
 
b. 
 
 
c. 
 
 
 
Figure 16: The conjugation of antibodies to polymers. a. antibody-polylysine 
conjugation via disulfide exchange b. antibody-PEI conjugation via thiol-ene reaction 
through linker SMCC. c. antibody-PEG-PEI conjugation via thiol-ene reaction. The 
figure was copied from the reference “P50,51,52P”( Mok, H.; Park, T. G. Macromolecular 
Bioscience 2009, 9, 731. Wu, G.; Barth, R. F.; Yang, W.; Chatterjee, M.; Tjarks, W.; 
Ciesielski, M. J.; Fenstermaker, R. A. Bioconjugate Chemistry 2003, 15, 185. Qian, Z. M.; 
Li, H.; Sun, H.; Ho, K. Pharmacol Rev 2002, 54, 561.). 
25 
 
 
3.2 Transferrin receptor mediated delivery 
Transferrin receptor (TfR) is a kind of glycoprotein overexpressed in many cancer 
cell lines. It has also been verified that TfR can mediate endocytosis and be recycled 
without intracellular degradationP53 P. Tf-PEI/DNA complexes can achieve 100-500 fold 
gene expression in tumor as adenovirus in mice. Although many peptide drugs are 
prevented from crossing blood brain barrier (BBB), therapeutics can be delivered to brain 
via BBB transporter such like TfR. While since the high endogenous plasma 
concentration of transferrin, the antibodies of TfR was applied to selective target BBB 
endothelium due to the high expression of TfRP53 P. Also, as mentioned in last chapter, 
Davis group had incorporated the Tf into the cyclodextrin based polymers for the siRNA 
formulations. 
3.3 Functional peptides mediated delivery 
3.3.1 RGD and analog mediated delivery 
Integrins are receptors sitting on cell membrane that mediate cell signaling and 
relate to adhesion, mobility and cell cycle. Arg-Gly-Asp (RGD) peptide has been 
intensively studied and applied in targeted delivery systems.  It can be recognized by 
integrin receptor αvβ3/αvβ5 which are overexpressed in angiogenic endothelial cells of 
tumor tissues.  Both linear (RGDC) and cyclic (cRGD) RGD like (CGRGDSPC) and 
(ACDCRGDCFCG) have been incorporated by conjugating to PEI (shown in Figure 17), 
poly(amido ester), modified PEG and other polymers via disulfide bond through cysteine.  
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Figure 17: The synthetic route of conjugating RGD to PEI. The figures were copied from 
reference “P54 P,P55 P”(Zugates, G. T.; Anderson, D. G.; Little, S. R.; Lawhorn, I. E. B.; Langer, 
R. Journal of the American Chemical Society 2006, 128, 12726.W Suh, S. H., L Yu, SW 
Kim Molecular Therapy 2002, 6, 664. ). 
One example showed above was the synthetic route of three kinds of polymers via 
Michael addition followed by linking to RGDC via disulfide exchange on the side 
chains P54 P.  The in vitro studies showed the RGD modified polymers exhibited higher 
efficiency in delivery pDNA to human heptatocellular carcinoma cell line than those not 
modified P54 P. The PEI-g-PEG-RGD was observed to have high selectivity toward 
angiogenic endothelial cells and much less toxicity. Surprisingly, one RGD unit per PEI 
chain would be sufficient to show high affinity to integrin receptor.P55 P   
3.3.2 Luteinizing hormone-releasing hormone 
It has been validated the luteinizing hormon-releasing hormone (LHRH) receptors 
are usually over-expressed in a variety of cancer cells. The LHRH has been used in the 
apoptosis-inducing agent camptothecin (CPT) formulation for tumor targeted deliveryP56 P. 
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The sequence of the conjugates is shown below. The peptide LHRH was PEGylated 
through amine group at the end. 
LHRH-NH-O-C-PEG-O-S-O-CH2-CH2-S-CH2-CH-C-O-CPT
O O
O
O
NH2
LHRH-PEG-CPT
 
Figure 18: Sequence of the modified LHRH, structure of CPT and LHRH-PEG-CPT 
conjugate. This figure was copied from reference “P56P” (Dharap, S. S.; Wang, Y.; Chandna, 
P.; Khandare, J. J.; Qiu, B.; Gunaseelan, S.; Sinko, P. J.; Stein, S.; Farmanfarmaian, A.; 
Minko, T. Proceedings of the National Academy of Sciences of the United States of 
America 2005, 102, 12962.).  
LHRH has also been used in targeted delivery for siRNA in the form of 
conjugating to sense strand of siRNAP57 P. PEG was linked to siRNA via disulfide bond 
with the other ending group carboxylic acid reacted with amine in LHRH. The synthetic 
scheme is shown as follows: 
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Figure 19: Synthesis of siRNA-PEG-LHRH conjugates and self assembly of 
polyelectrolyte. The figure was copied from reference “P57 P”( Kim, S. H.; Jeong, J. H.; Lee, 
S. H.; Kim, S. W.; Park, T. G. Bioconjugate Chemistry 2008, 19, 2156.). 
Then the so formed siRNA-PEG-LHRH conjugate associated with PEI via ionic 
interactions to form polyelectrolyte complex micelles. And they proposed the siRNA 
should sit in the core of the particle, and targeting groups will expose on the surface since 
the hydrophilic PEG chain will form outer shell structure.  
3.3.3 Folate mediated delivery 
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It has been demonstrated that the folate receptor, which is 
glycosylphosphatidylinositol-anchored glycoprotein over expressed in several types of 
tumor cells, and the binding affinity to folate could be as high as KRdR~10 P-9 PM. Though 
there are two carboxylic acid groups that can be applied to conjugate to polymers, the 
binding affinity will be disrupted if reacting with α-carboxylic acid. In amine terminated 
PEG-Polylysines, the folate can conjugated to the end of PEG via DCC or NHS coupling. 
The formed folate-PEG-PLL complexes had shown significant enhance in gene 
transfection in KB cells but not in A549 cells which do not have folate receptors over-
expressed P58 P.  Another in vitro folate mediated delivery system for siRNA was developed 
in McCormick’s group by coupling the folate to side chain of APMA unit in the polymer. 
The poly(HPMA-stat-APMA)-b-DMAPMA was synthesized via reversible addition-
fragmentation chain transfer (RAFT) polymerization with low polydispersityP59 P. Synthetic 
scheme is shown as follows: 
 
Figure 20:  The structure of folic acid and synthetic route of polymer (HPMA-stat-
APMA)-b-DMAPMA-folate conjugates. The figure was copied from reference 
“P59 P”( Zhang, Y.; Holley, A. C.; Guo, Y.; Huang, F.; McCormick, C. L. 
Biomacromolecules 2009, 10, 936.). 
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3.3.4 Carbohydrate mediated delivery 
Carbohydrate units play an important role in the molecular recognition on cell 
surface and immunological events, and usually oncogenic transformed cells will 
overexpress oligosaccharides which can be antigen to activate antigen presenting 
lymphocytesP60 P.  The strategy used in vaccine formulation can also be applied to 
lymphocyte targeting delivery. In Hanson’ group, the mannose had been conjugated to 
polymers like polylysine as targeting moiety into macrophages and dendritic cells which 
have overexpressed mannose receptors. In contrast, the pDNA bound to galactosylated 
polylysine didn’t show detectable gene expression in macrophages in vitroP61 P.  While, the 
monosaccharide galactose can be used to target hepatoma cell via asialoglycoprotein 
receptors, which can induce the receptor mediated endocytosis. The disaccharide lactose 
composed of β-D-galactose and β-D-glucose through 1,4 linkage used to be applied to 
specifically introduce the pDNA to hepatocyte via asialoglycoprotein receptor mediated 
pathwayP62 P. The DMAEMA and NVP were copolymerized though chain growth 
polymerization initiated by carboxyl containing azo-initiator, then the terminal carboxylic 
group was conjugated to PEG diamine after activated by NHS. The other terminal amine 
of the PEG block reacted with lactose by reductive coupling to yield a galactose 
containing transfection agents (shown in Figure 21) P62P. 
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Figure 21: Conjugating lactose to the block copolymer via reductive coupling. The 
figure was copied from reference “P62 P”. 
3.3.5 Aptamer mediated delivery 
Aptamer is a sequence of nucleic acid or peptide that can specific bind to target 
molecules. It is usually selected by large random screening. In Giangrande’s group, they 
used aptamer-siRNA chimeras to target prostate cancer cells via prostate specific 
membrane antigen (PSMA). In order to verify the binding of aptamer-siRNA chimeras to 
the receptor, they did competition studies using RNA free aptamers and antibodies. To 
further demonstrate the binding, they knocked down the expression of PSMA to see the 
delivery efficiency. The aptamer-siRNAs were also claimed to be substrates for Dicer P63 P.  
4. siRNA delivery tracking and theranostics development 
On top of traditional chemotherapeutic strategies, RNA interference becomes 
more promising as an alternative approach. Besides the advantages achieved by the RNAi 
strategy, the tracking of these molecules in vitro and in vivo in recent years has become 
more prominent and crucial to preclinical studies. The fundamental understanding of the 
mechanism of siRNA and vector complexation, stability, internalization, cellular 
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trafficking, dissociation and incorporation in to the RISC complexes, need to be 
addressed in order to lead to rational design of nano carriers. Among all the siRNA 
tracking methods, there are a few categories reported:  
4.1 Quantum dots (QD) based systems 
Quantum dots have been developed for a variety of purposes in biomedical 
applications due to its tunable optical properties and chemically stability.  Quantum dots 
can be coated with functional motifs and used as drug loading platform or can be 
absorbed into the complexes as an inclusive unit.  One successful example of co-delivery 
systems were developed by Mao et alP64 P,  where they  discovered that quantum dots were 
coated with beta-cyclodextrin coupled to amino acids such as L-Arg or L-His, and the 
drug doxorubicin (Dox) were encapsulated into the hydrophobic cavities of beta-
cyclodextrin. Significant down-regulation of target genes was observed via RT-PCR and 
Western Blot. The organization of the system provided a successful approach to combine 
the chemotherapeutic strategy with siRNA delivery and tracking.  
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Figure 22. Schematic representation of siRNA absorption and Dox loading onto L-amino 
acid β-CD modified QDs and illustration of multifunctional QDs as co-delivery system 
developed by Mao’s group. Figure adapted from publication: Li, J.-M.; Wang, Y.-Y.; Zhao, 
M.-X.; Tan, C.-P.; Li, Y.-Q.; Le, X.-Y.; Ji, L.-N.; Mao, Z.-W. Biomaterials 2012, 33, 2780. 
Lee et. al. developed systems by covalently conjugating the QDs onto siRNA 
backbones via thiol linkage and non-reducible linkage, therefore to track the release of 
the siRNA by reducing the bond and keeping the siRNA intact in cellular circulation 
respectivelyP65 P into the glioblamstoma cells U87. Also Gao et. al. reported the systems 
developed by using QDs and proton-absorbing polymeric coatings to monitor tracking in 
real-time during transfectionP66 P.  
 4.2 Organic dyes based systems 
Organic dyes are commonly used in various examinations and detections as these 
structures are flexible to incorporate into a variety of chemical structure systems. The 
choice can depend on the requirement of the systems and chemical structures.  Also 
FRET(Fluorescent resonance energy transfer) is commonly used to detect the stability, 
disassembly of the systems in a different environment to help understand the physical 
properties of the systems. Anderson et. al. has developed a nanosystem containing siRNA 
labeled with two different organic dyes as FRET pairs, therefore the complexation and 
release of the siRNA chains from the systems can be reflected via FRET P67P.  Yong et. al 
have developed Poly-L-lysine coated fluorescent upconversion nanoparticles for siRNA 
delivery, the tracking was performed to excite the candidate by NIR light to emit high 
signal-to-noise ratio light and enable imaging in deep tissue. Anna Moore’s group labeled 
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the membrane translocation peptide with Cy5.5 and siRNA with Dy547 to monitor the 
delivery into CNS cells. The co-localization and dissociation were visualized via confocal 
microscopyP68 P to demonstrate the release of the siRNA and the target gene knockdown 
was also observed and verified via imaging and qRT-PCR.  
 4.3 Lanthanide based systems 
Lanthanide containing systems have provided another approach for the drug 
delivery (nucleic acid delivery) tracking and MRI contrast capability. The Gd chelates are 
commonly used for MRI (nuclear magnetic resonance imaging), which is a non-invasive 
approach for high resolution tomographic imaging technique. The MRI doesn’t require 
ionizing radiation, and is the most reliable way to acquire soft tissue imaging. The Gd 
related magnetic resonance imaging is based on the TR1R relaxation. The TR1 Rrelaxation 
times are different among different tissues, such as in lipid tissues, the relaxation rate is 
much higher than those in hydrophilic tissues and the vasculature; therefore the relaxation 
time is shorter. In order to obtain better imaging for the area of interest, the agent that is 
administrated has to increase the relaxation rate. One approach is to increase the water 
coordinate sites of the paramagnetic substance; therefore the water exchanging will be 
accelerated. If the tumbling rate of the environment is similar to the Larmor frequencies 
of proximal water protons, they will absorb these emitted photons and relax to 
equilibrium. There are several parameters to affect the relaxivity of bulk water, like 
distance of the proton from the paramagnetic ion (r), rotational motion (τRr R), time of 
proton localization in the proximity of the paramagnetic ion (τRmR), electron relaxation time 
in the paramagnetic ion (τRe R), and number of water coordinate sites to the paramagnetic 
center (q). Gd(III) and Mn(II) which are the commonly studied contrast agents, yet are 
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toxic towards biological objects, therefore chelates that can stably frame the ions are 
required for the design for the purpose of biological applicationsP69 P.  The Gd based nucleic 
acid delivery systems have been developed according to the criteria that combining the 
delivery and imaging into one nanoparticle. Bryson and Reineke synthesized step growth 
polymers by combining the oligoamines and DTPA into one polymer chain, therefore 
obtaining polycation structures containing lanthanide chelatesP69 P.  
 
Figure 23.  Structures of polycations containing lanthanide chelates. Two analogous 
structures that differ in the length of the ethyleneamine block in the repeat unit (3a or 3b 
containing 3 or 4 ethyleneamines, respectively). These two analogs can be chelated with 
either EuP3+ Por GdP3+P for microscopy and MRI imaging respectively. Figure was used with 
permission from the publication: Bryson, J. M.; Fichter, K. M.; Chu, W.-J.; Lee, J.-H.; Li, J.; 
Madsen, L. A.; McLendon, P. M.; Reineke, T. M. Proceedings of the National Academy of Sciences 
2009. 
The polymers were chelated with Eu P3+ P and GdP3+ P respectively to achieve 
luminacent and MRI contrast properties. The oligoamines domains endowed the 
polymers with positive charges to electrostaticly bind to pDNA. The cellular uptake study 
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and confocal imaging showed the polyplexes were successfully uptaken by the HeLa 
cells. However, the target gene expression was not consistent with cellular uptake and 
showed no significant gene expression. In Sneha Kelkar et. al. study from Reineke’s 
group, she had extended the oligoamine domain to include five and six secondary amines 
in an effort to improve the performance of the polymers on pDNA delivery. In the 
flowcytometry and luciferase studies, significant pDNA uptake and expression was 
observed to demonstrate the success of rational design of polymeric vectorsP70P.  
Miller et. al. also developed Gd P3+ P containing liposomes that exhibited a size less 
than 100 nm. The particles were visualized to accumulated in tumor tissues via MRI. The 
capacity of pDNA transfection was also observed via fluorescence microscopyP71 P.   
Apart from the examples listed above, there are many other advances in 
nanomedicines that have combined the therapeutic, targeting and diagnostic functions 
covalently or non-covalently into a single nanoscaled compartment. For example, gold 
nanoshells form multifunctional nanosystems, radio active labeled nanosystems, carbon 
nanotubes have been developed for multifunctional purposes.   
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Chapter2: 
Carbohydrate Based Cationic Polymers for siRNA Delivery-- Role of 
Polymer Length, Carbohydrate Size, and Nucleic Acid Type 
 
This chapter is based on the publication: 
 L. Xue, N. Ingle, T. M. Reineke, “Highlighting the Role of Polymer Length, 
Carbohydrate Size, and Nucleic Acid Type in Potency of Glycopolycation Agents for 
pDNA and siRNA Delivery” Biomacromolecules, 2013, 14 (11), pp 3903–3915. 
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Background 
While nucleic acids such as small interfering RNA (siRNA) and plasmid DNA 
(pDNA) are promising research tools and therapeutic modalities, their potential in 
medical applications is limited by a fundamental mechanistic understanding and 
inadequate efficiency.  Herein, two series of carbohydrate-based polycations were 
synthesized and examined that varied in the degree of polymerization (n)—one 
containing trehalose [Tr4(n) series: Tr4(23), Tr4(55), Tr4(77)] and the other containing 
beta-cyclodextrin [CD4(n) series: CD4(10), CD4(26), CD4(39), CD4(143), CD4(239)]. 
In addition, two monosaccharide models were examined for comparison that contain 
tartaramidoamine (T4) and galactaramidoamine (G4 or Glycofect) repeats. Delivery 
profiles for pDNA were compared with those obtained for siRNA delivery and reveal that 
efficacy differs significantly as a function of carbohydrate type, nucleic acid type and 
dose, polymer length, and presence of excess polymer in the formulation. The Tr4 
polymers yielded higher efficacy for pDNA delivery, yet, the CD4 polymers achieved 
higher siRNA delivery and gene down regulation.   The T4 and Glycofect derivatives, 
while efficient for pDNA delivery, were completely ineffective for siRNA delivery.  A 
strong polymer length and dose dependence on target gene knockdown was observed for 
all polymers tested. Also, free polymer in solution (uncomplexed) was demonstrated to 
be a key factor in promoting siRNA uptake and gene down regulation.  
Introduction 
The discovery of RNA interference by Fire and Mello P1 P has been a milestone on 
the revolutionary journey of modern therapeutics. Dramatic attention has been drawn to 
the investigation and development of small interfering RNA (siRNA)-related gene 
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silencing techniques, both as research tools and potential therapeutic strategies. PP2, 
3_ENREF_2 Currently, the major challenge to the translation of this discovery into novel 
therapeutics is the inadequate delivery of siRNA to target sites of therapeutic interest.4 
Once in the cytoplasm, siRNA is able to assemble with the components of the RNA-
induced silencing complex (RISC) to initiate the cleavage and degradation of its 
corresponding mRNA. In this manner, the production of the corresponding protein is 
diminished.2 However, the anionic nature of siRNA and its vulnerability to enzymatic 
degradation (when unmodified) limits the cellular internalization of ‘naked’ siRNA.4, 5 
Therefore, development of safe and effective systems for siRNA delivery has received 
extraordinary attention.  
There are many different approaches currently being taken to the development of 
delivery vehicles for siRNA, including polymers, lipids, viruses, gold nanoparticles, 
carbon nanotubes, and other nanosystems.4, 6-12 In particular, polymer-based delivery 
vehicles offer tunable structures and versatile combinations of different functionalities 
that allow achievement of desirable properties, including particle size, surface charge 
(zeta potential), and targeting ligand incorporation.12 Cationic polymers can bind with 
anionic siRNA to form polyplexes via electrostatic interactions and hydrogen bonding, 
thereby neutralizing the siRNA negative charge and protecting it from degradation. An 
early example of an efficient nucleic acid delivery polymer is polyethylenimine (PEI), 
which has had limited use in the clinic due, in large part, to its high toxicity at effective 
doses.13,14 Currently, there are some polymer-based candidate siRNA formulations at 
different stages of clinical trials.4 The first targeted delivery of siRNA in humans, 
reported in 2009, is based upon the use of a cyclodextrin-containing cationic polymer.15  
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Figure 1. Schematic structures of the carbohydrate-containing cationic polymers [Tr4,16 
CD4,17 T4,18 and G4 (Glycofect)18] examined in this study, which span a large range in 
carbohydrate size (small to large). 
 
 
Figure 2. Schematic showing the different delivery destination of siRNA (cytoplasm) 
and pDNA (nucleus). In this study we also examine the role of free polymer, which also 
affects cellular entry and intracellular delivery.   
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Previously, we have developed several series of carbohydrate-based cationic 
polymers (Figures 1 and 2) that successfully deliver pDNA to various cell types in 
vitro.16-21 By alternating the carbohydrate type (both mono-, di-, and oligo-saccharides) 
and oligoethyleneamine length (between 1-6 in the repeat unit) within the polymer 
backbone, efficient pDNA delivery has been achieved with generally low concomitant 
cytotoxicity.16-21 The optimal structures for these series of polymers have mainly 
contained the pentaethylenetetramine moieties in the repeat unit.  The structure-activity 
relationships have been extensively studied and shown to be strongly dependent on the 
type of carbohydrate and oligoethyleneamine length for pDNA delivery.16-21 For example, 
when considering preliminary studies with cationic beta-cyclodextrin and trehalose click 
polymers (Figure 1A and 1B),  the delivery efficiency of pDNA and toxicity profile has 
been shown to depend on the molecular weight (typically, longer polymers reveal higher 
delivery efficiency and toxicity); however this is highly dependent on cell and polymer 
type.16, 17 Also, the trehalose analogs (Figure 1A) form stable polyplexes that have been 
found to remain mostly as discrete polyplexes in cell culture media containing fetal 
bovine serum, which could aid in cellular internalization and trafficking, promoting 
efficacy.19 While many delivery vehicles have been examined for pDNA delivery and 
assessed for structure-activity relationships (SAR) in vitro for gene expression, results 
examining siRNA SAR will likely be divergent.  Because of the significant differences 
between siRNA and pDNA, including molecular weight and subcellular target site, 
previously-derived structure-activity relationships cannot be directly translated from 
pDNA delivery to siRNA delivery.22-24_ENREF_24 In a recent study by Salcher et. al., a 
series of branched four-armed oligomers with either terminal cysteine or alanine groups 
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affected polyplex stabilization and delivery efficiency of siRNA and pDNA.25 Structures 
with terminal cysteines appeared to stabilize the complexes and promote high delivery of 
both nucleic acid types.  However, the type of oligoethyleneamine in the branches 
yielded clear differences in efficacy for siRNA (tetraethylenepentamine was best for gene 
knockdown) versus pDNA (pentaethylenehexamine was best to promote transgene 
expression).25 In addition, many new delivery systems are being developed and examined 
specifically for siRNA delivery. A related study by Frohlich et. al. has also reported the 
structure-activity relationships of a new family of oligo (ethane amino) amides with lipid 
modifications, which had different molecular shapes (described as ‘i’, ‘T’, and ‘U’ –
shaped oligos); the oligo shape affected siRNA delivery and  gene knockdown where 
C18 lipid modification appeared to play the largest role in increasing gene knockdown.26   
Herein, a systematic evaluation of siRNA-mediated gene knockdown has been 
examined for a series of carbohydrate-containing ‘click’ polymers. The series of 
polymers were synthesized to contain either a trehalose [Tr4(n)] or beta-cyclodextrin 
[CD4(n)] moiety copolymerized with a oligoethyleneamine monomer via copper-
catalyzed azide/alkyne cycloaddition. In addition, models containing galactaramidoamine 
(Glycofect) or tartaramidoamine (T4) repeats were also created for comparison, thus 
spanning a large range in saccharide size (small to large, Figure 1). The effects of 
saccharide type, polymer length, and nucleic acid type (pDNA and siRNA), and presence 
of free polymer on polyplex formation and cellular delivery were examined. We reveal 
that all of these parameters all play a large role in the formation of polyplexes and 
delivery efficacy of both pDNA and siRNA in cultured U-87 (glioblastoma) cells largely 
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due to chemical differences in the vehicles (Figure 1) and the inherent differences in 
mechanism/site of action for pDNA versus siRNA (Figure 2). 
Experimental Section 
Materials and Methods  
General 
U-87 MG-luc2 (U-87_luc2) cells, human glioblastoma cells genetically 
engineered to constitutively express luciferase, were obtained from Caliper LifeSciences, 
Inc. (Mountain View, CA). Luc2 siRNA, which targets luc2 luciferase, and a Cy5-labeled 
Luc2 siRNA were obtained from Integrated DNA Technologies, Inc. (Coralville, IA). 
The sequence of the sense strand of the Luc2 siRNA is 5’-
GGACGAGGACGAGCACUUCUU-3’, and the antisense strand sequence is 3’-
UUCCUGCUCCUGCUCGUGAAG-5’. The Cy5 fluorophore within the Cy5-labeled 
Luc2 siRNA was conjugated to the 3’ terminus of the sense strand (5’-
GGACGAGGACGAGCACUUCUU-Cy5-3’). Scrambled siRNA (siCon) was purchased 
from Dharmacon, Inc (Lafayette, CO). DMEM+GlutaMAXTM-I (DMEM), Opti-MEM 
I+GlutaMAXTM-I (Opti-MEM), UltraPureTM Agarose-1000, MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), propidium iodide (1.0 mg/mL 
solution in water), PBS pH=7.4, trypsin, antibiotic-antimycotic and Lipofectamine™2000 
(Lipo) were obtained from Invitrogen, Inc. (Carlsbad, CA). DEPC-treated water for the 
RNA work was obtained from Fisher Scientific (Pittsburgh, PA). INTERFERin™ was a 
gift from Polyplus-Transfection (Strasbourg, France). jetPEI™ was purchased from 
Polyplus-Transfection (above). The Luciferase Assay System was obtained from 
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Promega Corporation (San Luis Obispo, CA). Bio-Rad DC Protein Assay Reagent A, 
Reagent B, and Reagent S were obtained from Bio-Rad Laboratories, Inc. (Hercules, CA). 
CellScrub™ Buffer was obtained from Genlantin, Inc. (San Diego, CA).  Bovine albumin 
and all chemicals used in polymer synthesis were purchased from Sigma-Aldrich (St. 
Louis, MO). Spectra/Por® dialysis membranes (MWCO: 6,000-8,000 and MWCO: 3,500) 
were obtained from Spectrum Laboratories, Inc. (Rancho Dominguez, CA). Glycofect 
Transfection ReagentTM, having a degree of polymerization of approximately 11 was 
donated by Techulon, Inc. (Blacksburg, VA). Polymer T4 (nRwR=12) was synthesized by 
our previously published method. 21, 27.  
Synthesis and characterization of the carbohydrate-containing monomers and 
polymers 
The synthetic routes (scheme was listed at the end of this section and 
characterization in the results section) for the monomers and polymers have been 
reported in our previous publications,16, 17, 19 with some slight modifications. In brief, the 
dialkyne-pentaethylenetetramine monomers were synthesized from 
pentaethylenehexamine by protecting the primary amines with trifluoroacetyl groups and 
secondary amines with tert-butoxylcarbonyls (Boc). The product was recrystallized twice 
from ethanol, followed by the deprotection of the primary amines by refluxing in aqueous 
methanol with potassium carbonate. The primary amines were then coupled to propiolic 
acid using dicyclohexyl carbodiimide (DCC). The dialkyne-pentaethylenetetramine 
monomer was purified by chromatography [silica gel, 5% (v:v) ethanol in 
dichloromethane (DCM)] and further recrystallized from ethyl acetate/hexane (1:3 v:v). 
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The total % yield from starting material to final dialkyneoligoethylene amine monomer 
product was 34%.  
2,3,4,2’,3’,4’-hexa-O-acetyl-6,6’-diazido-6,6’-dideoxyl-D-trehalose was also 
synthesized according to a previously-published procedure.19 The final product was 
purified on a silica gel column using 10% (v:v) diethyl ether in DCM. Fractions 
containing the product were collected, the solvent was evaporated, and the products were 
further recrystallized from 10% (v:v) ethyl acetate in diethyl ether to yield fine white 
crystals. The total % yield from starting materials to final product was 33%.  
The protected (OAc) diazide-β-cyclodextrin monomers were synthesized and 
purified exactly according to our previously published procedure.17 The total % yield 
from starting materials to final product was 10%.  Generally, the polymerization of the 
trehalose and β-cyclodextrin monomers with the dialkyne-pentaethylenetetramine 
monomer was performed in a 1:1 (v:v) solution of tert-butyl alcohol and water under 
catalysis of copper(I), generated in situ from CuSOR4R and sodium ascorbate, at 50-70oC to 
yield the protected (OAc and Boc) polymers. The product was dried under vacuum, 
followed by the deprotection of the acetal groups with sodium methoxide in methanol 
and deprotection of Boc with trifluoroacetic acid in dichoromethane. The final products 
were purified by dialysis against ultrapure water, then lyophilized and analyzed by NMR 
and GPC (Table 1). The total % yields from polymerization to deprotection of the 
trehalose polymers and cyclodextrin polymers were 23% and 18% respectively. 
Characterization data for these polymers are available in result sections. 
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Synthetic routes for the click polymers 
1. Synthesis of acetylated diazido trehalose monomer 
 
2. Synthesis of dialkyne pentaethyleneamine monomer 
 
 
3. Synthesis of dialkyne cyclodextrin monomer 
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4. Copper(I) catalyzed azide alkyne click polymerization and polymer deprotection for 
trehalose polymers 
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4. Copper(I) catalyzed azide alkyne click polymerization and polymer deprotection for 
cyclodextrin click polymers 
 
Scheme 1. Synthesis of trehalose pentaethylene click polymer and cyclodextrin 
pentaethylene click polymer. 
Polymer siRNA binding studies via gel electrophoresis shift assays  
Agarose gels [2% (w/v)] were prepared by dissolving 1 g agarose in 50 mL TAE 
buffer (40 mM Tris-acetate, 1 mM EDTA) while heating. Immediately before the gel 
solution was poured in the gel electrophoresis chamber and cooled to ambient 
temperature, 4 µL of ethidium bromide (10 mg/mL) was added. The polyplexes were 
formed by adding 10 µL of each polymer solution at various concentrations to 10 µL of 2 
µM siRNA solution in RNase-free (DEPC-treated) water. The N/P ratio indicates the 
polymer/nucleic acid ratio for polyplex formulation (the number of secondary amines on 
polymer backbones to the number of phosphate groups on the nucleic acid backbones to 
form the polyplex solutions) as previously described.16, 17, 19 The polyplexes were 
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incubated at room temperature for 30 min. 2 µL of BlueJuice™ loading buffer 
(Invitrogen) was added to each polyplex solution shortly before loading onto the gel. 
Electrophoresis was performed at 65 V for 45 min. The complexation of siRNA by the 
polymer was indicated by the lack of gel migration (or shift) of the siRNA-containing 
bands.  
Polyplex formation and analysis via dynamic light scattering (DLS) 
Hydrodynamic diameters of the polymer-siRNA polyplex formulations were 
determined by dynamic light scattering (DLS) using a ZetaSizer (Nano ZS) instrument 
from Malvern, Inc. (Worcestershire, United Kingdom) equipped with a 633-nm laser. For 
each size measurement, polyplexes were formulated by addition of 33 µL of polymer 
solution in RNase-free water to 33 µL of 2 µM siRNA solution in RNase-free water at 
room temperature forming complexes at various N/P ratios. The formation of polyplexes 
was monitored by performing DLS measurements at 0, 5, 10, 15, 30 and 60 min after 
solution mixing.  Each polyplex solution was then diluted to a final volume of 750 µL 
with RNase-free water for zeta potential measurements of each sample in triplicate. 
The stability of the polyplexes in transfection media was studied by adding Opti-
MEM (70 µL) or serum-containing DMEM (70 µL) to polyplex solutions (66 µL) in 
RNase-free water 30 min after mixing of the polymer and siRNA solutions. DLS 
measurements were then performed at the indicated time points (up to 24 h).  
Cell culture studies 
In case of siRNA, luciferase-expressing glioblastoma cells (U-87_luc2) were used 
for target gene (luciferase) down-regulation efficiency experiments, cellular uptake 
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studies, and MTT assays for cell viability. In addition non-luciferase expressing 
glioblastoma cells (U87MG) were used in up-regulation efficiency experiments and 
cellular uptake with plasmid DNA. The cells were grown in complete DMEM 
(supplemented with 10% (v:v) fetal bovine serum (FBS) and 1% antibiotic-antimycotic 
solution (containing penicillin, streptomycin, and amphotericin B) at 37oC and 5% COR2R.  
Luciferase assay and protein assay 
Luciferase-expressing glioblastoma cells (U-87_luc2) were seeded at 50,000 
cells/well in 24-well plates 24 h prior to transfection. In general, anti-luciferase (Luc2) 
siRNA, control (siCon) siRNA, and polymer stock solutions were diluted with RNase-
free water, and the polyplexes were formed by the addition of 33 µL of polymer solution 
to 33 µL of siRNA solution, followed by incubation for 30 min at room temperature. The 
resulting polyplex solutions were then added to pre-warmed Opti-MEM or DMEM to 
yield transfection solutions. Cells were washed with PBS before the addition of 200 µL 
of the transfection solution.  
The formation of siRNA-containing lipoplexes using Lipofectamine™ 2000 and 
complexes with INTEFERin™ were performed according to the manufacturer’s protocol.  
Polyplexes with the carbohydrate polymers were formulated at various N/P ratios as we 
previously described.17, 18 The cells were incubated with polyplex/lipoplex solutions for 4 
h before complete DMEM was added.  Forty eight hours later, the cells were washed with 
500 µL PBS and treated with 1x cell lysis buffer (Promega, Madison, WI) for 15 min at 
room temperature.  Aliquots (5 µL) of cell lysate were examined on 96-well plates with a 
luminometer (GENios Pro, TECAN US, Research Triangle Park, NC) for luciferase 
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activity over 10 s. For each well, 100 µL of luciferase assay substrate (Promega, Madison, 
WI) was added. The average of duplicate measurements on each individual replicate was 
utilized for calculation. The amount of protein (mg) in cell lysates was calculated using a 
standard curve generated with bovine serum albumin by following the protocol included 
in Bio-Rad DC protein assay kit. The relative light unit (RLU)/mg protein was then 
calculated and averaged across replicate wells. The protein and luciferase levels of non-
transfected cells were used for normalizing the data and calculating the extent of gene 
knockdown. Each treatment was tested in triplicate in 24-well plates.  
For the experiments examining pDNA delivery, non-luciferase expressing 
U87MG cells were plated 24 hours prior to transfection at a cell density of 50,0000 
cells/well in 24-well plates in DMEM culture media containing 10% FBS. Polyplexes 
were formulated with luciferase plasmid DNA (gWiz-luc) at respective N/P ratios and 
incubated at room temperature for 1 h prior to transfection. The cells were then 
transfected in the presence of either (1) serum-free a OptiMEM media or (2) DMEM 
media containing 10% FBS. 
Cellular uptake measurement by flow cytometry 
Flow cytometry was performed to examine the cellular uptake of Cy5-labeled 
siRNA with various formulations at 3 h post-transfection. In general, U-87_luc2 
glioblastoma cells were seeded at 300,000/well in 6-well plates 24 h prior to transfection. 
To transfect, 33 µL of each polymer solution was added to 33 µL of 2 µM Cy5-labeled 
siRNA solution. After 30 min incubation at room temperature (to form the polyplexes), 
each polyplex solution was pipetted into 1584 µL of pre-warmed Opti-MEM to yield the 
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final transfection solution. Each well was treated with 500 µL of the obtained transfection 
solution. After 3 h, the media was removed and cells were washed with 500 µL/well 
CellScrub™ Buffer for 15 min at room temperature. The CellScrub™ Buffer was then 
aspirated and cells were exposed to trypsin (0.05% (w/v), 500 µL/well) for 3 min to 
provide detachment from the plate, then complete DMEM (500 µL/well) was applied to 
inhibit trypsin. The cell suspension was collected and centrifuged at 1000 rpm for 10 min 
at 4oC. The supernatant was removed and cells were twice washed with 0.5 mL PBS and 
centrifuged to remove the extracellular polyplexes. Finally, 1 mL PBS was added and the 
suspensions were kept on ice prior to flow cytometry analysis. Propidium iodide (2.5 µL) 
was added prior to the analysis. The flow cytometer (FACSCalibur and FACSVerse, 
Becton Dickenson, San Jose, CA) equipped with a helium-neon laser to excite Cy5 at 633 
nm was used to count twenty thousand events for each sample. The threshold 
fluorescence level was defined by manually adjusting the positive region such that <1% 
of negative control cells were positive for fluorescence.  Each treatment was performed in 
triplicate. For pDNA delivery experiments, non-luciferase expressing cells (U87MG) 
were transfected with Cy5 labeled plasmid DNA and analyzed for uptake via flow 
cytometry analysis. 
MTT assay 
MTT reagent (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) 
was used to estimate the cytotoxicity of the formulations.   Typically, U-87_luc2 
glioblastoma cells were seeded at 50,000 cells/well in 24-well plates 24 h prior to 
transfection. The polyplexes were formed following the procedure described above. 200 
µL of transfection media was added to each well; 4 h later, complete DMEM was added 
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at 1 mL/well. Then, 24 h later, the media was aspirated and the cells were washed with 
PBS (500 µL/well). 1 mL of serum-containing DMEM with 0.5 mg/mL of MTT was 
added to each well and cells were incubated for 1 h. The media was then replaced with 
600 µL of DMSO for 15 min at room temperature. A 200 µL aliquot of the media was 
transferred to a well of a 96-well plate for analysis by colorimeter with wavelength at 570 
nm. Samples of non-transfected cells were used for normalization.  
Statistical Analysis 
Statistical analysis was performed at alpha level of 0.05 using JMP software (SAS 
Campus Drive, Cary, NC). The Tukey-Kramer HSD (honestly significant difference) was 
used to test significant differences among all means. In addition, a Student’s t-test was 
used to further find significant differences in cases where the differences were apparent 
but not detectable by Tukey’s test.  All significant differences are denoted by asterisk (*) 
mark. 
Results 
Preparation and characterization of polymer vehicles 
We have previously published the main synthetic procedures for all of the model 
polymers examined in this study.  T4 and Glycofect (G4) were examined at one length 
(degree of polymerization, n ~ 12) due to difficulties in the synthesis of these models at 
longer lengths.18, 20, 27  For the click polymer models, we obtained two series of polymers 
that vary in the carbohydrate type (trehalose or beta-cyclodextrin) in the repeat unit and 
the polymer length (Table 1), which was obtained by varying the reaction conditions as 
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previously described.16, 17,19, 28  Each novel polymer prepared for this study is referred to 
by a name indicating the carbohydrate (i.e. ‘Tr’ for trehalose, ‘CD’ for β-cyclodextrin, “T” 
for tartarate), number of secondary amines (4), and the weight-averaged number of repeat 
units (nRwR).  
Table 1. GPC characterization of the click polymers. MRwR: weight-averaged molecular 
weight. MRnR: number-averaged molecular weight. Đ (MRwR/MRnR): polydispersity index. nRwR: 
weight-averaged number of repeat units.  The degree of polymerization (n) for Glycofect 
is ~11 according to the manufacturer. 
Polymer M Rw M Rn Đ (M RwR/M RnR) nRw 
T4(12) 4.3kDa 3.9kDa 1.1 12 
Tr4(23) 17.2 kDa 10.2 kDa 1.7 23 
Tr4(55) 40.5 kDa 18.4 kDa 2.2 55 
Tr4(77) 56.1 kDa 37.6 kDa 1.5 77 
CD4(10) 15.7 kDa 12.6 kDa 1.2 10 
CD4(26) 39.0 kDa 26.8 kDa 1.5 26 
CD4(39) 58.7 kDa 34.2 kDa 1.7 39 
CD4(143) 217.6 kDa 105.9 kDa 2.0 143 
CD4(239) 363.5 kDa 177.5 kDa 2.0 239 
 
NMR Measurements 
1H NMR measurements were performed with a temperature-controlled Varian 400-MR 
spectrometer operating at a frequency of 399.7 MHz. Samples were prepared in D R2RO 
(HOD internal standard).  
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A). 
 
B). 
 
Figure 3: 1H-NMR characterization of polymers Tr4 and CD4. A). Tr4(77): δ 2.90-3.05 
m 17H, 3.05-3.12 t 2H,  3.30-3.35 dd 2H, 3.50-3.52 d 4H, 4.00-4.02 t 2H,  8.28 s 2H.  
The corresponding peaks were assigned according to 1H1H-COSY. B). 1H-NMR of 
CD4(26). δ 3.30-3.60 m 20H, 3.65-4.11 m  42H, 5.15-5.33 d 7H, 8.60 s 2H.   
Size Exclusion Chromatography 
Size exclusion chromatography (SEC) was applied to determine the number-average 
molecular weight (Mn) and polydispersity indices (PDIs) for trehalose polymers and 
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cyclodextrin polymers.  The mobile phase for trehalose polymer is a solution of 0.5% 
sodium acetate (pH=5.5 with acetic acid) containing 20% acetonitrile.  The mobile phase 
for cyclodextrin polymers is a solution of water: methanol: acetic acid (70:25:5).  
 A flow rate of 0.3 mL/min in the column (Eprogen Inc., IL), on a Wyatt HELEOS II 
(Santa Barbara, CA) light scattering  d etector (λ = 6 6 2 n m), and  an Op tilab rEX 
refractometer (λ = 6 5 8  n m) were u sed . The Mn, PDI, and  d n/d c of the p oly mers were 
determined by Astra V (version 6.0, Wyatt Technologies).  
 
Figure 4: SEC characterization for trehalose polymer Tr4(77) (A) and cyclodextrin 
polymer CD4(26) (B). 
 
Gel electrophoresis study of polymer-siRNA complexation  
Formulations of siRNA at various N/P ratios (polymer-amines / siRNA-
phosphates) were prepared with each of the ten different cationic polymers.  Three 
trehalose-containing click polymers (Tr4(23), Tr4(55), and Tr4(77)) and five β-
cyclodextrin-containing click polymers (CD4(10), CD4(26), CD4(39), CD4(143), and 
CD4(239)) were examined. In addition, the results here in were compared to two 
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polymers described previously; the poly(glycoamidoamine) structures containing four 
secondary amines per repeat group and either L-tartarate (T4) or meso-galactarate (G4 or 
“Glycofect”).18,20 These formulations were subjected to electrophoretic analysis in an 
agarose gel to assess polymer-siRNA interaction (Figure 5).  
A). 
 
 
 
 
B). 
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Figure 5. The binding of polymers with siRNA examined by agarose gel electrophoresis 
shift assays. A). Photographs of gels for T4, Glycofect, Tr4(23), Tr4(77), CD4(10) and 
CD4(239) at various N/P ratios. The wells where the gel was loaded is at the bottom of 
each gel photograph (near the - electrode) and the pDNA, if uncomplexed, migrates to the 
top of the gel photograph (towards the + electrode). B). Photographs of gels for T4(55), 
CD4(26), CD4(39) and CD4(143) at N/P ratios: 1, 2, 3, 4, 5, 6, 8, 12 and 18. 
Polymer T4 containing 12 repeat units has been successfully used to complex 
pDNA at a low N/P ratio of 1 and effectively delivers pDNA to various cell lines at N/P 
ratios of 5-30; 27; however, surprisingly, evidence of free siRNA in the gel is apparent for 
all N/P ratios tested that were at or below 30.  At some N/Ps, blurred areas can be seen, 
which indicates some interaction between polymer and siRNA, but full complexation was 
not achieved even at the highest tested N/P ratio of 50.  A similar affect was noticed with 
Glycofect (complexes pDNA at an N/P ratio of 2),20   however, retardation of siRNA 
migration was noticed at a high N/P ratio of 30 and 50 (yet blurring of the pDNA band 
was still noticed).  Binding of siRNA by all analogs of the trehalose and β-cyclodextrin 
polymers was noticed at significantly lower N/P ratios, with N/P=4 being sufficient to 
ensure the complete retardation of siRNA migration (thus indicating binding and 
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polyplex formation) for even the shortest versions of these polymers [Tr4(23) and 
CD4(10)].  This indicates that carbohydrate type plays a role in complex formation since 
the T4, Glycofect, CD4(10), and Tr4(23) polymers all had similar degrees of 
polymerization yet very different N/P ratios of binding siRNA.  Comparing the binding 
ability among polymers of different length within the same series (Figure 5, no clear 
trend was observed; however, it should be noted that longer Tr4 and CD4 polymers tend 
to retard the migration of siRNA at somewhat lower N/P ratios than their shorter 
analogues. Because the siRNA-polyplexes with T4 and Glycofect did not appear to be 
stably complexed (Figure 5), the DLS data for these polymers was not reported in the 
subsequent section. 
Dynamic light scattering (DLS) study 
Particle size and zeta potential (surface charge) are two physical parameters that 
affect the performance of polyplexes both in vitro and in vivo for nucleic acid delivery. 
To study the complexation process, dynamic light scattering (DLS) measurements of 
polyplex hydrodynamic diameter were performed at 0, 5, 10, 15, 30 and 60 min time 
points after the addition of a polymer solution to siRNA solution (that were diluted with 
RNase free water).  After 60 min, size measurement was made and the zeta potential of 
each formulation was also measured.  The polyplexes were formulated at an N/P ratio of 
50 as that was found to yield optimal gene down regulation in culture experiments (vide 
infra).   
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A). 
 
 
 
 
 
B).                                                                       C).
 
Figure 6. Dynamic light scattering study to monitor complexation of siRNA at different 
conditions. A). Polyplexes formed at N/P=50 in RNase-free water at 25 oC.  Nanoparticle 
size (hydrodynamic diameter) was measured at the indicated timepoints from 0 min to 60 
min. Zeta potential (triangles) was measured after the 60 min timepoint. All the 
experiments were completed in triplicate.  It should be noted here that both T4 and 
Glycofect did not form polyplexes with siRNA according to DLS. B). C). Stability of 
polyplexes in two kinds of transfection media as measured by dynamic light scattering. 
Both (B) reduced-serum Opti-MEM and (C) complete DMEM (with 10% FBS) were 
applied to polyplexes as transfection media, and particle size was measured at indicated 
68 
 
time points through 24 h at room temperature. Tr4(77) was the polymer used in this study 
with three N/P ratios (10, 30, and 50) tested.  
To study the stability of the polyplexes in reduced-serum and serum-containing 
transfection media, Tr4(77)-siRNA polyplex sizes were examined in both transfection 
media at selected timepoints up to 24 h at room temperature (Figure 6B-C).  In Opti-
MEM, the polyplexes were relatively large (~400-800 nm) and measurement results 
fluctuated significantly; however, most measured sizes were larger for all subsequent 
timepoints than they were for t=0 (this was true for Lipofectamine and for Tr4(77) at 
N/P=10 and N/P=30; only Tr4(77) at N/P=50 showed no apparent trend in size change 
over time).  In serum-containing DMEM, particles formed with Lipofectamine decreased 
in size significantly (from ~600 nm to ~200 nm) at 24 h versus all prior timepoints.  It is 
also should be noted that, in contrast to the particles formed with Lipofectamine, the size 
of polyplexes formed using Tr4(77) differs significantly between Opti-MEM (~400-800 
nm) and complete DMEM (~150-300 nm). In addition, the relative amount of Tr4(77) in 
the formulation (N/P=10, 30, or 50) did not influence the size of nanoparticles in either 
transfection medium.   
By monitoring the formation of polyplexes over 60 min (Figure 6), we did not 
observe any significant change in size over time. That is, the hydrodynamic diameter 
measured immediately after mixing the siRNA and polymer solutions (0 min) is 
essentially the same throughout 60 min of incubation, indicating that the polyplex 
formation is extremely rapid and that, once formed, the complexes do not change in size.  
For the Tr4 series of polymers, Tr4(23) and Tr4(55) form polyplexes with hydrodynamic 
diameters of around 200 nm; Tr4(77), however, yields significantly smaller (36 nm) 
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polyplexes. The same phenomenon was observed for the CD4 series: while shorter 
polymers (10, 26 and 39 repeat units) form polyplexes with siRNA of about 130-180 nm, 
the longer structures (143 and 239 repeat units) yielded polyplexes with hydrodynamic 
diameters around 40 nm.   It is interesting to note that T4 and Glycofect “complexes” at 
N/P = 50 were also analyzed via DLS, however, these polymers did not form polyplexes 
with siRNA according to DLS measurements (also in line with the gel shift assay data).   
All of the Tr4 and CD4 series of polymers tested form polyplexes with siRNA 
that have positive ζ-potentials. For the Tr4 series, a trend was observed where it was 
noticed that the ζ-potential decreased with increasing polymer length.  The ζ-potential 
drops from +24 mV for polyplexes formed with Tr4(23) to +12mV for Tr4(77)-
containing polyplexes. Surprisingly, a similar trend was not observed for the CD4 series. 
All of the CD4  poly mers, with an ex cep tion of CD4 (2 6 ), formed  p olyplexes with ζ-
potential of +25 to +30 mV.  Because of the high N/P ratio (50) used for all formulations 
tested, there is expected to be a significant amount of “free” polymer in solution (that is, 
polymer not complexed within the polyplexes), which may contribute to these results.    
Effect of polyplex formulation on siRNA delivery to cultured glioblastoma cells 
The N/P ratio and siRNA concentration were systematically examined in 
evaluation of siRNA sequence-specific target (luciferase) down-regulation (Figure 5). 
The siRNA concentrations were varied from 1 to 100 nM and N/P ratios from 8 to 50. As 
shown in Figure 5 for both polymer vehicles tested [Tr4(77) and CD4(143)], the most 
potent target gene down-regulation was observed at a siRNA concentration of 100 nM 
and N/P=50. Both polyplex types exhibited a dependence of luciferase down-regulation 
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on siRNA concentration; an inhibitory effect was observed at 30 nM, although to a lesser 
extent than at 100 nM, while no inhibitory effect was seen for siRNA concentrations of 
10 nM and below.  Similarly, dose dependence with respect to the amount of polymer 
(N/P ratio) was noticed for both polymers.  The luciferase down-regulation was strongest 
at N/P=50 and was close to 60% for both vehicles.  At an N/P ratio of 20, the down 
regulation was slightly reduced, and a biological effect was completely absent for the 
polyplexes at an N/P ratio of 8.  Finally, all samples in which luciferase expression was 
reduced showed the expected siRNA sequence specificity, for example, the same 
polyplex siRNA concentration and N/P ratio, substitution of siCon for siLuc2 abrogated 
target down-regulation, which indicates that the gene knockdown was not due to off 
target effects or toxicity of the polymer vehicle.  T4 and G4 were also examined for 
siRNA delivery (vide infra) and were completely ineffective for siRNA delivery 
(promotion of gene down regulation). 
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Figure 7.  Influence of siRNA concentration and N/P ratio on polyplex-induced target 
gene (luciferase) down-regulation in U-87_luc2 glioblastoma cells.  Notation is as 
follows: hashed bar (lighter color) indicates treatment with polyplexes containing siRNA 
and the solid bar (darker color) indicates treatment with polyplexes containing siCon. The 
numbers above the bars indicate percentage of gene down-regulation.  The notation 
Tr4(77) 50/100 indicates that polyplexes were formulated with siRNA and Tr4(77) at an 
N/P ratio of 50 and with 100 nM siRNA concentration. “siLuc2” indicates anti-luciferase 
siRNA; “siCon” indicates scrambled siRNA negative control. (A) Knockdown efficiency 
response to polyplexes formed with Tr4(77) with 100 nM siRNA at differing N/P ratio, 
(B) Extent of knockdown response to Tr4(77) polyplexes formulated at an N/P ratio of 50 
at siRNA concentrations from 1 nM to 100 nM. (C) Knockdown efficiency response to 
polyplexes formed with CD4(143) with 100 nM siRNA at differing N/P ratios, (D) Extent 
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of knockdown response to CD4(143) formulated at an N/P ratio of 50 at siRNA 
concentrations from 1 nM to 100 nM. [Note: The “*” symbol indicates significantly 
different values as compared to ‘cells only’ control (p<0.05)]. 
Promotion of siRNA-mediated gene down regulation by addition of free polymers 
 
 
Figure 8. Enhancement of siRNA delivery by polymer vehicles Tr4(77) and CD4(143) 
upon the addition of free polymer to solution. To understand the role of free polymer in 
gene down regulation, polyplexes formed at N/P = 8 were added to cells, then at time 
points of 0.5 h or 2.5 h after initial transfection, a solution containing free polymer 
equivalent to N/P=42 was added to the wells (brining effective polymer-siRNA ratio to 
N/P=50 after a time delay). For luciferase gene down regulation (graphs A and C), the 
cells were transfected with 200 µL/well of siRNA or siCon (at a final RNA concentration 
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of 100 nM/well). For Cy5-siRNA cellular uptake (graphs B and D), the cells were 
transfected with 500 µL/well of Cy5-siRNA (at a final concentration 40 nM/well). (A) 
Luciferase gene down-regulation 48 h after transfection with CD4(143)-siRNA 
polyplexes. (B) Cellular uptake of Cy5-siRNA in the different polyplex formulations with 
CD4(143) 3 h after transfection. Data is reported as the percentage of live cells positive 
for Cy5.  (C) Luciferase gene down-regulation 48 h after transfection with Tr4(77)-
siRNA polyplexes. (D) Cellular uptake of Cy5-siRNA in the different polyplex 
formulations with Tr4(77) 3 h after transfection. Data is reported as the percentage of live 
cells positive for Cy5.  Notation is as follows: hashed bar (lighter color) indicates 
treatment with polyplexes containing siRNA and the solid bar (darker color) indicates 
treatment with polyplexes containing siCon negative control. The numbers above the bars 
indicate percentage of gene down-regulation.   [Note the * symbol indicates significantly 
different values as compared to the cells only control (p<0.05)]. 
To investigate the effect of free polymer, we treated U-87_luc2 glioblastoma cells 
with free polymer 0.5 h or 2.5 h after initial exposure of the cells to CD4(143)/siRNA or 
Tr4(77)/siRNA polyplexes that were formulated at an N/P ratio of 8 (Figure 8).  The 
amount of free polymer added was such that the total amount of polymer to which cells 
were exposed (sum of polymer in polyplexes plus subsequently-added free polymer) was 
equivalent to N/P=50 (Figure 8). Addition of free polymers at the earlier time point (0.5 h 
after initiation of polyplex exposure), significantly increased siRNA internalization and 
gene down regulation for the Tr4(77) formulations but not as dramatically for the 
CD4(143) formulation, which was found to be very high at low N/P. There was close to a 
10-fold increase (from 8% to 77%) in the percentage of Cy5 positive cells for Tr4(77) 
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polyplexes with addition of free polymer, however, for CD4(143) polyplexes, a smaller 
increase from 91% to 97% was noticed. Likewise, when comparing the extent of target 
gene down-regulation for these formulations, siRNA-mediated gene knockdown 
increased from 5% for CD4(143) and 25% for Tr4(77) at N/P of 8 to 65% and 74% in 
cells with free polymer 0.5 h after transfection for CD4(143) and Tr4(77) respectively, 
achieving an effect comparable to that obtained with polyplexes formulated at N/P=50. 
Addition of free polymer at a later time point (2.5 h after original polyplex exposure) was 
shown to promote cellular internalization of siRNA to a lesser degree for Tr4(77) from 8% 
to 50%, and for CD4(143) from 91% to 94%. The increase in luciferase gene knockdown 
was also lower for this time point for polyplexes formed with both Tr4(77) (increased 
from 25% to 47%) and for CD4(143) (increased from 5% to 33%). Overall, these results 
indicate that addition of free polymer during polyplex exposure increases uptake and 
potency, suggesting that free polymer within polyplexes formed at high N/P ratios 
contributes significantly to their efficacy and likely endosomal escape.   
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Influence of polymer length on polyplex uptake and efficacy 
 
Figure 9. siRNA-mediated gene down regulation with U87-luc2 cells as a function of 
polyplex type (formed with either Tr4 or CD4 polymers) and polymer degree of 
polymerization. (A) Luciferase gene down-regulation facilitated by polyplexes 
formulated with polymer Tr4 (nRwR =23, 55, 77) at an N/P = 50 using 100 nM siRNA 
(50/100). (B) Uptake of Cy5-labeled siRNA within Tr4-containing polyplexes formulated 
at an N/P = 50 with 40 nM of siRNA (50/40) as measured by flow cytometry 3 h after 
transfection. (C) Luciferase gene down-regulation facilitated by polyplexes formulated 
with polymer CD4 (nRwR =10, 26, 39, 143, 239), at an N/P = 50 using 100 nM siRNA 
(50/100). (D) Uptake of Cy5-labeled siRNA within CD4-containing polyplexes 
formulated at an N/P = 50 with 40 nM of siRNA (50/40) as measured by flow cytometry 
3 h after transfection. In graphs A and C, the hashed bars indicate data for cells treated 
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with siRNA-containing polyplexes and the solid bars indicate data for cells treated with 
siCon-containing polyplexes (control).   The numbers above the bars indicate percentage 
of gene down-regulation. Note the * symbol indicates significantly different values as 
compared to the cells only sample (p<0.05).  
The molecular weight of polymeric biomaterials may play a significant role in 
their properties. We investigated the influence of the molecular weight (polymer length) 
on the siRNA delivery efficiency and target gene down-regulation of polyplexes made 
with Tr4 or CD4 polymers (Figure 9). For the Tr4 series, an increase in polymer length 
improves the cell internalization (denoted by an increase in the percentage of cells 
positive for Cy5-siRNA Figure 9B and 9D) and the extent of luciferase down-regulation 
(Figure 9A and 9C). Interestingly, polyplexes made with Tr4(23) yield virtually no 
detectable siRNA internalization. However, Tr4(55) and Tr4(77) polyplexes deliver 
siRNA into 90%+ of the cells. The CD4 series also demonstrated a similar trend.  
Polyplexes created from the shortest polymer, CD4(10), were only internalized by about 
30% of cells and did not reveal gene down regulation. Indeed, longer polymers were 
needed to achieve maximal siRNA uptake and target gene down-regulation up to a point, 
and then the highest molecular weight analog was not as effective.  Interestingly, 
polyplexes formed with CD4(26) and CD4(39) were found to be internalized by about 80% 
of the cells and yielded significant gene knockdown (80% and 92% respectively). This 
result was surprising as Tr4(23) was completely inactive and Tr4(55) also was less potent 
than CD4(26).  A similar result was found for CD4(143) were polyplexes were 
internalized by close to 100% of cells and 90% gene down regulation was found.  Yet, 
while polyplexes formed with the longest system, CD4(239), were internalized by close 
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to 100% of cells, gene down regulation decreased to 75%.  It should be noted that for all 
polymer-containing formulations examined in this study, no apparent cytotoxicity was 
observed 24 h after transfection according to MTT assays (for polyplexes formulated at 
an N/P=50 and siRNA concentration of 100 nM, as shown in Figure 11 in the later 
section. 
Comparison of pDNA and siRNA delivery profiles 
 
Figure 10. Comparison of pDNA and siRNA delivery efficiency for luciferase 
expression and down regulation respectively, in the absence and presence of serum. (AU, UB) 
Delivery of pDNA encoding the firefly luciferase reporter gene into U87 glioblastoma 
cells with the carbohydrate-containing polymers and controls in (A) OptiMEM and (B) 
DMEM.  Trehalose (Tr4) or β-cyclodextrin (CD4)-containing polyplexes were 
formulated with pDNA at N/P=7, while pDNA complexes with T4 or G4 were 
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formulated at N/P=20 (maximum gene expression as previously published).20, 27 (C, D) 
Delivery of anti-luciferase siRNA into U87-luc2 glioblastoma cells with the 
carbohydrate-containing polymers and controls in (C) OptiMEM and (D) DMEM. All of 
the carbohydrate-containing polymers were formulated at a siRNA concentration of 100 
nM and N/P=50. Note the asterisk “*”, symbol indicates significantly different values as 
compared to the ‘cells only’ sample (p<0.05).  
As indicated in Figure 10A, polyplexes created from pDNA and all polymers in 
the Tr4 and CD4 series (and controls), delivered pDNA to U87 glioblastoma cells as 
significant luciferase activity is observed in cells transfected in OptiMEM. For cells 
transfected in DMEM supplemented with 10% fetal bovine serum (FBS), the luciferase 
activity was lower than in OptiMEM (Figure 10C).  As published previously, both 
Glycofect and T4 yield high efficiency for pDNA delivery as indicated by high luciferase 
gene expression in H9c2(2-1) and HeLa cells.18, 29 Also, initial work has shown the Tr4 
and CD4 polymer vehicles were very active for pDNA delivery with these cell types 
_ENREF_17 and in some cases a trend was noticed that gene expression increased with 
increasing polymer molecular weight.16, 17  However, these polymers have not been 
directly assessed for siRNA delivery and these data not directly compared for pDNA 
delivery.  For the CD4 series, luciferase expression increased with polymer length from 
nRwR=10 to nRwR=39, but this trend did not continue for the high molecular weight versions 
nRwR=143 or nRwR=239. For the Tr4 series, the longest polymer tested (nRwR=77) yielded the 
highest transgene expression (Figure 10A) out of any polymer and control in serum-free 
OptiMEM and second only to PEI in DMEM.  When comparing siRNA delivery results, 
as shown in Figure 10C, polymers T4, Glycofect, Tr4(23) and CD4(10) failed to 
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effectively deliver anti-luciferase siRNA in U87_luc2 glioblastoma cells as a significant 
reduction in cellular bioluminescence was not observed. In contrast, for both the Tr4 and 
CD4 series, polymers of larger molecular weight—Tr4(55), Tr4(77), CD4(26), CD4(39), 
CD4(143) and CD4(239), all yielded significant luciferase down-regulation. The results 
in serum-free OptiMEM were dramatic, where 80-90% gene down regulation was found.  
Polymer CD4(39) yielded the highest gene down regulation of all the glycopolymers. In 
DMEM (contains 10% serum), the siRNA-mediated gene down regulation results were 
less dramatic (Figure 10D), where 60% gene knockdown was observed.  Similar to the 
pDNA delivery results, maximum delivery efficacy was obtained for both pDNA and 
siRNA for both the Tr4(77) and CD4(39) polymers. Interestingly, while T4 and 
Glycofect are potent pDNA delivery vehicles, they are completely inactive for siRNA 
delivery.  In addition, at similar N/P ratios, the Tr4 polymer series yielded higher delivery 
efficacy for pDNA (than the CD4 series); however, the opposite was true with siRNA, 
the CD4 series yielded the highest efficacy (Figures 9 and 10). 
MTT assay to evaluate the cytotoxicity 
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Figure 11: MTT assay to measure the cytotoxicity of siRNA-containing complexes in 
U87-luc2 glioblastoma cells 24 h after transfection at N/P=50 and a siRNA concentration 
of 100 nM. All the experiments were performed in triplicate. The y-axis label 
“Percentage cell viability” stands for the relative activity of mitochondria reductase 
compared with those without treatment. 
 As indicated in the Figure 11, all the formulations showed no cytotoxicity in the 
MTT study. The result indicates the polymers are promising for the future applications 
towards biomedical studies.  
Discussion 
In an effort to optimize the siRNA delivery performance with glycopolymer-
based polyplexes and understand the polymer structure – siRNA delivery efficiency 
relationships, we assessed and compared how polyplex formation and nucleic acid 
delivery (pDNA versus siRNA) differed with a series of glycopolycation vehicles 
developed in our laboratory. The chemical structure of polymeric vehicles has a direct 
influence on its ability to deliver pDNA or siRNA.23 Numerous studies have been 
published in the literature that are devoted to understanding the structure-activity 
relationships for pDNA delivery. For example, with PEI, both branched and linear 
versions of this polymer have been found to effectively deliver pDNA.30  However, when 
considering siRNA delivery, that study also revealed that branched PEI was much more 
effective at siRNA-mediated gene down regulation (60% gene knockdown) when 
compared to linear PEI, which proved completely inactive.30 It was hypothesized that the 
branched structure of PEI was able to form more stable polyplexes with siRNA.30  The 
81 
 
current study herein was undertaken to investigate the influence of carbohydrate type, 
polymer length, dose response, and the presence of excess polymer on polyplex 
formation, and nucleic acid delivery efficiency with siRNA.  With this family of polymer 
vehicles (Figure 1), we also sought to compare siRNA delivery to efficiency of pDNA 
delivery, which have much different intracellular locations and mechanisms of action 
(Figure 2).  The polymer-siRNA binding was examined by gel electrophoresis (Figure 5). 
We observed that Glycofect can minimally retard siRNA migration at N/P ratios below 
10, however, full binding of siRNA was still not observed until an extremely high N/P 
ratio of 50.  Also, with polymer T4, there is no retardation of siRNA migration at N/P 
values below 30. These results are in stark contrast to what has been previously published 
by our group for pDNA delivery (where these polymers fully bind pDNA and retard 
migration on the gel at low N/P=2).31, 32  These data indicate that these short oligomeric 
polymers (n ≈12) containing monosaccharides have very low relatively binding affinity to 
siRNA (but much stronger to pDNA).  Molecular weight of both the polymer and the 
nucleic acid play a large role in polyplex formation. It should be noted that CD4(10), 
which has the same degree of polymerization as Glycofect and T4, exhibited a significant 
improvement in siRNA binding affinity (fully bound at N/P = 4, Figure 5) according to 
the gel shift assays. Despite having the same number of repeats, these polymers differ 
significantly in molecular weight due to the large difference in sizes of their carbohydrate 
units (and the presence of the triazole groups). Interestingly, this indicates that the 
carbohydrate size plays a role in polyplex formation and binding; previous studies from 
our group have shown that this is likely promoted through hydrogen bonding between the 
nucleic acid and the hydroxyl units in the polymerized carbohydrate monomer.33, 34  
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When comparing the CD4 and Tr4 polymer series, there was little to no difference in 
siRNA binding among the polymers of different lengths as all polymer analogs bound 
siRNA at low N/P ratios (between 2-4), which is similar to that previously published by 
our group for pDNA.16, 17, 28 There is a possibility that such a difference could be 
observed for even shorter (nRwR<10) polymers within these series; however, such shorter 
polymers are likely to be poor candidates for siRNA delivery, as can be seen from the 
trends observed in the gene knockdown experiments (vide infra).   
To examine the polymer-siRNA complexation process in aqueous conditions, we 
monitored the sizes of species present over 60 min after mixing siRNA and polymer 
solutions. All of the Tr4 and CD4 polymers can readily form polyplexes (Figure 6).   As 
observed with the gel experiments, T4 and Glycofect (G4) did not form well-defined 
polyplexes (not able to observe polyplex formation in DLS) likely due to their low 
molecular weight and low binding affinity. Again, this is in contrast to the ability of these 
polymers to form well defined polyplexes with pDNA.16-21,31, 32 Similar to that observed 
with pDNA, rapid siRNA complexation was observed for all of the Tr4 and CD4 polymer 
series, and the dimensions of the polyplexes did not change significantly over 60 min 
incubation in water at room temperature. The size of the polyplexes formed with the Tr4 
or CD4 polymers decreased with increasing polymer length; the shorter Tr4 and CD4 
polymers yielded complexes having diameters of ~100 nm or above, while polymers 
Tr4(77), CD4(143), and CD4(239) yielded complexes of <50 nm (Figure6). It is also 
interesting to compare the siRNA polyplexes formed with the longer cyclodextrin 
polymers of ~50 nm diameter (N/P=50; CD4(143), CD4(239)) to that previously reported 
for pDNA, where polyplexes of ~100 nm diameter were formed with comparable 
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polymers of similar length (N/P=10; time = 45 min; CD4(93) and CD4(200)).17 On the 
contrary, the smaller cyclodextrin polymers formed larger polyplexes with siRNA of 
~150 to 200 nm diameter (CD4(26), CD4(39)), which is similar to the reported a size of 
~70 to 100 nm for pDNA polyplexes (N/P=10; time = 45 min; CD4(27) and CD4(47)).17    
These data suggest that the mechanism of polyplex formulation with long/flexible 
pDNA and short/rigid siRNA may be different. The plasmid DNA used in this study is 
several kilobase pairs, which ranges in size from 30 to 100 nm in solution.  However, 
siRNA is typically 21-27 bp and is quite small, ranging in size from 2 to 7 nm.23 Thus, 
the number of negative charges on each siRNA for electrostatic attraction of cationic 
polymers is substantially less than pDNA.23 The short polymers nRwR=23 to 55 do not seem 
to be optimal for wrapping siRNA strands into a compact polyplex. A small increase in 
the polymer length to nRwR=77 seems to offer enough length for stable siRNA polyplex 
formation. A similar trend was observed with the CD4 polymer series. When considering 
these data along with that previously published for these polymers for pDNA, it appears 
that polymers with larger molecular weight are needed to serve as a “template” for stable 
siRNA polyplex formation.  Yet, stable and compact polyplexes are able to be formed 
with short oligos/polymers and large plasmids, which may serve as the template.16, 17, 19 
Nucleic acid type (DNA versus RNA) could also drive differences in binding due to 
variances in helicity and the ribose sugar, which could affect complexation and H-
bonding.  Collectively, when considering the size, zeta potential, cellular uptake, and 
gene knockdown efficiency of different polyplex formulations, correlations relating size 
and Zeta potential to delivery efficiency were not observed. For example, polymeric 
vehicles Tr4(23) and CD4(10) failed to achieve significant siRNA delivery efficiency in 
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vitro, despite having similar polyplex size and Zeta potential to Tr4(55) and CD4(39), 
respectively, both of which demonstrated markedly improved cellular uptake and gene 
knockdown in U-87 glioblastoma cells (Figure 9).   
The observation that gene knockdown was enhanced at higher N/P ratios despite 
being able to retard siRNA migration in the gel shift assays at lower N/P ratios, led us to 
hypothesize that the polyplex solutions contain significant free polymer, which may 
strongly influence delivery efficiency. To investigate the effect of addition of free 
polymer, transfection was performed with the timed addition of free polymer to the 
culture medium. As can be seen from Figure 7, transfection of U87_luc2 glioblastoma 
cells with CD4(143)-siRNA complexes at a low N/P=8 followed by the addition of free 
polymer into the transfection medium had a dramatic impact on the transfection 
efficiency. The addition of free polymer (up to a total polymer amount equivalent to 
N/P=50) at an early time point (0.5 h after the initiation of transfection) substantially 
improved the target gene (luciferase) down-regulation;  the extent of down-regulation 
increased 7-fold compared to the polyplexes samples only formulated at N/P=8 (without 
free polymer addition). When free polymer was added at a later time point (2.5 h after the 
initiation of transfection), the efficiency improved to a lesser extent (2-fold increase in 
luciferase down-regulation). With the CD(143) delivery system, free polymer did not 
have a substantial effect on internalization as polyplex uptake was found to be above 80% 
at N/P ratios of 8, 50, and in the experiments with the timed polymer addition. A similar 
study was performed with Tr4(77) polymer and the results follow a similar trend as 
compared to CD4(143) polymer with some key differences. Polyplexes formulated at N/P 
= 8 did not show significant gene down regulation (Figure 8C). Significant luciferase 
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knockdown was observed at N/P=50 (Figure 8C). Similar to the CD4(143) polyplexes, 
addition of free polymer (up to a total polymer amount equivalent to N/P=50), increased 
the gene knockdown significantly (~ 74 %) for the earlier addition time point (0.5 h post 
transfection) and to a lower degree for the later time point. However, with Tr4(77) 
internalization was much lower at N/P=8 (~10% cells) but the cells positive for polyplex 
internalization did significantly improve at N/P= 50 and after free polymer addition, 
again indicating that the CD4 series yields more effective siRNA delivery.  The results 
further indicate that for the free polymer to enhance gene knockdown, the free polymers 
needed to be present near the beginning of the transfection experiment (a longer duration 
time of 3.5 h incubation). The shorter incubation time of 1.5 h (for 2.5 h post transfection 
time point) showed lower (~ 47 %) gene knockdown (Figure 8C). This may be explained 
by the reduced uptake for Tr4(77) polyplexes at the 2.5 h post transfection time point. 
Taken together, these data validate the hypothesis that free polymer is necessary to 
achieve maximal siRNA delivery efficiency.    Others have also shown this to be true, for 
example, Boeckle et al. revealed the effects of free polymer addition during transfection 
of CT 26 (fibroblast cells derived from colon of BALB/c mouse) cells with non-purified 
(contained free polymer) and purified PEI (did not contain free polymer) polyplexes at 1 
h and 4 with varying concentrations of pDNA. They found that free polymer increased 
the luciferase expression by many fold as compared to purified PEI polyplexes.35   When 
considering the data for CD4(143), although 90% of cells were positive for siRNA 
internalization at N/P 8, target gene down regulation was minimal at this low N/P ratio.  
However, when free polymer (equivalent to N/P = 42) was added to the culture media 0.5 
hours after transfection at N/P 8, gene down regulation was equivalent to that observed 
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for polyplexes formulated at N/P =50.  This was not the case for Tr4(77) at N/P 8, both 
internalization and gene down regulation was minimal.  These results could indicate that 
free polymer aids in endosomal escape of siRNA formulations, which intern, aids gene 
knockdown and was particularly noticed with the cyclodextrin analogs.  We speculate 
that the known affinity for cyclodextrin to extract cholesterol from cell membranes36-39 
could play a role in aiding endosomal disruption and polyplex release into the cytoplasm 
with the CD4 polymer series. 
Despite the ability of Tr4(23) and CD4(26) to bind siRNA, Tr4(23) was unable to 
effectively deliver siRNA into glioblastoma cells, but CD4(26) was effective for siRNA 
internalization to a large fraction (80%) of U87 cells. Interestingly, at equivalent N/P 
ratios, the cyclodextrin polymers were found to be more potent than the analogous Tr4 
polymer in terms of both cellular uptake and gene down regulation (Figures 8-10). These 
findings suggest that cyclodextrin, a larger carbohydrate unit, seems to be more suitable 
than trehalose for designing polymer vehicles that are active for siRNA delivery, in terms 
of both uptake and target gene down-regulation and could be related to more stable 
complex formation, enhanced endosomal release, and greater cytoplasm delivery.  
When the polyplexes were collectively examined for transfection efficiency 
(Figure 10), the shortest polymers [including T4(10), Glycofect, CD4(10), as well as 
Tr4(23)] were completely inactive towards siRNA-mediated luciferase gene down 
regulation with U87_Luc cells, which is likely due, in part, to their inability to form 
stable complexes (Figure 7).  Yet, the longer Tr4 and CD4 polymers achieved siRNA-
mediated gene knockdown and a polymer length dependence on delivery efficacy was 
evident (Figure 9 and 10). Importantly, all but the short Tr4 and CD4 polymer analogs 
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were effective at promoting internalization of Cy5-labeled siRNA in 80%+ of U87 cells.  
In addition, while toxicity was not revealed according to MTT assays, the decrease in 
gene down regulation with increasing molecular weight could point towards an off target 
effect or decreased siRNA release. 
Previously, we have shown with pDNA that the trehalose polymers reveal a 
distinct trend of an increase in gene expression with an increase in polymer length 
(nRwR=35, 53, 75, 100) with HeLa cells.16 However with H9c2(2-1) cells, such a trend was 
not observed, as the gene expression levels plateau with polymer lengths greater than 
nRwR=35.16 In the current study with U87MG cells, the observed gene expression was 
equivalent for pDNA being carried with Tr4 polymers nRwR=23 to 55; however it then 
increased at nRwR=77 (which is seen in both Opti-MEM and DMEM). Interestingly, for 
siRNA polyplexes formed with Tr4 polymers, gene down regulation was insignificant for 
Tr4(23) but drastically increased to ~90% for Tr4(55) and Tr4(77) in the presence of 
Opti-MEM.  In the presence of DMEM containing 10% serum, a similar result was found 
but gene down regulation was dampened (~30% knockdown). Thus, the length of the 
trehalose and cyclodextrin polymers appears to be an important variable in cellular 
delivery of siRNA and pDNA.  Many other reports have shown that varying polymer 
length affects delivery; for example Stand et. al. showed that the most efficient gene 
silencing was achieved using fully de-N-acetylated chitosans with intermediate chain 
lengths (DPRnR 100–300).40  
When directly comparing the efficacy of the T4, Glycofect, Tr4, and CD4 
polymers for pDNA versus siRNA delivery, clear differences and trends in the combined 
data were observed (Figure 10).  As we have previously published, both T4 and 
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Glycofect are effective pDNA delivery vehicles. Among all the polymers tested, Tr4(77) 
obtained the highest transgene expression in U87 glioblastoma cells, yielding over two 
orders of magnitude higher transgene expression for than CD4(39), the most potent 
cyclodextrin polymer for pDNA delivery. Also, Tr4(77) revealed over an order of 
magnitude higher gene expression than Glycofect. In contrast to their high potency for 
siRNA delivery, the CD4 polymers were shown to be less effective in the delivery of 
pDNA than the other polymers examined (Figure 10). A comparison of these 
carbohydrate-containing polymers for pDNA delivery revealed a slight correlation to the 
polymer length for both the Tr4 and CD4 series. As shown, the longest trehalose polymer 
revealed the highest gene expression, also, there was some correlation to the polymer 
length for the cyclodextrin polymers, where pDNA expression increased as the polymer 
molecular weight increased up to CD4(39), then the gene expression slightly decreased. 
In the presence of serum, however, gene expression was dampened.  This is likely due to 
the presence of serum proteins in this media that may bind to the polyplexes. Because the 
CD4 series does promote nucleic acid delivery to a large amount of cells, the low gene 
expression efficacy could be due to two possible combined factors: i) the CD4 polymer 
series could promote higher delivery of nucleic acids to the cytoplasm than the Tr4 series 
(wrong destination for pDNA delivery), and ii) the CD4 polymers could bind very tightly 
to pDNA, discouraging release. 
The dependence of potency on polymer type and length was more dramatic for 
siRNA delivery. We were surprised to discover that, despite the high potency of T4 and 
Glycofect for pDNA delivery, both of these polymers were completely ineffective at 
forming polyplexes with and delivering siRNA in vitro (Figure 5 and Figure 10D). Also, 
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a dramatic dependence on molecular weight was observed with the trehalose and 
cyclodextrin polymers.  Both the low molecular weight versions of these systems [Tr4(23) 
and CD4(10)] revealed no activity for siRNA delivery.  However, interestingly, as the 
degree of polymerization was further increased, the cyclodextrin polymers CD(26) and 
CD(39) were very active for siRNA delivery (80%, and 90% gene down regulation 
respectively), more so than the Tr4 polymer series. However, the two highest molecular 
weight analogs of the CD4 series were less effective for delivery.  Collectively, these data 
reveal two very important trends: i) length of the polymer has an effect on gene 
expression and gene knockdown and ii) the carbohydrate type/size plays a clear role in 
siRNA binding, compaction, and delivery. The collective data for the CD4 series is 
particularly intriguing; the CD4 polymers clearly promote effective binding and 
encapsulation of both pDNA and siRNA, polyplex internalization into 90% of cells even 
at low N/P ratio, low gene expression but high siRNA-mediated gene knockdown.  This 
points toward the direct role of the sugar in mediating both binding and delivery of 
nucleic acids.  Cyclodextrin clearly promotes higher binding affinity, likely due to H-
bonding via the hydroxyl groups and the polymerized nucleotides.  In addition, 
cyclodextrin likely plays a role in promoting endosomal release of siRNA (as Tr4 analogs 
had lower affinity) possibly due to the known affinity of the hydrophobic cyclodextrin 
cup to extracting cholesterol out of the membrane, which could promote leaky 
endosomes.  This was also clearly noticed when free polymer was added, which also 
clearly plays a role in promoting endosomal release of polyplexes carrying siRNA. Lastly, 
the efficacy was significantly reduced in serum, possibly due to the affinity of the 
cyclodextrin to binding serum proteins, which likely coat the polyplexes.  
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In conclusion, the observations with these polymers illustrate that, because of their 
structural differences and the difference in intracellular sites of action, indeed, knowledge 
based upon pDNA delivery cannot necessarily predict the performance of polymers for 
siRNA delivery.  These findings also highlight the potential of utilizing the Tr4 and CD4 
series of polymers as therapeutic pDNA and siRNA delivery agents and demonstrate the 
subtle effects of chemical structure on the activity of pDNA and siRNA delivery.  
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Chapter 3: 
 
Promotion and stabilization effect of poly carbohydrate coating for the 
nanosystems in siRNA delivery into cancer cells. 
 
This chapter is based on the publication: 
1. Antons Sizovs, Lian Xue, Zachary P. Tolstyka, Nilesh P. Ingle, Yaoying Wu, 
Mallory Cortez, and Theresa M. Reineke. “Poly(trehalose): Sugar-Coated 
Nanocomplexes Promote Stabilization and Effective Polyplex-Mediated siRNA 
Delivery”.  Journal of the American Chemical Society 2013 135 (41), 15417-
15424.  
2. Adam E. Smith, Antons Sizovs, Giovanna Grandinetti, Lian Xue, and Theresa M. 
Reineke. "Diblock Glycopolymers Promote Colloidal Stability of Polyplexes and 
Effective pDNA and siRNA Delivery under Physiological Salt and Serum 
Conditions." Biomacromolecules. 2011 12(8), 3015-3022. 
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Background 
In the macromolecular interaction, the surface properties of  nanosystems play a 
crucial role. In the biological environment, the biological recognition and transformation 
rely highly on the nature of the surface. The monosaccharide glucose and disaccharide 
trehalose are two of the most commonly used carbohydrate chemicals in biological 
research. The trehalose, known for its special biological stabilization effect, is well 
enriched in ocean creatures and used in supplementary treatment for Alzheimer’s disease. 
In this chapter, two different strategies were investigated to evaluate the sugar coating 
effect on siRNA delivery as well as pDNA delivery.  Two series of polymers have been 
synthesized via aqueous reversible addition-fragmentation chain transfer (RAFT) 
polymerization. Those composed of 2-deoxy-2-methacrylamido glycopyranose (MAG) 
with primary amine containing N-(2-aminoethyl) methacrylamide (AEMA) and those 
composed of 6-methacrylamido-6-deoxytrehalose with AEMA were investigated and 
evaluated to elucidate the coating effect on nucleic acid delivery. We demonstrate that the 
polyglucose and polytrehalose coating can ensure the colloidal stability of the polyplexes 
containing siRNA in the presence of high salt concentrations and serum proteins. The 
polytrehalose show the capability to lower the phase transition energy associated with 
freezing and protect the siRNA polyplexes during freeze-drying cycles and maintain the 
biological functions of the polyplexes after resuspension. The siRNA transfection 
efficiency facilitated by sugar coated polymers was conducted to show that the 
polytrehalose has exceptional cellular uptake and target gene knockdown while 
polyglucose coating doesn’t show the same effect. Moreover, the cellular uptake of 
siRNA facilitated by polytrehalose polymers showed zero order kinetics. The amount of 
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siRNA copies delivered into the cells can be controlled by the siRNA concentration in 
cell culture media. The confocal microscopy has shown that trehalose-coated polyplexes 
undergo active trafficking in cytoplasm upon internalization and significant siRNA-
induced target gene down-regulation was achieved with ICR50R of 19 nM. While the 
polyglucose-coated polyplexes do not show significant siRNA delivery efficiency, the 
polymers can achieve successful pDNA delivery. The performance of the coated 
polymers on siRNA highly depends on the choice of sugar type. All the formulations 
tested show no cytotoxicity in cellular studies. These findings suggest that polytrehalose 
has the potential to serve as an important component of therapeutic nanoparticle 
formulations of nucleic acids and has great promise to be extended as a new coating 
approach for nanotechnologies in biomedical application.  
Introduction 
Polymers with proper charge and surface profile have been proven to be effective 
to complex with nucleic acids and facilitate the cellular uptake. In order to develop 
biocompatible materials for biological applications, coating materials that promote the 
stabilization of nanosystems from nonspecific interactions and colloidal aggregation are 
of high interest. To address this, several approaches have been proposed as PEG 
alternatives, such as poly-(amino acid)s, poly(glycerol), poly(2-oxazoline)s and vinyl 
polymers1. Inspired by their nature, the carbohydrate family offers abundant and 
sustainable alternatives to conventional stabilizing materials, among which, glucose and 
trehalose are two most representative candidates for monosaccharide and disaccharide. 
Synthetic glycopolymers have received broad interest as benefiting from the abundance 
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and ability of carbohydrate to initiate specific interaction and recognition with biological 
systems2. With emergence of controlled/living radical polymerization (CLRP) such as 
NMP (nitroxide-mediated polymerization)3, ATRP (atom transfer radical 
polymerization)4 and RAFT (reversible addition-fragmentation chain transfer 
polymerization)5, researchers are capable of synthesizing the well defined structures of 
copolymers to study the structure- property relationships. Of all the techniques, RAFT is 
of particular significance because of the wide range of functional monomers and reliable 
conditions required for the reactions6-8.  
The glucose, as one of the most abundant carbohydrate, participate in a variety of 
biochemical reactions, signal pathways and energy metabolism9.   The dysfunction of the 
glucose metabolism is associated with a variety of diseases such as diabetes and 
cardiovascular diseases10. The α,α-D-trehalose, a non-reducing disaccharide is very stable 
to acidic hydrolysis11  and has been found to protect cells during oxidative stress12 and 
freezing.13,14 Trehalose is a known protective factor of autophagy, effectively shielding 
intracellular organelles from distortion during sudden environmental changes, such as 
aggregation and water crystallization. This has been readily observed and demonstrated 
in the plant called Selaginalla lepidophyll, known also as the resurrection plant or Rose of 
Jericho that contains about 12% of trehalose in dry mass. The restoration to normal 
metabolism is observed by exposing the lifeless resurrection plant to water within a few 
hours, which is a marvelous self protection against dryness and sudden dehydration 
environment15. Trehalose is also accumulated under stress in a number of animals and 
insects with cryptobiotic ability(for example, tardigrades16,17).  In addition, trehalose has 
been reported to improve the cognitive and learning ability of patients with Alzheimer ’s 
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disease and reduce the Aβ deposit in hippocampus to show neural protective effect in 
clinical study.18,19 
The property of trehalose has long been recognized, studied and utilized by 
cryobiologists and pharmacists to freeze, freeze-drying, and hypothermal storage of 
various bioactive molecules including proteins, antibodies, DNA, liposomes, DNA/lipid 
complexes, cells and even organs20. However, the human body does not biosynthesize 
trehalose but is able to metabolize it into two glucose molecules.   
In previous studies, we have synthesized trehalose pentaethyleneamine click 
polymers with different polymer lengths. The preliminary studies have shown the 
trehalose containing click polymers can promote serum stability of the polyplexes and 
achieve significant pDNA delivery into cancer cells.21 In the study of siRNA delivery, the 
trehalose click polymers also showed polymer length dependent efficacy for successful 
siRNA delivery22. Tseng et. al. have shown that the presence of free trehalose in cell 
culture media promotes plasmid DNA (pDNA) delivery by polyethyleneimine (PEI)-
based complexes to various cell lines.23 The neuroprotective effect of trehalose in 
Huntington, Parkinson, and prion diseases can attribute to the presence of polymers of 
trehalose in induction of autophagy in brain.24-26_ENREF_26 More recently Maynard et al. 
reported that p-formylpolystyrene modified with trehalose via an acetonide moiety is 
capable of imparting both lyo- and heat protectant properties to lysozyme when 
covalently attached to this enzyme.27  
In this study, two series of RAFT block copolymers are synthesized, characterized 
and compared for siRNA delivery. For the family of diblock glycopolymers, the colloidal 
stabilizing block was formed by polymerizing 2-deoxy-2-methacrylamido glucopyranose 
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(MAG), followed by polymerization with aminoethylmethacrylate (AEMA) via RAFT 
polymerization. For the family of polytrehalose polymers, the colloidal stabilizing block 
was synthesized via polymerizing 6-methacryamido-6-deoxytrehalose via RAFT. In both 
approaches, we rationalized that a block copolymer comprised of densely-placed 
carbohydrate units would deter non-specific aggregation/adsorption and confer 
lyoprotective and cryoprotective properties as a surface layer on nanoparticles by 
insuring a high local concentration and significant topology. _ENREF_15Its polymeric 
nature would be expected to impart an increase in the local viscosity on the particle 
surface, thus enhancing vitrification of the surface-bound water and colloidal stability.28 
In addition, considering that the trehalose has neural protective effect, we reasoned that 
polytrehalose on the nanoparticle surface may significantly improve cellular 
internalization into glioblastoma cells, as the overexpress GLUT-1 is also reported.29 For 
the first time, we demonstrate that synthetic polytrehalose motif enhances colloidal 
stability in salt, serum, and during lyophilization while still retaining high cellular 
internalization and effective payload delivery of inter-polyelectrolyte nanosystems. 
 
Figure 1. Schematic illustration of polyplexes formation from diblock copolymers 
complexed with siRNA. 
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Materials 
All reagents for synthesis were obtained at the highest possible purity from Fisher 
Scientific Co (Pittsburgh, PA) or Sigma-Aldrich Co (St. Louis, MO) and used as received 
unless noted otherwise. N(2-aminoethyl)methacrylamide was purchased from 
Polysciences (Warrington, PA). JetPEI was obtained from PolyPlus Transfections 
(Illkirch, France). Dialysis membranes were obtained from Spectrum Laboratories, Inc. 
(Rancho Dominguez, CA). Dry methylene chloride, dimethyl formamide, methanol and 
tetrahydrofurane were obtained using an MBRAUN MB solvent purification system 
manufactured by M. Braun Inertgas-Systeme GmbH (Garching, Germany), using HPLC 
grade solvents obtained from Fisher Scientific Co (Pittsburgh, PA).  
Thin layer chromatographies (TLC) were done using aluminum-backed silicagel 
plates (silicagel 60, FR254R) obtained from Merck (Darmstadt, Germany) and visualized 
using UV light (254 nm) or staining agents: ninhydrin solution in ethanol for the 
visualization of amines, p-anisaldehyde solution in HR2RSOR4R/acetic acid/ethanol for the 
visualization of carbohydrates.  
Preparative chromatographies were performed using a Buchi Separcore 
chromatography system, (Buchi Labortechnik AG, Switzerland) using Buchi plastic 
chromatography cartridges or homemade glass columns manually packed with 60-200 
mesh Premium Rf silicagel (Sorbent Technologies Inc., Atlanta, GA). All solvents used 
for preparative chromatography were HPLC grade obtained from Fisher Scientific Co 
(Pittsburgh, PA). 
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LC-MS data was obtained with an Agilent system, Agilent Technologies (Santa 
Clara, CA) with a time-of-flight (TOF) analyzer coupled to a Thermo Electron TSQ-
LC/MS ESI mass spectrometer. 
NMR spectra were recorded using 400MR Varian-400 Hz spectrometer in 
deuterated solvents, namely D R2RO, dR4R-MeOD, dR6R-DMSO, CDClR3R, CDR2RClR2. RAll deuterated 
solvents were purchased from Cambridge Isotope Laboratories, Inc. (Andover, MA). 1H-
NMR spectra were recorded at 399.7 MHz and 13C-NMR spectra were recorded at 101 
MHz. Spectra were analyzed using MNova software (version 7.0.1-8414, Mestrelab 
Research S.L. (Santiago de Compostela, Spain)). 
SEC was conducted using 1.0 wt% acetic acid/0.1 M NaR2RSOR4R as the eluent at a 
flow rate 0.3 mL/min on size exclusion chromatography columns [CATSEC1000 (7μ, 
50×4.6), CATSEC100 (5μ, 250×4.6), CATSEC300 (5μ, 250×4.6), and CATSEC1000 (7μ, 
250×4.6)] obtained from Eprogen Inc. (Downers Grove, IL). Signals were acquired using 
Wyatt HELEOS II light scattering detector (λ = 662 nm) and an Optilab rEX 
refractometer (λ = 658 nm). SEC trace analysis was performed using Astra V software 
(version 5.3.4.18), Wyatt Technologies (Santa Barbara, CA). Biological sample 
fluorescence was measured with GENios Pro luminometer (TECAN US, Research 
Triangle Park, NC). Quartz Crystal Microbalance (QCM) experiments were performed on 
Q-Sense E4 QCM (Q-sense; Vastra Frolunda, Sweden) instrument. Differential scanning 
calorimetery (DSC) was conducted on a TA Instruments Q100 under nitrogen. 
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Polymer Synthesis 
A. Synthesis of glucose containing RAFT polymer P(MAGR46R-b-AEMARxR) (this work was 
accomplished by Dr. Adam Smith and Dr. Anton Sizovs). 
 
Scheme 1. Synthesis of P(MAGR46R-b-AEMARxR) via RAFT Polymerization 
The diblock copolymers of MAG and AEMA were synthesized according to 
Scheme 1. A trithiocarbonate, CPP, was used to mediate the aqueous RAFT 
polymerization of MAG in the presence of the free radical initiator V-501 to yield 
PMAG R46R. The PMAG R46R macroCTA was subsequently chain-extended with AEMA to 
produce three diblock copolymers with varying AEMA block lengths. All 
polymerizations were performed in an aqueous acetate buffer to minimize hydrolysis and 
maintain the trithiocarbonate chain ends. SEC chromatograms of PMAG R46R and the three 
block copolymers, P1, P2, and P3, were unimodal with low PDIs (<1.25) indicating near-
quantitative blocking efficiency and controlled polymerization (Figure 2-1). 1H NMR 
studies of the glycopolymers (Figure 2-2) revealed compositions in agreement with those 
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calculated from SEC molecular weight measurements. The molecular weight and 
composition data of the diblock copolymer series are summarized in Table 1.  
 
Polymer M RnRa PDIa(ᴆ) MAG DPb AEMA DPb 
macroCTA 11700 1.24 46  
P1 14400 1.15 46 21 
P2 16700 1.12 46 39 
P3 17800 1.12 46 48 
Table 1. As determined by aqueous size exclusion chromatography using a flow rate of 
0.3 mL/min of 1.0 wt % acetic acid/0.1 M NaR2RSOR4R, Eprogen CATSEC100, CATSEC300, 
and CATSEC1000 columns, a Wyatt HELEOS II light scattering detector (λ = 662 nm), 
and an Optilab rEX refractometer (λ = 658 nm). b As determined by 1H NMR 
spectroscopy (1.5 mg/mL in D R2RO at 65 oC). 
 
1). 
 
2).  
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Figure 2. Characterization of the glycopolymers.  1). SEC trace for the PMAG 
macroCTA and the three diblock glycopolymers. 2). 1H NMR spectra for (a) PMAG46, 
(b) P1, (c) P2, and (d) P3. 
 
Synthesis of polytrehalose diblock copolymers 
(This work was mainly accomplished by Anton Sizovs. Lian has contributed to the 
synthesis of 6-iodo-6-deoxy-2,3,4,5,2',3',4',5',6'-O-acetyl trehalose.) 
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Scheme 2. Synthesis of 6-methacrylamido-6-deoxytrehalose (MAT). 
 
Scheme3. Polymer synthesis via RAFT polymerization.  
In detail, typical procedure for the synthesis of 6-iodo-6-deoxy-2,3,4,5,2',3',4',5',6'-O-
acetyl trehalose (2)  
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Iodine (47.50 g, 0.1871 mol) was placed in a flame-dried 1.5 L round-bottom 
flask and 800 mL of dry dimethylformamide (DMF) was added. Triphenylphosphine 
(51.55 g, 0.1965 mol) was dissolved in 150 mL of dry THF and added to iodine 
suspension. Anhydrous trehalose (42.64 g, 0.1246 mol, used as received) was added 
quickly via a funnel for solids. The reaction flask was closed with a septum, flushed with 
nitrogen, and placed in an oil bath. The reaction was allowed to proceed at 80 °C for 4 h. 
Solvents were removed under vacuum yielding a thick yellow oil.  
The oil was poured into a 1 L solution of NaOMe in methanol through a funnel 
for liquids. The solution pH was measured by placing a drop of the methanolic solution 
on a piece of wet indicator paper. The pH was adjusted to 9 using NaOMe and the 
reaction mixture was then allowed to stir for 1h at room temperature. Acidic resin 
DOWEX-2H (H+ form) was added to neutralize the solution and subsequently filtered off. 
Methanol was removed on a rotary evaporator yielding a yellow oil. 
The oil was poured in 600 mL of water via a funnel for liquids causing PPhR3RO 
precipitation. Importantly, a thin-tipped funnel was used to avoid the formation of large 
clumps of triphenylphosphine oxide. This solution was placed in a refrigerator at 4 °C for 
12 h. 
The aqueous solution was then filtered to remove PPhR3 RO. The filtrate was 
extracted with 2x50 mL of dichloromethane (DCM) to remove any remaining organic 
impurities (PPhR3RO and PPhR3R). Water was removed on a rotary evaporator, and the 
obtained oil was dried for 20 h over PR2ROR5R at 500 mTorr. 
The dry oil was dissolved in 800 mL of dry pyridine (Py) and the solution was 
placed in an ice-bath. Acetic anhydride (190 mL, 205 g (d=1.08 g/mL), 2.01 mol) were 
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added over ca. 15 min using an additional funnel. The reaction was allowed to stir at 
room temperature for 14 h. The reaction mixture was then poured on ice, forming a sticky 
precipitant. The ice was allowed to melt and the reaction mixture was extracted with 
4x200 mL of DCM. The organic extracts were combined, washed with a dilute sulfuric 
acid solution to remove Py and dried over NaR2RSOR4R overnight. It should be noted that 
washing with NaCl(sat) solution leads to halogen exchange (RCHR2RI→RCHR2RCl) and must 
be avoided. 
NaR2RSOR4R was filtered off and DCM was removed on a rotary evaporator yielding a 
yellowish oil. The oil was loaded on a silicagel column (300 g of silicagel, DCM) and 
mixture of per-O-acetylated 6-iodo-6-deoxy and 6,6´-diiodo-6,6´-deoxy trehalose was 
separated from the rest of the mixture using DCM/Et R2RO=5/1 eluent. 
This mixture of two products was separated by column chromatography (ca. 2 
gram portions of mixture, 100 g of silicagel) using eluent gradient DCM → 
DCM/Et R2RO(5/1) to yield 22.3 g (24.0%) of 2. 
1H-NMR (400 MHz, CDClR3R) δ ppm: 5.56 – 5.45 (overlapping triplets, J = 10.2, 
2H), 5.40 – 5.36 (d, 3.9 Hz, 1H), 5.36 – 5.33 (d, 1H), 5.22 – 5.15 (dd, J = 10.3, 3.9 Hz, 
1H), 5.10 – 5.00 (m, 2H), 4.94 – 4.84 (dd, J = 10.0, 9.2 Hz, 1H), 4.27 – 4.19 (m, 1H), 
4.08 – 3.98 (m, 2H), 3.97 – 3.89 (dd, J = 10.0, 9.0, 2.4 Hz, 1H), 3.30 – 3.20 (dd, J = 11.0, 
2.6 Hz, 1H), 3.13 – 2.99 (m, 1H), 2.15 (s, 3H), 2.09 – 2.07 (m, 9H), 2.05 (s, 3H), 2.03 (s, 
3H), 2.02 (s, 3H). 13C-NMR (101 MHz, CDClR3 R) δ ppm: 170.67, 170.00, 169.94, 169.67, 
169.58, 169.57, 92.21, 91.68, 72.46, 70.31, 70.11, 69.84, 69.56, 69.27, 68.70, 68.38, 
68.05, 61.91, 25.70, 21.28, 20.79, 20.74, 20.68, 20.63, 2.61. ESI-MS positive ion mode: 
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calculated m/z [M+NHR4R]+ 764.1257, found m/z: 764.1297; calculated m/z [M+Na]+ 
769.0811, found m/z: 747.0832.  
Typical procedure for the synthesis of 6-azido-6-deoxy-2,3,4,5,2',3',4',5',6'-O-acetyl 
trehalose (3) 
 
Compound 2 (16.56 g, 22.19 mmol) and NaNR3R (1.63 g, 25.07 mmol) were placed 
in a dry 500 mL flask equipped with a stir bar and capped with a septum.  Next, 300 mL 
of dry DMF was added via cannula and nitrogen was bubbled through the solution for 20 
min. The reaction mixture was brought to 60 °C and stirred for 4 h. The reaction mixture 
was cooled down and concentrated on a rotary evaporator to a final volume of ca. 150 
mL. The resulting solution was poured into 700 mL of HR2RO at 0 °C. It was extracted with 
3x150 mL of ethyl acetate. Organic extracts were combined, washed with brine and dried 
over NaR2RSOR4R overnight. 
 The solids were filtered off and the solvent was removed on a rotary evaporator 
yielding a white crystalline material. The product was recrystallized from 
ethylacetate/hexanes(1/3) to yield 11.94 g of 3 upon drying. The filtrate was placed in a 
freezer (-27 oC) resulting in precipitation of 1.62 g of 3. The combined yield was 13.56 g 
(92.4%). 
1H-NMR (400 MHz, CDClR3R) δ ppm: 5.49 (ddd, J = 10.3, 9.3, 5.7 Hz, 2H), 5.35 – 5.30 (m, 
2H), 5.04 (m, 4H), 4.25 (dd, J = 12.1, 5.6 Hz, 1H), 4.13 – 3.98 (m, 3H), 3.36 (dd, J = 13.3, 
7.2 Hz, 1H), 3.17 (dd, J = 13.3, 2.5 Hz, 1H), 2.12 (s, 3H), 2.11 – 2.07 (2 overlapping 
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singlets, 6H), 2.06 (s, 3H), 2.05(s, 3H),  2.04 (2 overlapping singlets, 6H). 13C-NMR (101 
MHz, CDClR3R) δ ppm: 170.57, 169.97, 169.68, 169.53, 169.51, 92.82, 92.43, 70.03, 69.88, 
69.86, 69.77, 69.70, 68.54, 68.26, 61.77, 50.94, 20.67, 20.65, 20.63, 20.61. ESI-MS 
positive ion mode: calculated m/z [M+NHR4R]+ 679.2318, found m/z: 679.2276; calculated 
m/z [M+Na]+ 684.1872, found m/z: 684.1825. 
Typical procedure for the synthesis of 6-amino-6-deoxy-trehalose (4) 
 
6-azido-6-deoxy-2,3,4,5,2',3',4',5',6'-O-acetyl trehalose 3 (11.81 g, 17.85 mmol) 
was dissolved in 450 mL of MeONa/MeOH (pH~9) and sonicated to assist dissolution. 
The reaction mixture was stirred at room temperature for 4h. The reaction progress was 
monitored by TLC/p-anisaldehyde stain (eluent: EtOAc/MeOH/HR2RO=15/5/4). Ion 
exchange resin, DOWEX-50H, was added to reaction mixture, which was then stirred for 
20 minutes (Note: DOWEX-50H might result in coloration of the reaction mixture, 
therefore it is advisable to wash the resin with methanol prior to use). The resin was 
removed by filtration and the solvent evaporated to yield the crude produce, 6-azido-6-
deoxy-trehalose as amorphous solid. 
The crude 6-azido-6-deoxy-trehalose was dissolved in methanol. The reaction 
mixture was deoxygenated by bubbling nitrogen through the solution for 30 min. 
Palladium on carbon (5% dispersion, 499 mg, 0.234 mmol) was added and hydrogen gas 
was bubbled through the solution for 20 h using a gas diffuser. After 20 h, nitrogen was 
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bubbled through the solution to remove the remaining dissolved hydrogen. The Pd(C) 
was filtered off using Celite and the solvent was removed using a rotary evaporator to 
yield the title compound 4 (5.83 g, 95.8% yield). 1H-NMR (400 MHz, DR2RO) δ ppm: 5.10 
– 4.97 (two doublets, J = 4.4 Hz, 2H), 3.73 – 3.54 (m, 6H), 3.54 – 3.44 (dd, J = 9.9, 3.8 
Hz, 2H), 3.34 – 3.23 (t, J = 9.4 Hz, 1H), 3.21 – 3.10 (t, J= 9.4 Hz, 1H), 2.91 – 2.79 (dd, J 
= 13.7, 2.5 Hz, 1H), 2.64 – 2.53 (dd, J = 13.8, 7.8 Hz, 1H). 13C-NMR (101 MHz, DR2RO) δ  
ppm: 93.03, 92.91, 72.35, 72.30, 72.01, 71.26, 70.99, 70.89, 69.53, 60.35, 48.73, 41.32. 
ESI-MS positive ion mode: calculated m/z [M+H]+ 342.14, found m/z: 342.10. 
Synthesis of 6-methacrylamido-6-deoxy trehalose (5) 
 
2-Deoxy-2-aminotrehalose 4 (3.74 g, 11.0 mmol) was suspended in 200 mL of 
dry pyridine. The reaction mixture was placed in an ice bath and trimethylsilyl chloride 
(TMSCl, 10.0 g, 92.0 mmol, 1.2 eq per -OH) was added using an addition funnel. The 
reaction mixture was allowed to slowly warm to room temperature, and the reaction was 
allowed to proceed overnight. 
The reaction mixture was cooled down to ca. 0 ºC and poured into 600 mL of ice-
cold carbonate buffer (pH=9). The aqueous suspension was extracted with 3x150 mL of 
hexanes. The extracts were combined and washed with water, followed by brine and 
finally dried over NaR2RSOR4R. 
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The solid was filtered off and hexanes were removed under reduced pressure on a 
rotary evaporator. A white crystalline material was obtained upon evaporation and was 
then dried at 500 mTorr over PR2ROR5R to yield 8.83 g (95.2%) of the 6-amino-6-deoxy-
2,3,4,5,2 ,´3´,4´,5´,6´-nano-O-trimethylsilyl trehalose. 1H-NMR (400 MHz, CDR2RClR2R) δ 
ppm: 4.87 – 4.74 (two overlapped doublets J = 3.2 Hz, 2H), 3.90 – 3.77 (td, J = 9.0, 3.2 
Hz, 2H), 3.73 – 3.52 (m, 4H), 3.44 – 3.26 (m, 4H), 2.87 – 2.78 (dd, J = 13.2, 3.0 Hz, 1H), 
2.68 – 2.57 (dd, J = 13.2, 5.4 Hz, 1H). 
 The TMS protected aminotrehalose (1.687 g, 1.993 mmol) was dissolved in 2 mL 
of DCM and 35 mL of DMF. This solution was cooled down in an ice bath and 
triethylamine (0.55 mL, 0.40 g (d=0.726 g/mL), 3.9 mmol) was added. Freshly distilled 
methacryloyl chloride (0.22 mL, 0.24 g (d=1.07 g/mL) 2.3 mmol) was dissolved in 5 mL 
of dry DCM and was slowly (over ca. 10 min) added to the reaction mixture. The reaction 
was allowed to proceed at 0 ºC for 1H and, additionally, 3h at room temperature. 
 The reaction mixture was then cooled in an ice bath and poured into 200 mL of 
the ice-cold carbonate buffer (pH~8) that contained ice. The resulting suspension was 
extracted with 3x30 mL of hexanes. The organic extracts were combined and washed 
with water, followed by a brine wash, and finally the solution was dried over NaR2RSOR4 R 
overnight. 
 The solids were filtered off and the hexanes were removed under vacuum to yield 
a colorless oil. This oil was dissolved in 20 mL of dry methanol and placed in an ice bath. 
Next, 0.2 mL of a ~1.25M HCl solution in methanol was added and the reaction was 
allowed to warm to room temperature and further stirred for additional 10 min. Methanol 
was removed under vacuum using a rotary evaporator (the rotovap water bath 
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temperature was kept at 25 oC), yielding 0.765 g (93.3%) of the title compound (5) as a 
white solid foam. 1H-NMR (400 MHz, CDR3ROD) δ ppm: 5.77 – 5.61 (t, J = 0.9 Hz, 1H), 
5.40 – 5.35 (t, J = 1.4 Hz, 1H), 5.13 – 5.03 (dd, J = 16.1, 3.8 Hz, 2H), 3.98 – 3.90 (dt, J = 
9.7, 4.8 Hz, 1H), 3.86 – 3.74 (m, 4H), 3.72 – 3.64 (dd, J = 11.9, 5.4 Hz, 1H), 3.57 – 3.52 
(d, J = 4.8 Hz, 2H), 3.52 – 3.44 (td, J = 9.8, 3.8 Hz, 2H), 3.36 – 3.31 (dd, J = 9.8, 9.0 Hz, 
1H), 3.20 – 3.13 (dd, J = 9.8, 9.0 Hz, 1H), 2.00 – 1.84 (m, 3H). 
Synthesis of polytrehalose 6 (pMAT51)  
 
6-Methacrylamido-6-deoxy trehalose 5 (0.765 g, 1.867 mmol, 65 eq) was 
dissolved in 7.00 mL of acetate buffer in DR2RO. CPP (7.97 mg, 2.87x10-2 mmol, 1 eq) was 
dissolved in 645 µL of MeOD and added to the solution of 5, followed by V-501 (0.805 
mg, 2.87x10-3 mmol, 0.1 eq) in 244 µL of MeOD. Finally, 861 µL of MeOD was added 
to a final volume of 1.75 mL of MeOD in the mixture. The reaction flask was capped 
with a septum and connected to an NMR tube via cannula. The setup was deoxygenated 
by bubbling nitrogen through the solution for 45 min. At that time, 0.50 mL of reaction 
solution was transferred into the NMR tube. Polymerization was conducted in an NMR 
instrument at 70 °C while spinning the reaction tube at 20 Hz for 9 h. 1H-NMR spectra 
were acquired at various time points. The rest of the reaction mixture was kept in the 
refrigerator overnight.  
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Once the polymerization kinetics was established, the reaction mixture was 
removed from the refrigerator and deoxygenated by bubbling nitrogen through the 
solution for 45 min. The flask was placed in an oil bath pre-heated to 70 oC. The reaction 
was allowed to proceed for 6 h to yield 77% monomer consumption and a targeted degree 
of polymerization of 50. The reaction was stopped by removing the septum and cooling 
the reaction mixture on ice. The reaction mixture was then transferred to a dialysis bag 
having a 3500 Da molecular weight cut-off. It was dialyzed against ultra-pure water 
acidified to pH 4-5 with HCl. Water changes were performed every 8-10 h. After 3 d of 
dialysis, the polymer solution was frozen and lyophilized to yield 490 mg of white, fluffy 
material. 
SEC (eluent: 1.0 wt% acetic acid/0.1 M NaR2RSOR4R). A flow rate of 0.3 mL/min, light 
scattering detector (λ = 662 nm) and refractometer (λ = 658 nm). MRnR=21.0 kDa, 
dpRnR=50.7~51, PDI=1.04. 
1H-NMR (400 MHz, DR2RO) δ ppm: 5.76 – 5.28 (bs, 100H), 4.39 – 3.50 (m, 600H), 2.78 – 
2.66 (bs, 2H), 2.53 – 0.68 (m, 264H). 
Synthesis of diblock copolymers P1, P2 and P3  
 
Polytrehaloes 6 (327 mg, 1.56x10-2 mmol, 1.00 eq) was dissolved in 3.00 mL of 
acetate buffer and the resulting solution was placed in a flask that contained 
aminoethylmethacrylamide hydrochloride (AEMA·HCl, 311 mg, 1.89 mmol, 121 eq). To 
114 
 
this, 0.780 mL of a solution containing V-501 radical initiator (0.44 mg, 1.56x10-3 mmol, 
0.10 eq) was added and the flask was capped with a septum. The solution was 
deoxygenated by bubbling nitrogen through the reaction solution for 45 minutes. The 
flask was then placed in an oil bath preheated to 70 oC for polymerization. Two 1.25 mL 
samples were taken with a syringe at 30 min (P1) and 60 min (P2) of reaction time. Each 
sample was sprayed into a vial which was immediately cooled on ice. After 90 min (P3), 
the reaction was stopped by removing the septum and placing the reaction flask on ice. 
All three samples were placed in dialysis bags having a 3500 Da molecular weight cut-off 
and dialyzed against 3x4L of 0.5 M NaCl solution, followed by 3x4L 0.1 M NaCl and 
finally 6x4L of ultra-pure water. All dialysis media were acidified with HCl to pH 4-5. 
Upon completion of dialysis, polymer solutions were lyophilized to yield white, 
fluffy powders. 
UMAT URU51 URU-b-AEMAURU34 URU(P1), 113 mg. U SEC (eluent: 1.0 wt% acetic acid/0.1 M 
NaR2RSOR4R). A flow rate of 0.3 mL/min, light scattering  d etector (λ = 6 6 2 n m) and 
refractometer (λ = 658 nm). MRnR=23.4 kDa, PDI=1.04. 
UMAT URU51 URU-b-AEMAURU65 URU(P2), 141 mg. U SEC (eluent: 1.0 wt% acetic acid/0.1 M 
NaR2RSOR4R). A flow rate of 0 .3  mL/min, light scattering  d etector (λ = 6 6 2 nm) and 
refractometer (λ = 658 nm). MRnR=29.4 kDa, PDI=1.05. 
UMAT URU51 URU-b-AEMAURU84 URU(P3), 181 mg. U SEC (eluent: 1.0 wt% acetic acid/0.1 M 
NaR2RSOR4R). A flow rate of 0 .3  mL/min, light scattering  d etector (λ = 6 6 2 n m) and 
refractometer (λ = 658 nm). MRnR=31.8 kDa, PDI=1.06. 
Synthesis of MATR51R-b-(AEMAR33R-s-AEMA-fluoresceinR1R) (P1-FITC) 
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P1 (MATR51R-b-AEMAR34R·34HCl, 12.0 mg, 34 eq) was dissolved in 850 µL of 0.1 
M NaHCO R3R, which was previously deoxygenated (bubbling N R2R though the solution for 
30 min). The flask was placed in an ice bath and 20.0 µL of a DMSO solution containing 
fluorescein isothiocyanate (FITC, 0.18 mg, 1 eq) was added with a pipette. The reaction 
mixture was allowed to slowly reach RT. After 12 H of stirring the reaction mixture, it 
was placed in a dialysis bag (3500 Da molecular weight cut-off) and dialyzed for 8 h (in 
the dark) against each of the following aqueous solutions: 0.1 M NaCl (4 L x 2), 0.07 M 
NaCl (4L), 0.03 M NaCl (4L), HR2RO (4 x 3). The content of the dialysis bag was then 
transferred into a vial and lyophilized, yielding P1-FITC (11.1 mg (91.1%) as a bright 
yellow powder. 
Material preparation and properties study (this section is based on 
polytrehalose diblock copolymers. It was accomplished by Dr. Anton Sizovs and Lian 
Xue). 
Polyplex formulation of diblock copolymer with siRNA 
To a 2 μM solution of siRNA in RNase-free an equal volume of polymer solution 
at an appropriate concentration was added via autopipette. The solution was mixed well 
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by injecting/ejecting the solution with the pipette several times. The polyplexes were 
allowed to incubate undisturbed at room temperature for 1 h prior to transfection. 
Polyplex lyophilization  
Polyplexes formed with polytrehalose copolymers and siRNA were prepared in 1-
mL microfuge tubes according to the procedure described above using 35μL of a 2 µM 
siRNA solution and 35 μL of the corresponding polymer solution. Once formed, the 
polyplexes were allowed to incubate for 1h at room temperature. Microfuge tubes 
containing solutions of polyplexes were placed in a freezer at -27 ºC for ca. 2 h. 
Lyophilization was performed by placing the microfuge tubes in a 1L lyophilization jar at 
room temperature and 10-30 mTorr vacuum for 24 h. To re-dissolve polyplexes, 70 μL of 
RNase free water was added to lyophilized material and solution was allowed to incubate 
at room temperature for 1h. 
Gel electrophoresis of polyplexes 
A 0.6% w/w agarose gel was prepared by dissolving 0.3 g of agarose in 50 mL of 
TAE buffer while heating. The resulting agarose solution was allowed to cool to ca. 40-
45 oC and 3 µL of ethidium bromide solution was added. 
  The polyplex solutions (20 µL) were prepared by following the protocol for 
polyplex formulation described above. Loading buffer (2 µL of Blue juiceTM) was added 
to each sample. The polyplex solutions (10 µL) were each loaded into the wells of the gel, 
and electrophoresis was performed at 60V for 45 min. 
 Images of gels are obtained using 312 nm UV light to detect ethidium bromide. 
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Figure 3. Gel electrophoresis assay. Numbers under each well correspond to polymer 
amine/siRNA phosphate (N/P) ratio. Arrows point towards anode(+).  
Dynamic light scattering measurements 
Polyplexes were prepared according to the standard protocol using 20 µL of a 2 
µM siRNA solution and 20 µL of polymer P1, P2 or P3 solution of appropriate 
concentration to yield polyplexes at N/P ratios of 5, 10 and 20. After 1 h incubation at 
room temperature, polyplex solutions were diluted with water, OptiMEM, or DMEM 
with 10% serum to a final siRNA concentration of 400 nM. Solutions were transferred 
into cuvettes and particle sizes were measured at 25 ºC using 173º detection angle at 
various time points. 
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Figure 4 a. Hydrodynamic radii and ζ-potentials of polyplexes in water over the period of 
4 h. Labels signify “polymer_name-N/P” b. Hydrodynamic radii of polyplexes after 
lyophilization and resuspension in water. A star (*) denotes cases in which a second 
population of larger particles was present (500-1000 nm). Labels signify “polymer-N/P”. 
Evaluation of phase transitions of the polytrehalose and trehalose solutions with 
differential scanning calorimetry (DSC) 
Aqueous solutions of trehalose (0.58 mol%, 1.30 mol%, 2.21 mol%, 3.39 mol%, 
and 5.00 mol%) and polytrehalose (0.58 mol%, 1.30 mol%, 2.85 mol%, 3.39 mol%, 5.00 
mol%, and 6.19 mol%) were prepared by weight using ultrapure water and trehalose 
dihydrate (obtained from Fisher Scientific, used as received) and polytrehalose 
correspondingly. Solutions were incubated for 12 h at 40 ºC in closed containers to 
ensure the complete dissolution of the materials. Solutions were cooled down to room 
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temperature and 7-12 mg samples were immediately transferred into aluminum pans and 
hermetically sealed. An empty aluminum pan with a lid was used as a reference. Heating 
and cooling was done at 5 ºC/min rate. Isothermal conditioning was applied for 10 min at 
both highest temperature (70 ºC) and lowest temperature (-65 ºC). The data was recorded 
for the second heat/cool/heat cycle and analyzed using TA Instruments Universal 
Analysis 2000 software, version 4.5A (Waters Corporation, Milford, MA). 
 
Figure 5. Physical properties of polytrehalose and polyplexes. (a) Depression in heats of 
ice melting, HRmR and (b) water crystallization, HRcrR, of trehalose and polytrehalose 
solutions at various concentrations. Data was not obtained for trehalose solutions above 5 
mol% due to solubility limitations. (c) Differential scanning colorimetry of a 34 mol% 
solution of polytrehalose. Isothermal conditioning was applied for both cool-heat cycles 
at the lowest temperature for 30 min. The graphical representation of the exothermic peak 
does not display a ‘loop’ (*) which results from overcooling. 
The aforementioned lyoprotective properties of trehalose have been largely 
attributed to its ability to decrease water crystallization around biological membranes and 
proteins and to decrease the energy associated with phase transitions of HR2RO 
(crystallization and melting).30 To examine whether polytrehalose retained this property, 
we analyzed both trehalose and polytrehalose solutions of various concentrations via 
differential scanning calorimetry (DSC).  Polytrehalose was similar to trehalose in 
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depressing both the heat of ice melting (HRmR) and the heat of water crystallization (HRcrR), 
up to a concentration of 2.2 mol%, and was even more effective than trehalose itself at 
higher solution concentrations (Figures 5a and 5b). At 5 mol%, polytrehalose lowers HRmR 
by an additional 24 J/g and HRcr R by an additional 35 J/g compared to trehalose; that 
concentration corresponds to about 23 water molecules per trehalose residue, which is 
nearly twice as many water molecules as are present in the hydration sphere of trehalose 
alone.31 It is known that high viscosity favors glass formation over crystallization and the 
observed enhanced efficiency is likely a result of the increased viscosity of the 
polytrehalose solution compared to that of a solution of trehalose.32,33 Importantly, it was 
also discovered that if the polytrehalose solution is cooled significantly below 0◦C but at 
least 5◦C above the temperature at which the onset of water crystallization is observed, no 
crystallization occurs even after storage (Figure 5c). These data pointed toward the 
promising attributes of utilizing polytrehalose as a barrier to increase payload stability 
and decrease nanocomplex aggregation. 
Biological studies to evaluate the copolymers on siRNA delivery (this 
section was accomplished by Lian Xue) 
Cell culture experiments 
Diethylpyrocarbonate (DEPC)-treated water for experiments involving the use of 
siRNA was obtained from Fisher Scientific (Pittsburgh, PA). Propidium iodide, 
Lipofectamine™2000, UltraPureTM Agarose-1000, trypsin, (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT), phosphate buffer saline (PBS), modified 
essential minimum eagle medium (Opti-MEM®) and Dulbecco’s modified eagle medium 
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(DMEM) were purchased from Invitrogen, Inc. (Carlsbad, CA). CellScrub™ Buffer was 
obtained from Genlantin, Inc. (San Diego, CA).  Bovine albumin was purchased from 
Sigma-Aldrich (St. Louis, MO). The Luciferase Assay Kit and cell lysis buffer were 
obtained from Promega (Madison, WI). Bio-Rad DC Protein Assay Reagent A, Reagent 
B and Reagent S were obtained from Bio-Rad Laboratories, Inc. (Hercules, CA). Anti 
luc2 luciferase siRNA (sense strand sequence 5´-GGACGAGGACGAGCACUUCUU-3´; 
antisense strand sequence 3´-UUCCUGCUCCUGCUCGUGAAG-5´) and Cy5-labeled 
anti Luc2 siRNA (sense strand sequence 5´-GGACGAGGACGAGCACUUCUU-Cy5-3´; 
antisense strand sequence 3´-UUCCUGCUCCUGCUCGUGAAG-5´) was purchased 
from Integrated DNA Technologies (Coralville, Iowa). Scrambled siRNA was obtained 
from Dharmacon, Inc (Lafayette, CO). Luciferase expressing human glioblastoma cells 
U-87 MG-luc2 (U-87_luc2) were obtained from Caliper LifeSciences, Inc. (Mountain 
View, CA).  Luciferase-expressing glioblastoma cells (U-87_luc2) were used for target 
gene (luciferase) down-regulation efficiency experiments, cellular uptake studies, and 
MTT assays for cell viability. The cells were grown in complete DMEM [supplemented 
with 10% (v:v) fetal bovine serum, 1% antibiotic-antimycotic solution (containing 
penicillin, streptomycin, and amphotericin B)] at 37 ºC and 5%.  
Cellular uptake measurement by flow cytometry  
Flow cytometry was performed to examine the cellular uptake of fluorescently-
labeled siRNA within various formulations at 3 h post-transfection. In general, luciferase-
expressing U-87_luc2 glioblastoma cells were seeded at 300,000/well in 6-well plates 24 
h prior to transfection. To transfect, 66 µL of polyplex solutions were prepared following 
the protocol described above. Each polyplex solution was pipetted into 1584 µL of pre-
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warmed Opti-MEM to yield the final transfection solution, of which 500 µL was added to 
each well. After 3 h, the media was removed and cells were washed with 500 µL/well 
CellScrub™ Buffer for 15 min at room temperature to remove any surface-bound 
polyplexes (and to ensure that the signal was coming only from internalized polyplexes). 
The CellScrub™ Buffer was then aspirated and cells were exposed to trypsin (0.05% 
(w/v), 500 µL/well) for 3 min to provide detachment from the plate, then complete 
DMEM (500 µL/well) was applied to inhibit trypsin. The cell suspension was collected 
and centrifuged at 1000 rpm for 10 min at 4oC. The supernatant was removed and cells 
were twice washed with 0.5 mL PBS and centrifuged to remove any remaining the 
extracellular polyplexes. Finally, 1 mL PBS was added and the suspensions were kept on 
ice prior to flow cytometry analysis. Propidium iodide (1.0 mg/mL, 2.5 µL) was added 
prior to the analysis. The flow cytometer (FACSCalibur, Becton Dickinson, San Jose, CA) 
equipped with a helium-neon laser to excite Cy5 at 633 nm was used to count twenty 
thousand events for each sample. The threshold fluorescence level was defined by 
manually adjusting the positive region such that <1% of negative control cells were 
positive for fluorescence.  Each treatment was performed in triplicate. 
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Figure 6. (a) Cell viability assessed by MTT assay after the incubation with various 
concentrations of polytrehalose (mean ± s.d., n = 3). (b) Cellular uptake by U-87 cells at 
siRNA concentration of 100 nM (mean ± s.d., n = 3). (c) Dependence of cellular uptake 
by U-87 cells on siRNA concentration using polymer P1 at N/P of 10 in (c) OptiMEM 
(mean ± s.d., n = 3) or (d) DMEM with 10% FBS (mean ± s.d., n = 3). (e) The rate 
of the uptake of P1−P10 polyplexes at 100 nm siRNA concentration in (e) OptiMEM 
(mean ± s.d., n = 3) or (f) DMEM with 10% FBS (mean ±s.d., n = 3). Red lines indicate 
Mean Cy5 intensity data; blue lines denote Cy5-positive cells (%). 
Upon administration and biodistribution, cellular internalization is the first barrier 
that polyplexes encounter during the delivery process. To a large degree, this is defined 
by the interactions between the nanoparticle surface and cell membranes. We have 
reported previously that incorporation of another glycopolymer, polyglucoseamine into 
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nanoparticle formulations improves cellular uptake by glioblastoma cells.34 It is also 
known that glioblastoma cells not only overexpress GLUT-129 but also that this glucose 
transporter can be employed by nanoparticles (virus) for cellular entry.35 Trehalose is 
composed of two glucose units linked via an α,α-glycosidic bond, therefore, the ability of 
polytrehalose-coated polyplexes to undergo cellular internalization in glioblastoma cells 
was studied in detail. 
Polyplexes were formulated with fluorescently-labeled siRNA, and the extent of 
their internalization by U-87 glioblastoma cells was measured with flow cytometry. All 
three polymers yielded efficient delivery of siRNA to cells and did so homogeneously 
across the cell population. More than 90% of the cells tested positive for siRNA with all 
formulations studied (Figure 4b). Polymer P1 was the most efficient among the three 
polymers tested, delivering the greatest number of siRNA copies per cell (as indicated by 
the greatest mean cellular fluorescence). It is important to note that polyplexes formed 
with each of the three polymers at N/P of 20 have similar sizes and ζ-potentials (Figure 4).  
However, the principle difference between the formulations is that the polytrehalose 
content.  Polymer P1 contains 83% of polytrehalose by mass, whereas P2 and P3 contain 
71% and 66%, respectively) which suggests that polytrehalose has a direct positive 
impact on the efficiency of U-87 uptake of these nanoparticles. Based on these initial 
uptake results, polymer P1 at N/P ratio 10 was chosen for further investigations.  
The influence of siRNA concentration in the media on uptake (Figures 6c and 6d) 
was assessed. It was observed that the number of siRNA molecules that are internalized 
by cells is linearly proportional to the concentration of siRNA in serum containing 
DMEM (Figure 6d), and with nearly perfect linearity (R2>0.99) in serum-free OptiMEM 
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(Figure 6c). The deviation from the linear dependence in serum containing DMEM is 
likely due to uptake in the presence of serum being slower. This finding shows that the 
amount of siRNA delivered to the cells can be controlled by altering the siRNA 
concentration in the media. Importantly, delivery is not saturated even at 100 nM siRNA 
concentration, meaning that this polymer can deliver higher doses of siRNA if necessary. 
The rate of the uptake was studied at 100 nM siRNA concentration and revealed 
interesting phenomena (Figure 6e and 6f). First, it is clear that polytrehalose coated 
nanoparticles internalize homogeneously across the cell population: more than 80% of U-
87 cells are transfected with siRNA within the first 30 minutes. More importantly, the 
amount of siRNA delivered is linearly dependent on time in both serum-free and serum 
containing media, with R2 values of 0.99 and 0.97 respectively. Thus, the rate of 
internalization is constant with time (zero order). In addition, in serum-free media, the 
fluorescence reaches a plateau after 2h, indicating that uptake is complete. These 
observations attest to the saturation of the internalization pathway. At this point, we are 
speculating specific receptor involvement in the uptake of the polytrehalose–coated 
polyplexes. It is worth noting that GLUT-1 operates in a saturated mode at physiological 
conditions,36 it is overexpressed in glioblastoma cells29 and is used by viruses (a 
nanoparticle-sized object) for cellular entry.35 Considering the obtained uptake results 
and the known correlation between GLUT-1 and poor response to treatment in several 
types of cancer,37-39 further investigation into polytrehalose promoted cellular entry is 
warranted. 
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Cellular uptake study via cell confocal microscopy (this work was accomplished by 
Nilesh Ingle) 
Live cell imaging experiments were performed at 1, 3, 6, 12, 24, 36 and 48 h post 
transfection. The cells were plated in 35 mm glass bottom dishes with coverslip number 
1.5 (MatTek Corporation, Ashland, MA). The cells were plated at a density of 80000 
cells/dish at 24 hours prior to transfection in 4 mL DMEM supplemented with 10 % FBS 
and 1 % AB/AM and incubated at 37 oC and 5 % COR2R.  Polyplexes were formulated by 
adding 15 µL of FITC-polymer P1 at 10 N/P ratio to 15 µL of Cy5-siRNA at 2 µM in 
DEPC treated water and then incubated for 1 h at room temperature. Prior to transfection, 
the polyplex solution was diluted by adding 270 µL of OptiMEM® to make a final 
volume of 300 µL (final siRNA concentration of 100 nM). The cells were transfected by 
adding 300 µL/dish of diluted polyplex solution. The cells were allowed to transfect for 3 
h at 37 ºC and 5 % COR2R.R RFor the timepoints of 1 and 3 h, the cells were washed with PBS 
and 4 mL of phenol red-free DMEM was added to each dish and imaged directly. For 
time points 6, 12, 24, 36 and 48 h, the cells were washed with PBS and 4 mL of 10 % 
FBS DMEM was added to the dish and further incubated for subsequent time points prior 
to imaging. In addition, for time points 36 and 48 h, the media was replaced with 4 mL of 
fresh 10 % FBS-containing DMEM at 24 hours post transfection. The controls were: (1) 
cells only, where the cells were not transfected, (2) FITC only, where the cells were 
transfected with polyplexes (where the only the polymer was labeled with FITC), (3) Cy5 
only control cells were transfected with polyplexes where only the siRNA was labeled 
with Cy5.  
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Olympus FluoView FV1000 inverted confocal microscope was used for imaging. 
The image size was 1024*1024 pixels (12 bits).  Sampling speed was 2.0 µs/pixel. The 
oil immersion objective used was PLAPON 60X O NA:1.42. The fluorophores used were 
FITC (fluorescein isothiocyanate) and Cy5 (Cyanine 5). The polymer was labeled with 
FITC in our laboratory as described above, and the Cy5 labeled siRNA was ordered from 
Integrated DNA Technologies (Coralville, Iowa). The FITC fluorophore was excited by a 
488 nm laser and the Cy5 fluorophore was excited by 633 nm laser and all the images 
were acquired at the same laser settings and analyzed using Olympus FLUOVIEW 
software. 
 
Figure 7. Confocal microscopy of U-87 cells transfected with Cy5-labeled siRNA 
(magenta) and FITC-labeled P1 (green) at N/P ratio 10. Cells were images at 0, 1, and 3 h 
after transfection (the time point of 0 = cells only).  
Efficient uptake was also observed with confocal microscopy using Cy5-labeled 
siRNA and FITC labeled polymer P1 (Figure 7). After the first hour of incubation, the 
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punctuate nature of the fluorescence was observed in both Cy5 and FITC distributed 
throughout the cytoplasm. Distribution of the polyplexes inside the whole cell, rather than 
near the cellular membrane, indicates that trafficking of the particles is a rapid process. 
To visualize this polyplex trafficking, live cell imaging was used to compile a 6 minute 
video of P1polyplex (formulated at N/P 10) trafficking in U-87 cells 2 hours after 
transfection (see SI for the time-lapse video). The video reveals that the polymer and 
siRNA are associated as discrete polyplexes and active trafficking appears to take place 
as the polyplexes are shuttled around the cytoplasm. 
Luciferase assay and protein assay 
Luciferase-expressing glioblastoma cells (U-87_luc2) were seeded at 50,000 
cells/well in 24-well plates 24 h prior to transfection. The anti-luciferase (Luc2) siRNA, 
control (siCon) siRNA, and polymer stock solutions were diluted with RNase-free water, 
and polyplexes were prepared following the protocol. The polyplex solution was diluted 
to a desired siRNA concentration (1 nM, 3 nM, 10 nM, 30 nM, 100 nM) with pre-
warmed Opti-MEM or DMEM with 10% FBS to yield the transfection solutions. Cells 
were washed with PBS before the addition of 200 µl of the transfection solution. The 
formation of siRNA-containing lipoplexes using Lipofectamine2000 was performed 
according to the manufacturer’s protocol.  
The cells were incubated with polyplex/lipoplex solutions for 4 h before complete 
DMEM was added. After 48 h, the cells were washed with 500 µL PBS and treated with 
1x cell lysis buffer for 15 min at room temperature.  Aliquots (5 µl) of cell lysate were 
examined on 96-well plates with a luminometer for luciferase activity over 10 s with 100 
μL of luciferase substrate added in each well immediately prior to relative light unit 
129 
 
(RLU) determination. The average of duplicate fluorescence measurements was utilized 
for calculation.  
The amount of protein (mg) in cell lysates was calculated using a standard curve 
generated with bovine serum albumin by following the protocol included in Bio-Rad DC 
protein assay kit. The relative light unit (RLU)/mg protein was then calculated and 
averaged across replicate wells for comparison. The protein and luciferase levels of non-
transfected cells were used for normalizing the data and calculating the extent of gene 
knockdown. Each treatment was tested in triplicate in 24-well plates. 
U1. Luciferase assay to evaluate the pDNA and siRNA delivery facilitated by 
polyglucose diblock copolymers. 
A)      B) 
 
Figure 8. A) Luciferase gene expression and cell viability observed in HeLa cells 
transfected with polyplexes formed at N/P ratios of 2, 5, and 10 with pDNA and P1, P2, 
and P3 in (a) Opti-MEM and (b) DMEM. Error bars represent the standard of deviation 
of analyzed data from three replicates. Measurements found to be statistically significant 
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(p < 0.05) compared with cells only marked with an asterisk. B). Luciferase gene 
expression (bars, left y axis) and cell viability (points, right y axis) in U-87 cells that 
stably express luciferase. The cells treated with polyplexes formed at an N/P ratio of 20 
with an antiluciferase siRNA (100 nM) and glycopolymers P1, P2, and P3 in Opti-MEM. 
The percentage gene knockdown compared with the cells only control is given as 
numbers above the corresponding bars. Measurements found to be statistically significant 
(p < 0.05) compared with cells only are marked with an asterisk. Error bars represent the 
standard of deviation of analyzed data from three replicates. 
 
As indicated in Figure 8A, the pDNA delivery was conducted in two different 
media. For most of the formulations, there is no significant gene expression observed, 
while for polyplexes P1/pDNA at N/P=10, dramatic luciferase expression was observed 
in the tranfection conducted in Opti-MEM. Cells treated with polyplexes formed with the 
glycopolymers P1 and P2 and the antiluciferase siRNA did not show significant gene 
knockdown compared with the negative controls. Remarkably, glycopolymer P3 
demonstrated luciferase gene knockdown on par with Lipofectamine 2000 (72% for P3 
and 77% for Lipofectamine 2000). The polyplexes composed of P3 + siCon also 
demonstrated statistically significant gene knockdown (17%), potentially due to the 
positive charge on P3 after releasing siCon leading to increased off target effects. As 
denoted in Figure 8B (right y axis), the cell viability was very high at these polyplex dose 
ratios, and thus the toxic effects were minimal. These results demonstrate how small 
differences in the polymer structure can have a large impact on delivery and efficacy of 
both pDNA (to the nucleus for gene expression) and siRNA (to the cytoplasm for gene 
knockdown). 
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U2. Luciferase gene knockdown via siRNA facilitated by polytrehalose diblock 
copolymers. 
 
Figure 9. Luciferase gene knockdown in luciferase-expressing U-87 cells. Cells were 
transfected in a. OptiMEM and b. serum-containing DMEM (mean ±s.d., n=3). c. 
Evaluation of the efficiency of gene down regulation on siRNA concentration. 
Transfections were performed in OptiMEM (mean ±s.d., n=3). d. Comparison of target 
gene down-regulation in luciferase-expressing U-87 cells between freshly-prepared P1 
polyplexes and previously-lyophilized P1 polyplexes. Transfections were performed at an 
siRNA concentration of 100 nM in OptiMEM (mean ±s.d., n=3). Labels signify “polymer 
name-N/P ratio”, Lipo=Lipofectamine, siCon=siRNA with scrambled sequence (negative 
control), “cells” = no treatment was applied to cells (negative control). 
The major goal of the biological investigation was to establish cellular 
internalization properties of the polytrehalose containing nanoparticles and cationic block 
was not optimized for siRNA release, but it was also important to investigate the ability 
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of polyplexes to down-regulate a target gene. The evaluation was performed in U-87 
glioblastoma cells that stably express luciferase. The extent of gene down-regulation was 
assessed by the decrease in light production via luciferase assay. All three polymers 
promoted significant gene knockdown in OptiMEM (Figure 9a). The efficiency of gene 
down-regulation increased with an increase in N/P ratio and at an N/P of 20 was similar 
to that of Lipofectamine. In serum-containing DMEM, only polymer P1 was capable of 
promoting gene knockdown. We also investigated the dose response of the gene down-
regulation. In contrast to the uptake response, which was linearly dependent on siRNA 
concentration (Figures 6c and 6d), the dependence of the extent of gene knockdown 
exhibited a logarithmic dependence on siRNA concentration (Figure 9c). The ICR50R value 
for luciferase gene down-regulation promoted by P1 at N/P 10 with siRNA was 
calculated to be 19 nM.   
It was of interest to probe the ability of the polytrehalose containing nanoparticles 
to retain siRNA-mediated gene down regulation after lyophilization and subsequent 
resuspension.  Polymer P1 was chosen for these studies because it contains the largest 
amount of polytrehalose among three polymers and it was found to promote the optimal 
polyplex resuspension after lyophilization and also revealed to be the most effective at 
siRNA delivery.  Therefore, we hypothesized that it would impart the greatest ability to 
preserve the biological activity of polyplexes. 
Formulations of P1-siRNA polyplexes were lyophilized, and the dry powder was 
resuspended in RNase-free water. Gene down-regulation by the resuspended polyplexes 
was compared to freshly-prepared polyplexes made with the same polymer (Figure 9d). 
The extent of luciferase gene down-regulation induced by the lyophilized/resuspended 
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polyplexes was identical to that observed with the freshly-prepared analogs. This result 
shows that this polytrehalose motif displayed on the surface of the polyplexes indeed 
retains the lyoprotective property of trehalose in inter-polyelectrolyte siRNA 
nanoparticles during the freeze-drying process. 
Using confocal microscopy we have investigated fluorescently-labeled polyplexes 
after uptake into U-87 cells for 48 hrs when gene down-regulation was measured (Figures 
10 A-B). 
A). 
 
B). 
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Figure 10 A-B. Confocal microscopy images obtained at various time points for cells 
transfected with polyplexes that were prepared with P1-FITC and Cy-siRNA at N/P ratio 
10 and siRNA concentration 100 nM.  
Despite the active trafficking observed immediately following the uptake as 
discussed above, the punctuate nature of the fluorescence remains visually unchanged up 
to 12 h (Figure 7). At 24 h, however, there is a sharp drop in Cy5 fluorescence, indicating 
that siRNA release takes place between 12 and 24 hours post transfection. At the same 
time FITC fluorescence that corresponds to the polymer FITC-P1 is maintained 
throughout the microscopy experiment (up to 48 h, Figure 10B) and remains punctuate. 
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Assessment of toxicity via MTT assay 
MTT reagent (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) 
was used to estimate the cytotoxicty of the formulations. MTT can be reduced to purple 
formazan in living cells under the catalysis of mitochondrial reductase. Typically, U-
87_luc2 glioblastoma cells were seeded at 50,000 cells/well in 24-well plates 24 h prior 
to transfection. The polyplexes were formed following the procedure described above. 
Transfection media (200 µL) was added to each well; 4 h later, complete DMEM was 
added at a concentration of 1 mL/well. Twenty four hours later, the media was aspirated 
and the cells were washed with PBS (500 µL/well). Serum-containing DMEM (1 mL) 
with 0.5 mg/mL of MTT was added to each well and the cells were incubated for 1 h. The 
media was then replaced with 600 µL of DMSO for 15 min at room temperature. A 200 
µL aliquot of the media was transferred to a well of a 96-well plate for analysis by 
colorimeter with wavelength at 570 nm. Samples of non-transfected cells were used for 
the normalization. 
  
Figure 11.  MTT assay in U-87 cell line with various polyplex formulations. Bars 
indicate cellular metabolism (mean ±s.d., n=3). siRNA concentration was 100 nM in all 
cases. Labels signify “polymer–N/P ratio (e.g. P1-10).  
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As indicated in Figure 11, all the polyplexes in the test didn’t show cytotoxicity at 
selective N/P values through MTT assay.  
Discussion and conclusion 
The siRNA-based therapeutics has great potential although there are still a lot of 
challenges to be addressed. From the luciferase gene knockdown experiments for 
polyglucose copolymers, we have observed the P3 with longest chain length of AEMA 
achieved significant target gene knockdown whereas P1 and P2 didn’t show any effect on 
siRNA mediated gene knockdown. Therefore the length of primary amine block on the 
polymer chains plays an important role in search of effective polymers for siRNA 
delivery. On the other hand, the polytrehalose motif presented in this study has many 
valuable and interesting properties that make it a candidate for inclusion within the outer 
layer of macromolecules and nanosystems.  
Both series of polymers can be readily synthesized via RAFT polymerization. The 
monomers for polyglucose can be readily synthesized, but trehalose monomer 
preparation requires several steps to prepare and can be achieved on a multigram scale 
starting with trehalose. Additionally, aided by RAFT polymerization, polyglucose, 
polytrehalose and polyglucose/polytrehalose containing diblock polymers can be 
synthesized with a predefined length and low polydispersity via polymerization without 
use of protecting groups.  
It was demonstrated that polytrehalose, similar to trehalose itself lowers the 
energy of phase transition (liquid to solid, and solid to liquid) of an aqueous solution, and 
this property allowed us to lyophilize siRNA polyplexes without loss of biological 
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function. Moreover, the polytrehalose did not exhibit cytotoxicity at all concentrations 
tested (up to 10 mg/ml). 
Polytrehalose was shown to promote polyplex internalization by U-87 
glioblastoma cells. The cellular uptake had zero order kinetics in both tested cell culture 
media and is directly proportional to the concentration of polytrehalose containing 
polyplexes in the media. Based on the results of the uptake experiments, we speculate 
that a carbohydrate-binding receptor may be responsible for the high efficiency of uptake. 
The successful use of polytrehalose in polymers for siRNA delivery was demonstrated in 
luciferase expressing U-87 glioblastoma cells. This activity was preserved following the 
lyophilization of polyplexes, potentially enabling the storage of the therapeutic siRNA 
formulations as dry powders and simplifying transportation.  The remarkable properties 
demonstrated by polytrehalose make it particularly interesting stabilizing structure for 
study in macromolecule and nanoparticle formulations including micelles, liposomes, 
proteins, gold nanoparticles, and quantum dots.  
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Chapter 4. 
 
Trehalose Containing Lanthanide Click Polycations for 
 siRNA Delivery and Tracking  
 
This chapter is based on the manuscript: 
1. Lanthanide-Containing Polycations for Monitoring Polyplex Dynamics via Lanthanide 
Resonance Energy Transfer. Sneha S. Kelkar, Lian Xue, S. Richard Turner, and Theresa 
M. Reineke Biomacromolecules 2014 15 (5), 1612-1624  
2. Trehalose containing lanthanide click polycations for siRNA delivery and tracking into 
glioblastoma cells. Lian Xue, Nilesh Ingle and Theresa M. Reineke. Manuscript in 
preparation for ACS publication. 
 
 
Background 
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Lanthanide containing polymers have driven increasing attention in search of 
effect MRI contrast agents and sensors for biomedical applications. Trehalose, known for 
its preservation and stabilization effects, has been found to be prevalent in natural living 
beings and used broadly in pharmaceutical industries.  Previously, we had demonstrated 
the effectiveness of incorporating trehalose into polymers to promote siRNA delivery 
profile. Here, we have developed the alternating polymers that combine the structures of 
trehalose, lanthanide-chelating domains and oligoamines. By chelating with europium, 
gadolinium and terbium ions, the polymers offered the corresponding properties for 
luminescence and MRI contrast capabilities. The presence of trehalose in the polymers 
has greatly increased the effectiveness of siRNA mediated gene knockdown in 
glioblastoma cells. The polymer chelates were calculated to show that there is 
approximately one water coordination site per chelate according the Horrock’s equation 
upon measuring luminescent lifetimes of Terbium containing polymers. Compared with 
commercially available MRI contrast agent Magnevist®, gadolinium-chelating polymers 
are found to achieve more than twice longitudinal relaxivities (r1 per Gd) in two different 
magnetic fields. Dynamic light scattering study shows that sizes of polyplexes formed 
with siRNA are all below 100 nm and zeta potentials are above 25 mV, which are 
significantly different from those polymers without trehalose domains. From 
flowcytometry and luciferase gene knockdown experiments, the trehalose containing 
polymers achieved efficiency in siRNA delivery than those polymers without trehalose 
domains. Fluorescence resonance energy transfer (FRET) studies were applied to monitor 
polyplexes association and dissociation. The donor-acceptor pairs in the two systems are 
europium-chelating polymers with cyanine dyes (Cy5)-labeled siRNA and terbium-
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chelating polymers with tetramethyl rhodamine (TMR)-labeled siRNA. All the 
polyplexes formed with siRNA have shown no cytotoxicity. This preliminary research 
has provided the evidence for effectiveness of trehalose containing lanthanide polymers 
as both siRNA delivery and monitoring materials.  The trehalose domain has been 
demonstrated to play an important role in effective siRNA delivery. 
Introduction 
Nucleic acid based therapeutics has been emerging in the last two decades as a 
new approach in addition to traditional small molecular drugs1,2.  The small interference 
RNA (siRNA) has been studied and optimized to be suitable for RNA interference (RNAi) 
both in laboratory and clinical trials3-5. The major challenge for developing siRNA 
delivery is the negatively charged nature of siRNA that prevents it from cellular uptake6,7 
and immunogenicity8_ENREF_6. In addition, siRNA is more vulnerable to enzymatic 
degradation compared with pDNA7,9. A variety of vehicles have been developed to help 
encapsulate siRNA into nanoparticles for cellular uptake10-13. The nanoparticles then will 
be released into cytoplasma from endosomes/lysosomes to reach the RISC (RNA 
intermediated silencing complex), which is the machinery responsible for siRNA 
processing and binding to corresponding mRNA to initiate the degradation2,7,14. The non-
virus delivery vectors, they can be categorized into two types, the lipid based and 
polymer based. There are two pioneer polymer based materials: poly(ethylene) imines 
(PEI) and chitosan. Inspired by the two pioneers in nucleic acid delivery, PEI and 
chitosan, we had developed the trehalose click cationic polymers by combining the 
disaccharide trehalose with oligoamines via copper(I) catalyzed click reaction to balance 
the pros and cons of the two materials. Trehalose as a non-reducing disaccharide is stable 
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to acidic hydrolysis and protects the cells from dehydration and oxidative stress. The 
preliminary research has shown that the trehalose click polycations could successfully 
form nanoparticles with siRNA and effectively deliver them into glioblastoma cells with 
no toxicity found. Several researches also showed that the trehalose could have an anti-
aggregation effect for pathological proteins and prevent nanoparticles from aggregation 
in serum media15,16.  During the freezing cycles and dehydration, the trehalose can help 
preserve the biological structures of the creatures as well as biological products in these 
extreme conditions17-20. It is also reported that in the presence of trehalose, the delivery 
efficiency of PEI for pDNA can be improved through a variety of cell lines21.  By coating 
the poly(trehalose) block to polycationic block, the diblock copolymers can be applied to 
deliver siRNA into glioblastoma cells in a dose dependent manner22. The poly(trehalose) 
block also showed lyoprotective and cryoprotective properties.  
The interdisciplinary research in fields of nanomaterials and biomedical sciences 
has led to the increasing demands for smart materials that can combine therapeutic and 
imaging into one functional entity23. Visualizing the pathological tissues and guiding the 
drug delivery is challenged by many biological barriers. To reduce the multiple dosage of 
drug administration for diagnosis and real-time drug delivery monitoring, the theranostic 
materials are required. There are a variety of imaging agents involved to monitor delivery 
process, including fluorescent markers24-27, MRI contrast components28,29 and radio-
labeled domains30. FRET(Förster resonance energy transfer)31,32, which indicates non-
radioactive energy transfer between two chromophores in a distance dependent manner, 
has been applied in a variety of biomaterials to monitor gene delivery profiles by 
functionalizing the delivery system with organic dyes 33,34 . Two chromospheres with an 
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emission and excitation spectra closely overlap and spatial proximity of 1-10 nm can act 
as “FRET” pairs31. The complexation and dissociation of the drugs and vehicles will 
trigger the FRET signal diminishment and restoration, and in this way, the researchers 
can monitor the drug delivery profile35. Also, FRET was found to be a sensitive method 
to measure the transition of monomer-dimer transition in biological studies36.  A variety 
of studies have shown that FRET with organic dyes have issues, such as photobleaching, 
short fluorescence lifetime, and emission spectral overlaps37, therefore, ideal FRET pairs 
that can prevent these problems are desired. To overcome these limitations, inorganic 
quantum dots38 or luminescent lanthanide have been explored.  
In this study, we have developed a series of trehalose based lanthanide-containing 
polycations for siRNA delivery and detection. In the previous study, polymers that are 
synthesized by polymerization of tetraethyleneamines or pentaethyleneamines and 
gadolinium or europium chelates had been reported to successfully deliver the pDNA to 
HeLa cells and reveal the property of MRI contrast capability39. The microscopy of the 
luminescent europium ion chelated polymers had shown the localization of the 
polyplexes in cytoplasma after successful cellular uptake, while the tranfection efficiency 
of pDNA as expression profiles were found to be low39.  Therefore, we propose that the 
biodegradability and charge density of polymer backbones can be major factors that 
hinder the dissociation of the polyplexes, escaping from endosome and entering into the 
nucleus. In order to deliver siRNA, biodegradable and biocompatible polymers that can 
release the siRNA into the target sites are needed. Therefore, we sought to extend the 
polymer with trehalose motif in an alternating manner with lanthanide chelates and 
pentaethyleneamines. The trehalose domains are proposed to be a component in 
146 
 
increasing the biodegradability of the polymer and promoting the stability in the 
biological conditions; the lanthanide domain provides the imaging property and 
oligoamines domains provide the electrostatic interaction with negative charged siRNA. 
Further, we developed the lanthanide based FRET method to monitor the polyplexes 
packing and unpacking process in vitro using two FRET pairs: the Tb3+  chelated polymer 
(donor) with tetramethyl rhodamine(TMR) labeled siRNA (acceptor) and the Eu3+ 
chelated polymer (donor) with cyanine dye (Cy5) labeled siRNA (acceptors). Several 
research groups have also developed the FRET system to monitor siRNA, such as 
Anderson’s group, who built the nanocomplexes that can aggregate the fluorophores 
locally to facilitate the FRET monitoring 40. Kissel’s  group has developed triblock 
copolymers with quantum dots mediated FRET to monitor nucleic acid unpacking41. The 
lanthanide-organic dye FRET pairs have been reported to be used for examining protein 
conformational changes in biochemistry studies, while the use of lanthanide based FRET 
to study the polymer siRNA complexation and dissociation is reported for the first time. 
In vitro cell transfection studies have shown that all three trehalose containing lanthanide 
polymers can deliver siRNA into glioblastoma cells and achieve target gene knockdown. 
A significant enhancement of transfection efficiency was observed by inserting trehalose 
motif in the polymers. No apparent cytotoxicity was found throughout all the experiments 
with these type of polymers. The preliminary results of the experiments suggest that these 
structures could be applied for both siRNA delivery and imaging in the future 
development. 
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Figure 1. Structures of trehalose containing lanthanide click polycations and illustration 
of FRET for polymer and siRNA.   
 
Experiments and results 
Materials 
U-87 MG-luc2 (U-87_luc2) cells, human glioblastoma cells genetically 
engineered to constitutively express luciferase, were obtained from Caliper LifeSciences, 
Inc. (Mountain View, CA). Luc2 siRNA, which targets luc2 luciferase, and a Cy5-labeled 
Luc2 siRNA were obtained from Integrated DNA Technologies, Inc. (Coralville, IA). 
The sequence of the sense strand of the Luc2 siRNA is 5’-
GGACGAGGACGAGCACUUCUU-3’, and the antisense strand sequence is 3’-
UUCCUGCUCCUGCUCGUGAAG-5’. The Cy5 fluorophore within the Cy5-labeled 
Luc2 siRNA was conjugated to the 3’ terminus of the sense strand (5’-
GGACGAGGACGAGCACUUCUU-Cy5-3’).  The TMR fluorophore within the TMR-
labeled Luc siRNA was conjugated covalently to the 3’ terminus of the sense strand (5’-
GGACGAGGACGAGCACUUCUU-TMR-3’). (Scrambled siRNA (siCon) was 
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purchased from Dharmacon, Inc (Lafayette, CO). DMEM+GlutaMAXTM-I (DMEM), 
Opti-MEM I+GlutaMAXTM-I (Opti-MEM), UltraPureTM Agarose-1000, MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), propidium iodide (1.0 mg/mL 
solution in water), PBS pH=7.4, trypsin, antibiotic-antimycotic and Lipofectamine™2000 
(Lipo) were obtained from Invitrogen, Inc. (Carlsbad, CA). DEPC-treated water for the 
RNA work was obtained from Fisher Scientific (Pittsburgh, PA). INTERFERin™ was a 
gift from Polyplus-Transfection (Strasbourg, France). The jetPEI™ was purchased from 
Polyplus-Transfection (above). The Luciferase Assay System was obtained from 
Promega Corporation (San Luis Obispo, CA). Bio-Rad DC Protein Assay Reagent A, 
Reagent B, and Reagent S were obtained from Bio-Rad Laboratories, Inc. (Hercules, CA). 
CellScrub™ Buffer was obtained from Genlantin, Inc. (San Diego, CA).  Bovine albumin 
and all chemicals used in polymer synthesis were purchased from Sigma-Aldrich (St. 
Louis, MO) at the highest possible purity. Spectra/Por® dialysis membranes (MWCO: 
1000) were obtained from Spectrum Laboratories, Inc. (Rancho Dominguez, CA). 
Glycofect Transfection ReagentTM, having a degree of polymerization of approximately 
11 was donated by Techulon, Inc. (Blacksburg, VA).  
Dry methylene chloride, dimethyl formamide and methanol were obtained using 
an MBRAUN MB solvent purification system manufactured by M. Braun Inertgas-
Systeme GmbH (Garching, Germany), using HPLC grade solvents obtained from Fisher 
Scientific Co (Pittsburgh, PA). Thin layer chromatographies (TLC) were done using 
aluminum-backed silicagel plates (silicagel 60, FR254R) obtained from Merck (Darmstadt, 
Germany) and visualized using UV light (254 nm) or staining agents: ninhydrin solution 
in ethanol for the visualization of amines, p-anisaldehyde solution in HR2 RSOR4R/acetic 
149 
 
acid/ethanol for the visualization of carbohydrates. Preparative chromatographies were 
performed using a Buchi Separcore chromatography system, (Buchi Labortechnik AG, 
Switzerland) using Buchi plastic chromatography cartridges or homemade glass columns 
manually packed with 60-200 mesh Premium Rf silicagel (Sorbent Technologies Inc., 
Atlanta, GA). All solvents used for preparative chromatography were HPLC grade 
obtained from Fisher Scientific Co (Pittsburgh, PA). LC-MS data was obtained with an 
Agilent system, Agilent Technologies (Santa Clara, CA) with a time-of-flight (TOF) 
analyzer coupled to a Thermo Electron TSQ-LC/MS ESI mass spectrometer. NMR 
spectra were recorded using 400MR Varian-400 Hz spectrometer in deuterated solvents, 
namely DR2RO, dR4R-MeOD, dR6R-DMSO, CDClR3 R, CDR2RClR2. RAll deuterated solvents were 
purchased from Cambridge Isotope Laboratories, Inc. (Andover, MA). 1H-NMR spectra 
were recorded at 399.7 MHz and 13C-NMR spectra were recorded at 101 MHz. Spectra 
were analyzed using MNova software (version 7.0.1-8414, Mestrelab Research S.L. 
(Santiago de Compostela, Spain)). 
SEC was conducted using 1.0 wt% acetic acid/0.1 M NaR2RSOR4R as the eluent at a 
flow rate 0.3 mL/min on size exclusion chromatography columns [CATSEC1000 (7μ, 
50×4.6), CATSEC100 (5μ, 250×4.6), CATSEC300 (5μ, 250×4.6), and CATSEC1000 (7μ, 
250×4.6)] obtained from Eprogen Inc. (Downers Grove, IL). Signals were acquired using 
Wyatt HELEOS II light scattering detector (λ = 662 nm), and an Optilab rEX 
refractometer (λ = 658 nm). SEC trace analysis was performed using Astra V software 
(version 5.3.4.18), Wyatt Technologies (Santa Barbara, CA). Biological sample 
fluorescence was measured with GENios Pro luminometer (TECAN US, Research 
Triangle Park, NC). Quartz Crystal Microbalance (QCM) experiments were performed on 
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Q-Sense E4 QCM (Q-sense; Vastra Frolunda, Sweden) instrument. Differential scanning 
calorimetery (DSC) was conducted on a TA Instruments Q100 under nitrogen. 
Synthesis of the monomers and polymers  
Synthesis of 2,3,4,2’,3’,4’-hexa-O-acetyl-6,6’-diazido-6,6’-dideoxyl-D-trehalose  
 
Scheme 1. Synthesis of the hexa-O-acetyl-diazido -D-trehalose 
The compound was synthesized according to a previously-published procedure. 
The final product was purified on a silica gel column using 10% (v:v) diethyl ether in 
DCM. Fractions containing the product were collected, the solvent was evaporated, and 
the products were further recrystallized from 10% (v:v) ethyl acetate in diethyl ether to 
yield fine white crystals. The total % yield from starting materials to final product was 
33%.  
1H-NMR (400 MHz, CDClR3R) δ ppm: 5.49 – 5.40 (overlapping triplets, 2H, 3,3’), 5.39 – 
5.29 (d, 2H,1,1’), 5.19 – 5.07 (dd, 2H, 2, 2’), 5.01 – 4.96 (t, 2H, 4,4’), 4.06-4.12(m,2H, 
5,5’), 3.39-3.34, 3.19-3.15(dd, 4H, 6, 6’), 2.12-2.03 (m, 18H, COCHR3R), 13C-NMR (101 
MHz, CDClR3R) δ ppm: 171.3, 104.5, 71.4, 70.3, 67.7, 49.3, 22.0. ESI-MS positive ion 
mode: found m/z [M+Na]+ 667.18, [M+NHR4R]+662.21, [M+H]+ 645.19.  
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a)                                                                b)
 
Figure 2.  Structural determination of 2,3,4,2’,3’,4’-hexa-O-acetyl-6,6’-diazido-6,6’-
dideoxyl-D-trehalose. a). 1H-1H COSY to assign the proton peaks on trehalose backbones. 
b). ESI-MS to confirm the mass of the compound.   
 Synthesis of trehalose Pentaethyleneamine click macromonomer 
 
Scheme 2: Synthesis the Trehalose Pentaethyleneamine click macromonomer.  
The pentaethylene amines were purified via reflux prior to the reaction.  The 
primary amines of each side of pentaethylene amines were protected via reacting 
with 48Tethyl trifluoroacetate, then di-tert-butyl dicarbonate were added dropwise under 
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room temperature to yield the fully protected pentaethylene amines. The deprotection of 
primary amines from fully protected pentaethylene amines were performed by refluxing 
with potassium carbonate in methanol. One of the primary amines is further protected 
with carboxybenzyl group at reaction ratio of 1:1.2, then the other primary amine reacted 
with propiolic acid via DCC (dicyclohexylcarbodiimide) coupling to yield 48T1-alkyne-6-
carboxybenzyl-2,3,4,5-tetra(48Ttert-butyloxycarbonyl48T)-pentaethylenetetraamine(compound48T 
g). The compound g then reacted with compound c (2,3,4,2’,3’,4’-hexa-O-acetyl-6,6’-
diazido-6,6’-dideoxyl-D-trehalose) via copper(I) mediated azide– alkyne cycloaddition to 
yiel48Td dicarboxybenzyl pentaethylenetetraamine click trehalose macromonomers h. The 
products then underwent hydrogenation with Pd on carbon to remove the carboxybenzyl 
group from each side to yield the macromonomer I with primary amines on both sides.  
1). 2,3,4,5-tetra (48Ttert-butyloxycarbonyl 48T)-pentaethylenetetraamine  
The starting material (d) was purified via reflux in oxygen free condition. The 
purified d (yellowish oil like liquid) 62.23g (268.23mmol) was dissolved in 400 ml 
anhydrous MeOH processed via solvent purification system. The CF3COOEt 84.0g 
(591.4 mmol) was dissolved in 300 ml anhydrous MeOH. The so formed solution was 
added into reaction dropwise under NR2R for 24 hrs. The (Boc)R2RO 244.5g (1120 mmol) was 
dissolved in MeOH and added into the solution. The nitrogen was removed and the 
solution was stirred for another 4 hrs.  Extra (Boc)R2RO of 10g was added into the solution 
and stirred for another 2 hrs. The solid was removed from the reaction and the solution 
was concentrated for flash column. The unreacted (Boc)R2RO was washed off as an oil like 
liquid. The solution was further concentrated, and the impurity was washed off by EtOAc 
to yield white solid. The whole mixture was dispensed in hexane and the solid was 
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collected, followed by using EA: hexane 1:1 to recrystalize the compound to yield white 
powder N6CF3Boc 55.34 g. 27.06 g of the N6CF3Boc was dissolved in 1000 ml round 
bottom flask and dissolved in MeOH, 20 ml water and 28.97 g KR2RCO R3 Rwas added into the 
solution. The mixture was refluxed at 80oC for 12 hrs. The white solid was filtered off, 
then the solution was concentrated and the solvent was evaporated. The solid was 
dispensed in chloroform then the solid was filtered off.  The solution was dried via 
addition of NaR2RSO R4R then filtered and concentrated. The product was further recrystalized 
in EtOAc:hexane=3:1. The white solid was collected, dried and characterized. Yield of 
two steps is calculated to be 37%. 
1H-NMR (400 MHz, CDClR3R) δ ppm: 3.32-3.23 (overlapping d, 20H, -NBocCHR2R-), 2.83-
2.79 (dd, 4H, NHR2RCHR2R-), 1.61-1.45(s, 36H, -NCOO(CHR3R)R3R). 
2). 1-carboxylbenzyl-2,3,4,5-tetra(tert-48Tbutyloxycarbonyl) pentaethyleneamines 
48T he 2,3,4,5-tetra (tert-butyloxycarbonyl) pentaethyleneamines (compound e, 
N6Boc) 2.47g (3.92 mmol) and carboxylbenzyl chloride (CbzCl) 0.65 g(3.81 mmol) are 
dissolved in two flasks respectively with DCM. Then the CbzCl solution was added 
dropwisely into the N6Boc solution at -25oC (the ice bath was prepared with NaCl mixed 
with ice) for 4 hrs. Then the solvent was evaporated, and the products was separated via 
silica gel chromatography with gradual polarity of mobile solution from Hexane:EA=3:1 
to EA to EA:EtOH=5:1.  Then the products were collected and concentrated, followed by 
recrystalization in Hexane: EA=1:1 to yield 1.59 g product f. 
1H-NMR (400 MHz, CDClR3R) δ ppm: 7.26-7.23 (m, 5H, -C6H5), 5.12-5.09 (s, 2H, -
COOCHR2 RPh), 3.38-3.22 (br, 20H, -CH2CH2-), 1.53-1.23 (br, 36H, -OC(CHR3R)R3R).  
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3).1-alkyne-6-carboxybenzyl-2,3,4,5-tetra(48Ttert-butyloxycarbonyl48T) 
pentaethylenetetraamine 
48T he product f (N6BocCbz) (50.2mg) was dissolved in DCM. The DCC (N,N'-
Dicyclohexylcarbodiimide) (50mg) and propiolic acid (15 mg) were mixed in the DCM. 
Then the solution of N6BocCbz was added dropwise into the mixture of DCC and 
propiolic acid at 0oC. The ice bath was removed once the addition was over followed by 
an overnight reaction. The mixture was washed with water 3 times and organic layers 
were collected and dried with Na2SO4. Then the solvent was removed via evaporation, 
and the product was separated via chromatography using the gradient mobile phase of 
MeOH: DCM=0-0.2. Then 42.3 mg (% yield of 79.4%) of white powder was obtained 
and examined.  
48T
1H-NMR (400 MHz, CDCl3) δ ppm: 7.32-7.24 (br, 5H, -C6H5), 5.07 (s, 2H, -COOCH2-), 
3.41-3.30 (br, 20H, -CH2CH2-), 2.73 (s, 1H, -CCH), 1.46-1.43(br, 36H, -OC(CH3)3). 
ESI-MS: calculated mass: 819.0, found [M+H]+ : 819.49. 
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Figure 3. ESI-MS characterization of compound 1-alkyne-6-carboxybenzyl-2,3,4,5-tetra 
( 48Ttert-butyloxycarbonyl 48T) pentaethylenetetraamine.   
4). di-pentaethylenetetraamine click trehalose macromonomers (N4-Tr-N4) 
The 1-alkyne-6-carboxybenzyl-2,3,4,5-tetra (48Ttert-butyloxycarbonyl 48T) 
pentaethylenetetraamine (compound g) (212.7 mg), 2,3,4,2’,3’,4’-hexa-O-acetyl-6,6’-
diazido-6,6’-dideoxyl-D-trehalose (80 mg), sodium ascorbate (9.84 mg) were put into 
flask and 1ml tBuOH was added. CuSOR4R (18.9 mg) was dissolved in 1ml HR2RO and added 
into the reaction. The mixture was stirred for 24hrs at 50oC. The mixture was then 
dispensed in 1ml DMSO, followed by dispersed into 10 ml H R2RO. The white solid was 
collected and dried to yield the product h 261.8 mg (% yield of 90.2%).  
48T
1H-NMR (400 MHz, CDCl3) δ ppm: 8.02-8.01(s, 2H, triazole H), 7.20-7.19(m, 10H, -
CR6RH R5R), 5.34(t, 2H, -1,1’ trehalose H),  5.10-4.92 (s, 4H, -CHR2R-Ph),  4.83-4.41 (m, 8H, -
2,2’,3,3’,4,4’,5,5’-trehalose H), 3.42-3.21(s, 40H, -CHR2RCHR2R-), 2.32-2.08(br, 18H, -
COCHR3 R), 1.39-1.30(s, 72H, -OC(CHR3R)R3R).  
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ESI-MS: calculated mass: 2281.15, found [M+Na]+: 2305.14. 
48T
 
Figure 4. 1HNMR characterization of di-carboxylbenzyl-di-pentaethylenetetraamine 
click trehalose macromonomers (h). 
Then the di-carboxylbenzyl-di-pentaethylenetetraamine click trehalose 
macromonomers (0.208 g) and Pd/C 20 20mg were added into dry CH R2RClR2 R. The 
hydrogen was kept bubbling using a balloon for 24 hrs at room temperature. Then the 
Pd/C was filtered out. The filtrate was concentrated and washed using flashing 
chromatography to remove the impurity to yield pale powder 0.15 g (% yield of 79.4%).  
1H-NMR (400 MHz, CDCl3) δ ppm: 8.02-8.00(s, 2H, triazole H, 5.38(t, 2H, -1,1’ 
trehalose H),  4.78-4.46 (m, 8H, -2,2’,3,3’,4,4’,5,5’-trehalose H), 3.42-3.24(s, 40H, -
CHR2RCHR2R-), 2.34-2.03(br, 18H, -COCHR3R), 1.38-1.32(s, 72H, -OC(CHR3R)R3R).  
ESI-MS: calculated mass: 2013.07, found [M+H]+: 2014.15.  
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Synthesis of DTPA-BA (diethylenetriaminepentaacetic acid bisanhydride) monomer 
 
 Scheme 3. Synthetic scheme of diethylenetriaminepentaacetic acid bisanhydride. 
The diethylene triamine pentaacetic acid (5.50 g) was added into dry flask. The 
pyridine and acetic anhydride were added and stirred at 65oC for 24 hrs. Then the solid 
was filtered out and washed with acetic anhydride and diethyl ether. The product was 
dried on a vacuum pump to yield white powder 4.35 g (% yield of 87.1%).  
1H-NMR (400 MHz, CDCl3) δ ppm: 3.68 (s, 8H, -NCHR2RCOOCO-), 3.28 (s, 2H,-
NCHR2RCOOH), 2.74-2.71 (t, 4H, -CHR2RN-), 2.59-2.56 (t, 4H,-NCHR2RCOOH). 
 
Figure 5. 1HNMR characterization of DTPA-BA (diethylenetriaminepentaacetic acid bis 
anhydride). 
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Polymerization, polymer deprotection, and lanthanide chelation of the polymers 
 
Scheme 4. Synthetic scheme of trehalose based lanthanide containing polymers.  
The di-pentaethylenetetraamine click trehalose macromonomers (compound i) 201.3 
mg and diethylenetriaminepentaacetic acid bisanhydride (compound k) 35.8 mg was 
dissolved in 1 ml dry DMSO respectively. Then the k solution was added dropwise into i 
solution using a syringe. The mixture was stirred for 18 hrs and put into dialysis against 
MeOH for 48hrs and dried on vacuum pump to yield pale powder TrN6DTPABocAc 
( compound l). Then TrN6DTPABocAc was added into MeOH. The pH was adjusted to 9 
using NaOMe. The solution was dialysised against MeOH for 24 hrs and concentrated. 
Then the product was added into 5 ml DCM, and 5 ml acetic acid was added dropwise for 
3 hrs. The solvent was evaporated and the product was dissolved in water for dialysis 
against ultra pure water for 48 hrs. Then the product was collected and dried to yield 
white solid. The products were characterized via NMR and SEC.  
1H-NMR (400 MHz, DMSO) δ ppm:  8.31 (s, 2H, triazole H), 4.65-4.61(dd, 2H, 1,1’-
trehalose), 4.53-4.50(s, 4H, 6,6’-trehalose),  4.15-4.0, 3.62-3.46(m, 8H, trehalose H), 
159 
 
3.39-3.31(s, 4H, triazole CONHCH R2R),  3.25-3.09 (s, 10H, DTPA-NCHR2RCOOH), 3.07-
2.65 (s, 40H, -NCHR2RCHR2RN-). 
a).  
 
b). 
 
MRwR=1.296×104 , MRnR=1.233×104 ,  Đ=1.082, nRwR= 10, nReqR=20, dn/dc=0.1350. 
Figure 6.  a). 1HNMR spectra of trehalose pentaethylene polymers with lanthanide 
chelation domain. b). The SEC analysis of the polymer.   
After deprotection, the polymers were chelated with europium, gadolinium and terbium 
ions at pH=5 to yield polymer TrN4Eu, TrN4Gd and TrN4Tb. The products were 
160 
 
dialyzed against ultra pure water for 48 hrs, and then dried on vacuum pump to yield 
white fluffy powder.  
The synthetic scheme is guided by the criteria that allow the trehalose motif, 
lanthanide chelating domain and pentaethylene amines on the same polymer chain in an 
alternating manner. The crucial part of the synthesis is the trehalose pentaethyleneamine 
macromonomer. The synthesis started from difunctionalizing the primary hydroxyl on 
trehalose molecule and protected the rest of the hydroxyls with acetyl group to yield 
hexa-O-acetyl-diazido -D-trehalose. For the pentaethyleneamine part, after protecting the 
secondary amine with Boc (tert-Butyloxycarbonyl) and deprotecting the primary amine 
on each side, one of the primary amine was further protected by the Cbz (carboxylbenzyl) 
group, while the other primary amine was functionalized with propiolic acid via DCC 
(dicyclohexylcarbodiimide )coupling to yield mono functionalized pentaethyleneamine. 
The trehalose pentaethyleneamine click macromonomer was then synthesized via copper 
(I) catalyzed alkyne azide reaction with hexa-O-acetyl-diazido -D-trehalose followed by 
the deprotection of the Cbz groups. Then the macromonomer was copolymerized with 
DTPA-BA to yield the alternating polymers. After deprotection and chelating with 
lanthanide ions, the polymers were purified via exhaustive dialysis against ultrapure 
water for 48hrs, lyophilized, and analyzed on GPC, NMR, etc. The SEC analysis showed 
that the weight averaged number of repeating units is 10, for pentaethyleneamine block, it 
is equally 20 (nReqR=20), as one macromonomer has two pentaethylene blocks. 
 
 
161 
 
Investigation on properties of polymers 
Determination of the number of water coordinate sites  
The number of water coordination sites (q) per chelate was determined by 
measuring the luminescence lifetimes of the Tb3+ labeled polymer TrN4Tb in DR2RO and 
HR2RO (Table 1) using a Cary Eclipse fluorescence spectrometer (Agilent Technologies, 
USA; formerly Varian). The data was processed with Agilent Cary WinFLR software.  
The samples were prepared at 1 mM concentration (800µL) using DR2RO and HR2RO and 
deposited into a small-volume quartz cuvette. Lifetime measurements were performed 
with the excitation wavelength of 350 nm (slit 5nm), emission wavelength of 550 nm (slit 
5 nm, a delay time of 0.1 ms, a gate time of 0.1 ms, and data were at number of cycles of 
50. All the measurements were performed in triplicate.  
Compound Solution Ave. lifetime (τ) 
TrN4Tb HR2RO 1.265 
TrN4Tb DR2RO 1.616 
Calculated No. of Coordinate Sites 1.24 
Table 1. Determination of number of water coordination sites (q) for polymer TrN4Tb 
via lifetime measurement in Uv-vis.  
The revised Horrocks equation was applied to calculate the number of water 
coordination sites (q) per chelate unit. The number of coordinate sites was found to be 
1.24, which is close to 1 for the polymers. The revised Horrocks equation is listed as 
follows: 
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    qTb = 5 �� 1τH2O − 1τD2O � –  0.06x�                                                    
x = number of N-H oscillators from amide groups coordinated to the Tb3+though the 
carbonyl.  
Inductively coupled plasma optical emission spectroscopy 
Inductively coupled plasma optical emission spectroscopy (ICP-OES) was 
performed (to determine lanthanide content of the polymers) at University of Illinois at 
Urbana-Champaign using PerkinElmer 2000DV ICP-OES system.   
Element Theroretical  Found Diff 
Eu  11.49% 7.86% -3.63% 
Gd  11.95% 8.65% -3.30% 
Tb 12.02% 8.32% -3.70% 
Table 2. ICP-OES analysis of the lanthanide content of polymers TrN4Eu, TrN4Gd and 
TrN4Tb respectively.  
Three polymers chelated with different lanthanide ions were characterized via 
inductively coupled plasma optical emission spectroscopy (ICP-OES) for the content. 
The difference between theoretical values and found values is ranged from 3.30%-3.70% 
based on mass percentile.  The value of percentile difference can attribute to the 
arrangement of the monomers in the polymer backbone as difference in ending group can 
lead to significant difference in content of chelating ions. These values provide useful 
structure information and are important for relaxivity calculation and comparisons with 
commercially available MRI contrast agent, which in this study is Magnevist.  
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Polymer siRNA binding assay 
The polyplexes were prepared by adding 33 µL of polymer solution in RNase-free 
water to 33 µL of 2 µM siRNA solution in RNase-free water at room temperature at 
various N/P ratios.  
Agarose gels [2% (w/v)] were prepared by dissolving 1 g agarose in 50 mL TAE 
buffer (40 mM Tris-acetate, 1 mM EDTA) while heating. Immediately before the gel 
solution was poured in the gel electrophoresis chamber and cooled to ambient 
temperature, 4 µL of ethidium bromide (10 mg/mL) was added. The polyplexes were 
formed by adding 10 µL of each polymer solution at various concentrations to 10 µL of 2 
µM siRNA solution in RNase-free (DEPC-treated) water. The N/P ratio indicates the 
polymer/nucleic acid ratio for polyplex formulation (the number of secondary amines on 
polymer backbones to the number of phosphate groups on the nucleic acid backbones to 
form the polyplex solutions) as previously described. The polyplexes were incubated at 
room temperature for 30 min. 2 µL of Blue Juice™ loading buffer (Invitrogen) was 
added to each polyplex solution shortly before loading onto the gel. Electrophoresis was 
performed at 65 V for 45 min. The complexation of siRNA by the polymer was indicated 
by the lack of gel migration (or shift) of the siRNA-containing bands.  
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Figure 7.  Gel electrophoresis analysis of TrN4Ln(Ln=Eu, Gd, Tb). The binding 
efficiency, which is reflected by the binding ratio, can be determined by the absence of 
siRNA band towards the positive electrode. The formulation ratios were varied from 0-80, 
which indicates the siRNA only.  
After the purification and final deprotection of the polymers, TrN4Eu, TrN4Gd 
and TrN4Tb were examined on the gel electrophoresis to estimate the capability of the 
polymers to bind to siRNA. It was noticed that compared with trehalose polymers 
without chelating units, the binding between the polymers and siRNA is much stronger 
than the binding affinities between trehalose lanthanide containing polycations. The 
diminishment of the binding affinity can attribute to the negative properties of carboxylic 
groups on DTPA domain.  All three polymers TrN4Eu, TrN4Gd and TrN4Tb can fully 
retard the siRNA migration at around N/P=20.  Therefore, we chose N/P=40 to form 
polyplexes for the rest of the experiments.  
Relaxivity of Gd chelated polymers  
The effect on TR1R relaxation times of water in the presence of TrN4Gd polymers 
(chelated with Gd3+ ) and their polyplexes was studied with a Bruker Minispec (20 mq, 
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0.47 T and 60 mq, 1.41 T series) using an inversion recovery pulse sequence (1800- dRtR- 
900- acquire). Solutions of TrN4Gd polymers (5 different concentrations from 2.5 mg/ml 
to 0.5 mg/ml) and Magnevist® (a clinical contrast reagent) were prepared in ultrapure 
water (based on repeat unit molecular weight and on a per ‘Gd3+’ basis analyzed on ICP-
OES). All the measurements were performed in triplicate, and error bars represent the 
standard deviation of the three measurements.  
 
Figure 8. Relaxivity measurement of TrN4Gd according to water relaxation rate 
constants at 0.47 and 1.4 Tesla at 37 °C.  Five polymer concentrations ranged from 2.5 
mg/ml to 0.05 mg/ were used for the calculation. Each test was examined in triplicate.  
 The relaxivity has been adjusted according to Gd content percentile observed in 
ICP-OES.  The r1 at both 0.47T and 1.4T is between 10.7-10.9 mMGd-1s-1, and the r2 is 
between 12.3-12.9 mMGd-1s-1. Compared with commercially available MRI contrast 
agent Magnevist, the polymer TrN4Gd achieved more than two times of relaxivity.  
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Dynamic light scattering study 
Hydrodynamic diameters of the polymer-siRNA polyplex formulations were 
determined by dynamic light scattering (DLS) using a ZetaSizer (Nano ZS) instrument 
from Malvern, Inc. (Worcestershire, United Kingdom) equipped with a 633-nm laser. For 
each size measurement, polyplexes were formulated by addition of 33 µL of polymer 
solution in RNase-free water to 33 µL of 2 µM siRNA solution in RNase-free water at 
room temperature forming complexes at various N/P ratios. The formation of polyplexes 
was monitored by performing DLS measurements 60 min after solution mixing. Each 
polyplex solution was then diluted to a final volume of 750 µL with RNase-free water for 
zeta potential measurements of each sample in triplicate. 
A)                                                                                B) 
 
Figure 9. A). Dynamic light scattering study of polyplexes formed by lanthanide 
containing polymers with siRNA at N/P=40.  The sizes of the polyplexes were shown as 
the bars, and the zeta potentials were expressed as star shaped dots connected with a red 
line. N4Gd and N4Tb were two polymers with mass averaged repeating unit of 25. All 
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the experiments were performed in water solution in triplicate. B). Structures of N4Gd 
and N4Tb. 
In order to compare the polymers containing trehalose domains, two polymers 
without trehalose units was applied as reference: N4Gd and N4Tb. Since one repeating 
unit of trehalose containing polymer has two pentaethyleneamine domains, therefore the 
numbers of amine blocks of N4Gd and N4Tb are comparable with TrN4Eu, TrN4Gd and 
TrN4Tb. In the dynamic light scattering study, we can see that the trehalose containing 
lanthanide polymers TrN4Eu, TrN4Gd, TrN4Tb can form much smaller polyplexes than 
those formed with N4Gd and N4Tb.  In contrast, the zeta potentials of polyplexes formed 
with TrN4Eu, TrN4Gd and TrN4Tb are with higher zeta potential compared with those 
formed with N4Gd and N4Tb respectively, which is a favorable optimization for siRNA 
delivery. 
Stability of polyplexes upon addition of heparin 
 a)                                                                    b) 
                
    1             2            3           4           5 
Figure 10. Stability of polyplexes upon addition of heparin.  a) Gel electrophoresis of 
polyplexes formed by TrN4Tb and siRNA at N/P=40 in addition of different heparin 
concentrations.  1. siRNA only 2.TrN4Tb+siRNA 3. TrN4Tb+siRNA+0.5 mg/ml heparin 
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4.TrN4Tb+siRNA+1 mg/ml heparin 5. TrN4Tb+siRNA+2 mg/ml heparin. b) DLS study 
of size distribution of polyplexes upon addition of heparin in different concentrations.   
The polyplexes were all prepared at N/P=40 followed by 30 min incubation, then 
concentrated heparin was added to yield different final concentration of heparin. The 
addition of heparin at different concentrations has been monitored via both gel 
electrophoresis and DLS. In the gel electrophoresis, we can observe that the polyplexes 
dissociate upon addition of heparin at a concentration of as low as 0.5 mg/ml. The 
dissociation at different concentrations was also monitored by DLS shown as in Figure 
10B.  In the figure, we can see that at the concentration of 0.5 mg/ml heparin, the 
polyplexes started to swell, then when the concentration increased to 1 mg/ml, the 
polyplexes collapsed and the size dropped significantly.  Therefore, we chose 1 mg/ml 
heparin as the standard concentration for the following experiment to induce the 
dissociation of polyplexes.  
FRET(Fluorescence resonance energy transfer) of polymer/siRNA complexation 
Synergy™ H1 monochromator-based multi-mode microplate reader was applied 
in this study.  96 well plate (GENios Pro) was used for the measurement. The samples are 
prepared by adding 40 µl lanthanide chelated polymer solution into 40 µl 2 µM 
fluorescence labeled siRNA and incubated for 60 min. The addition of heparin (to yield 1 
mg/ml final concentration) 20 µl was performed after the polyplexes formation and 
incubated for 15 min. The same amount of RNase free water 20 µl was added to other 
polyplexes in order to achieve same concentration of polyplexes.  For the FRET pair of 
TrN4Eu/Cy5-siRNA, the sample was excited at 365 nm. For FRET pair TrN4Tb/TMR-
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siRNA, the sample was excited at 345 nm. All spectrums were collected from 400 nm to 
700 nm. The delay time is varied in order to monitor the dynamic of FRET.  
 
Figure 11. Illustration of monitoring polyplex formation via FRET.  
FRET, a mechanism illustrating the energy transfer between two chromophores, 
has been successfully applied to aid the biomedical research. The donor chromophores, 
which in this study are europium and terbium ions, will transfer energy to adjacent 
acceptor chromophores via nonradiative interaction. The acceptors in this study are Cy5 
and TMR that  are labeled at the end of the siRNA chain. As shown in the illustration 
shown in Figure 11, before the polyplex formation, the donor and acceptor are far away, 
therefore, there is no increase in acceptor emission. Once the polyplexes formed, the 
donor and acceptor are close enough for the energy transfer through dipole-dipole 
interaction; therefore, we will observe the diminishment of excitation of donor 
accordingly.  
   a).                                                                    b). 
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c).                                                                    d).                                    
                         
Figure 12. FRET study on the TrN4Eu/Cy5-siRNA and TrN4Tb/TMR-siRNA 
complexation and heparin mediated dissociation. a). Emission spectrum of TrN4Eu/Cy5-
siRNA excited at 365 nm (TrN4Eu only: blue; Cy5-siRNA: red; TrN4Eu/Cy5-siRNA 
polyplexes: purple dash). b). Emission spectrum of TrN4Tb/TMR-siRNA at N/P=20 and 
40 excited at 345 nm collected at delay time of 40µsec (TrN4Tb only: blue; TMR-siRNA: 
red dash; TrN4Tb/TMR-siRNA N/P=20: green dash; TrN4Tb/TMR-siRNA N/P=40: 
purple dash). c). Emission spectrum of TrN4Tb/TMR-siRNA at N/P=20 and 40 collected 
at delay time of 20 µsec (TrN4Tb only: blue; TMR-siRNA: red dash; TrN4Tb/TMR-
siRNA N/P=20: green dash; TrN4Tb/TMR-siRNA N/P=40: purple star dash). d). 
Emission spectrum of TrN4Tb/TMR-siRNA excited at 345 nm and collected at different 
delay time. 
The polyplexes complexation and dissociation were monitored via collecting the 
emission spectrum of solution formed in different conditions. Heparin, as mentioned in 
the study of stability of polyplexes, was used to induce the dissociation of polyplexes to 
illustrate the correlation of dissociation and restoration of emission from absence of 
FRET. The concentration used in the study is 1 mg/ml. In Figure 12. a) , we observe that 
after the TrN4Eu complexed with Cy5 labeled siRNA, the emission of Eu at 615 nm 
diminished dramatically due to FRET, then upon the addition of heparin, the emission of 
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Eu at peak of 615 nm was restored as indicated in the green dash line. In Figure 12 b), we 
formed the polyplexes in two different N/P ratios This time, the TMR-siRNA can also be 
excited and has an emission peak at 595 nm. The peak at 495 and 550 nm can attribute to 
the emission after exciting TrN4Tb at the N/P=20 as indicated in the green dash line, we 
can observe the peak at 495 and 550 nm decreased accordingly due to FRET, the peak at 
595 nm also decreased, which could largely attribute to steric hindrance and bleach effect 
caused by complexation with polymer. In contrast, when the N/P ratio increased to 40, 
the emission at 495 and 550 nm is found restored, while the emission at 595 increased 
dramatically. We think at higher N/P ratio, the polyplexes composition may become more 
compact and have more free polymer chains in the solution, therefore the FRET is more 
prominent at emission peak of TMR-siRNA 595 nm than that of the lower N/P ratio. But 
the emission at 495 and 550 nm is restored, because of the more free polymer chains in 
the solution. We then tried to collect the data at a shorter delay time of 20 µsec (Figure 12 
c)), and we saw that the peak at 595 nm for TMR-siRNA was higher than the polyplexes 
formed at N/P40. The phenomenon was just opposite from the experiment performed at a 
delay time of 40 µsec. In order to understand the correlation of delay time and FRET, we 
chose three different delay times 20 µsec, 40 µsec and 50 µsec.  As indicated in Figure 12 
d), FRET is more prominent at the earlier delay time, as we can observe the dramatic 
decrease in peak 550 nm and increase in peak 595 nm. The FRET effect was decreased 
dramatically as the delay time increased. Therefore, the choice of delay time is crucial for 
observation, because of the decay of the intensity as the collecting time point increased.   
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Cellular uptake of polyplexes and target gene knockdown in brain cancer cells 
Cellular uptake for polyplexes via flowcytometry 
Flow cytometry was performed to examine the cellular uptake of Cy5-labeled 
siRNA with various formulations at 3 h post-transfection. In general, U-87_luc2 
glioblastoma cells were seeded at 300,000/well in 6-well plates 24 h prior to transfection. 
To transfect, 33 µL of each polymer solution was added to 33 µL of 2 µM Cy5-labeled 
siRNA solution. After a 30 min incubation at room temperature (to form the polyplexes), 
each polyplex solution was pipetted into 1584 µL of pre-warmed Opti-MEM to yield the 
final transfection solution. Each well was treated with 500 µL of the obtained transfection 
solution. After 3 h, the media was removed and cells were washed with 500 µL/well 
CellScrub™ Buffer for 15 min at room temperature. The CellScrub™ Buffer was then 
aspirated, and cells were exposed to trypsin (0.05% (w/v), 500 µL/well) for 3 min to 
provide detachment from the plate, then complete DMEM (500 µL/well) was applied to 
inhibit trypsin. The cell suspension was collected and centrifuged at 1000 rpm for 10 min 
at 4oC. The supernatant was removed and cells were twice washed with 0.5 mL PBS and 
centrifuged to remove the extracellular polyplexes. Finally, 1 mL PBS was added and the 
suspensions were kept on ice prior to flow cytometry analysis. Propidium iodide (2.5 µL) 
was added prior to the analysis. The flowcytometer (FACSCalibur and FACSVerse, 
Becton Dickenson, San Jose, CA) equipped with a helium-neon laser to excite Cy5 at 633 
nm was used to count twenty thousand events for each sample. The threshold 
fluorescence level was defined by manually adjusting the positive region such that <1% 
of negative control cells were positive for fluorescence.  Each treatment was performed in 
triplicate.  
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Luciferase assay for siRNA mediated gene knockdown 
Luciferase-expressing glioblastoma cells (U-87_luc2) were seeded at 50,000 
cells/well in 24-well plates 24 h prior to transfection. In general, anti-luciferase (Luc2) 
siRNA, control (siCon) siRNA, and polymer stock solutions were diluted with RNase-
free water, and the polyplexes were formed by the addition of 33 µL of polymer solution 
to 33 µL of siRNA solution, followed by incubation for 30 min at room temperature. The 
resulting polyplex solutions were then added to pre-warmed Opti-MEM or DMEM to 
yield transfection solutions. Cells were washed with PBS before the addition of 200 µL 
of the transfection solution. The formation of siRNA-containing lipoplexes using 
Lipofectamine™ 2000 were performed according to the manufacturer’s protocol.  
Polyplexes with the carbohydrate polymers were formulated at various N/P ratios as we 
previously described.42,43 The cells were incubated with polyplex/lipoplex solutions for 4 
h before complete DMEM was added.  Forty eight hours later, the cells were washed with 
500 µL PBS and treated with 1x cell lysis buffer (Promega, Madison, WI) for 15 min at 
room temperature.  Aliquots (5 µL) of cell lysate were examined on 96-well plates with a 
luminometer (GENios Pro, TECAN US, Research Triangle Park, NC) for luciferase 
activity over 10 s. For each well, 100 µL of luciferase assay substrate (Promega, Madison, 
WI) was added. The average of duplicate measurements on each individual replicate was 
utilized for calculation. The amount of protein (mg) in cell lysates was calculated using a 
standard curve generated with bovine serum albumin by following the protocol included 
in Bio-Rad DC protein assay kit. The relative light unit (RLU)/mg protein was then 
calculated and averaged across replicate wells. The protein and luciferase levels of non-
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transfected cells were used for normalizing the data and calculating the extent of gene 
knockdown. Each treatment was tested in triplicate in 24-well plates. 
A). 
  
B).  
 
Figure 13. Cellular uptake and target gene knockdown studies of polyplexes formed 
from lanthanide polymers with siRNA. a). Flowcytometry study of polyplexes uptake 4 
hrs after transfection using Cy5 labeled siRNA. b). Luciferase gene knockdown 
experiments to estimate the delivery efficiency of lanthanide containing polymers on 
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anti-luciferase siRNA into luciferase expressing U87 cells.  The N/P ratio in both of the 
studies is chose to be 40 for all the polyplexes and lipofectamine was applied as positive 
control.N4Gd and N4Tb was used in the study for comparison. All the tests are in 
triplicate. 
  In order to estimate the efficiency of the polymers on siRNA delivery, 
flowcytometry and luciferase assay were conducted to monitor the cellular uptake and 
target gene knockdown in U87 glioblastoma cells. In Figure 13(a), the percentage of Cy5 
positive cells were measured to show that trehalose containing lanthanide polycations can 
successfully deliver Cy5-siRNA into glioblastoma cells and achieved higher cellular 
uptake than those facilitated by N4Gd and N4Tb. In Figure 13(b), the luciferase gene 
knockdown experiments have shown that TrN4Eu, TrN4Gd and TrN4Tb all achieved 
moderate target gene knockdown in glioblastoma cells. The % extent of gene knockdown 
achieved by TrN4Eu, TrN4Gd and TrN4Tb are 31%, 40% and 37% respectively. On the 
other hand, the polyplexes formed with N4Gd and N4Tb didn’t show significant gene 
knockdown. Therefore, the trehalose domains in the polymers play an important role in 
improvement of polymer performance. A similar phenomenon was observed in the study 
of structure and property relationships in carbohydrate containing polymers for siRNA 
delivery in systematic study in Chapter 2. The insertion of trehalose polymers can 
contribute to the biodegradability of the polymers in order to release the siRNA into 
cytoplasm. The detailed mechanism needs to be investigated in future studies. 
 Cytotoxicity study via MTT assay 
MTT reagent (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) 
was used to estimate the cytotoxicity of the formulations.   Typically, U-87_luc2 
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glioblastoma cells were seeded at 50,000 cells/well in 24-well plates 24 h prior to 
transfection. The polyplexes were formed following the procedure described above. 200 
µL of transfection media was added to each well; 4 h later, complete DMEM was added 
at 1 mL/well. Then, 24 h later, the media was aspirated and the cells were washed with 
PBS (500 µL/well). 1 mL of serum-containing DMEM with 0.5 mg/mL of MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5 Diphenyltetrazolium Bromide) was added to each well and 
cells were incubated for 1 h. The media was then replaced with 600 µL of DMSO for 15 
min at room temperature. A 200 µL aliquot of the media was transferred to a well of a 
96-well plate for analysis by colorimeter with wavelength at 570 nm. Samples of non-
transfected cells were used for normalization.  
 
Figure 14. Cytotoxicity examined via MTT assay at 24 hrs incubation after transfection. 
All the polyplexes were formed at N/P=40. The transfection concentration of siRNA is 
100 nM. All the tests are in triplicate. 
Throughout all the tests, no cytotoxicity in U87 cells at N/P ratio of 40 was found. 
From the preliminary in vitro biosafety study of the polymer/siRNA complexes,  the 
polymers are shown to be promising for future investigation to understand polyplexes 
dynamics.   
177 
 
Conclusion 
In order to improve the performance of lanthanide containing cationic polymers 
for nucleic acid delivery, we have successfully synthesized a series of polymers with 
trehalose domain alternately distributed in the polymers with pentaethyleneamine and 
lanthanide chelating domains. The structure and molecular weight profiles have been 
verified via NMR and SEC respectively. Various properties of the polymers were 
examined upon the complexation with siRNA, including binding efficiency, dynamic 
light scattering studies, stability upon addition of heparin and FRET studies based on two 
pairs: TrN4Eu/Cy5-siRNA and TrN4Tb/TMR-siRNA. The relaxivity of the polymers 
TrN4Gd was examined and shown to be much larger than commercially available reagent 
Magnevist in two different magnetic fields. The number of water coordinate sites based 
polymer TrN4Tb were also examined via measuring the luminescence lifetime in H R2RO 
and DR2RO.  The calculated number of water coordinate sites is 1.24, which is 
approximately 1 water coordinate site for each chelate. The FRET was monitored via 
using two different pairs TrN4Eu/Cy5-siRNA and TrN4Tb/TMR-siRNA. By adding the 
heparin into the polyplexes, we have observed the diminishment of FRET caused by 
dissociation of the polyplexes. The FRET has been demonstrated to be a strong time 
dependent event as we changed the delay times for spectra collection. The FRET 
decreased significantly while the delay time increased from 20 µsec to 50 µsec. The 
flowcytometry and luciferase gene knockdown experiments were conducted on luciferase 
expression cell line U87. The result showed that by incorporating the trehalose domains 
into the polymers, the performance on siRNA delivery is improved, which indicates the 
role of trehalose in improving the performance of the polymers. All the tests show no 
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cytotoxicity found. The polymer structure is also a good model to demonstrate the 
significant impact of carbohydrate on polymer performance for biomedical applications.  
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Chapter 5. Conclusions 
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siRNA has driven dramatic attention in search of alternative medicine in addition 
to conventional therapeutics. The major challenge is that siRNA has poor 
pharmacokinetic profile and can cause various side effects such as immunogenicity. 
Therefore, designing proper materials to facilitate the delivery and transport the siRNA to 
the RNAi machinery is the key requirement to achieve effective therapeutic outcomes.  
In this research, we are driven by the ideal to obtain biocompatible and 
biodegradable materials that can encapsulate the siRNA into nanoparticles with proper 
surface parameters, to facilitate the cellular uptake and release them in the cytoplasm 
where the siRNA machinery locates.  To examine the roles of carbohydrate in the 
polymer structures, we have synthesized and evaluated different structuralized 
carbohydrate containing polymers, including step growth polymers and RAFT diblock 
copolymers. In addition, alternating polymers containing lanthanide chelates are also 
synthesized and examined in order to obtain potential biocompatible theranostic agents.  
In the structure-property relationship study for the step growth carbohydrate 
oligoamines polymers, we were surprised to discover that despite the high potency of T4 
and Glycofect for pDNA delivery, both of these polymers were completely ineffective at 
forming polyplexes with and delivering siRNA in vitro. The dependence of potency on 
polymer type and length was more dramatic for siRNA delivery. Also, a dramatic 
dependence on molecular weight was observed with the trehalose and cyclodextrin 
polymers. Both the low molecular weight versions of these systems [Tr4(23) and 
CD4(10)] revealed no activity for siRNA delivery.  However, as the degree of 
polymerization was further increased, the cyclodextrin polymers CD(26) and CD(39) 
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were very active for siRNA delivery, more so than the Tr4 polymer series. The two 
highest molecular weight analogs of the CD4 series were less effective for delivery.  
Upon the comparison, these data reveal two very important trends: i) length of the 
polymer has an effect on gene expression and gene knockdown and ii) the carbohydrate 
type/size plays a clear role in siRNA binding, compaction, and delivery. Cyclodextrin 
clearly promotes higher binding affinity, likely due to H-bonding via the hydroxyl groups 
and the polymerized nucleotides. In addition, cyclodextrin likely plays a role in 
promoting endosomal release of siRNA (as Tr4 analogs had lower affinity) possibly due 
to the known affinity of the hydrophobic cyclodextrin cup to extracting cholesterol out of 
the membrane, which could promote leaky endosomes.  This was also clearly noticed 
when free polymer was added, which also clearly plays a role in promoting endosomal 
release of polyplexes carrying siRNA. While, the efficacy of step growth polymers was 
significantly reduced in serum, possibly due to the affinity of the carbohydrate to binding 
serum proteins, which likely coat the polyplexes.  All the observations with these 
polymers illustrate that, knowledge based upon pDNA delivery cannot necessarily predict 
the performance of polymers for siRNA delivery. These findings also highlight the 
potential of utilizing the Tr4 and CD4 series of polymers as therapeutic pDNA and 
siRNA delivery agents and demonstrate the subtle effects of carbohydrate choice on the 
activity of pDNA and siRNA delivery.  
Apart from the step growth polymers, we have obtained series of carbohydrate 
containing diblock copolymers via RAFT polymerization. The carbohydrate containing 
blocks were synthesized by polymerizing either glucose containing monomers or 
trehalose containing monomers. From the study on polyglucose polymers, we have found 
185 
 
that the effectiveness of siRNA mediated knockdown is dependent on the length of the 
length of the amine containing block. The proper chain length of primary amine block on 
polymers chains plays an important role to reach effective target gene knockdown. On the 
other hand, polytrehalose polymers have shown significant gene knockdown with all 
three different primary amines blocks. It was demonstrated that polytrehalose similarly to 
trehalose itself lowers the energy of phase transition (liquid to solid, and solid to liquid) 
of an aqueous solution and this property allowed us to lyophilize siRNA polyplexes 
without loss of biological function. Polytrehalose was shown to promote polyplex 
internalization by U-87 glioblastoma cells. The cellular uptake had zero order kinetics in 
both tested cell culture media and is directly proportional to the concentration of 
polytrehalose containing polyplexes in the media. Based on the results of the uptake 
experiments we speculate that a carbohydrate-binding receptor may be responsible for the 
high efficiency of uptake. The successful use of polytrehalose in polymers for siRNA 
delivery was demonstrated in luciferase expressing U-87 glioblastoma cells. This activity 
was preserved following the lyophilization of polyplexes, potentially enabling the storage 
of the therapeutic siRNA formulations as dry powders and simplifying transportation.   
In order to improve the performance of lanthanide containing cationic polymers 
for nucleic acid delivery, we have successfully synthesized a series of polymers with 
trehalose domain alternately distributed in the polymers with pentaethyleneamine and 
lanthanide chelating domains. Various properties of the polymers were examined upon 
the complexation with siRNA, including binding efficiency, dynamic light scattering 
studies, stability upon addition of heparin and FRET studies based on two pairs: 
TrN4Eu/Cy5-siRNA and TrN4Tb/TMR-siRNA. The relaxivity of the polymers TrN4Gd 
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was examined and shown to be much larger than commercially available reagent 
Magnevist in two different magnetic fields. The number of water coordinate sites based 
polymer TrN4Tb were also examined via measuring the luminescence lifetime in H R2RO 
and DR2RO.  The calculated number of water coordinate sites is 1.24, which is 
approximately 1 water coordinate site for each chelate. The FRET was monitored via 
using two different pairs TrN4Eu/Cy5-siRNA and TrN4Tb/TMR-siRNA. By adding the 
heparin into the polyplexes, we have observed the diminishment of FRET caused by 
dissociation of the polyplexes. The results showed that by incorporating the trehalose 
domains into the polymers, the performance on siRNA delivery is improved, which 
indicates the role of trehalose to improve the performance of the polymers. All the tests 
show no cytotoxicity found. The polymer structure is also a good model to prove the 
significant impact of carbohydrate on polymer performance for biomedical applications.  
Above all the findings in the research, we have revealed the importance of 
incorporating carbohydrate units in the polymers to improve the performance of the 
polyplexes on siRNA delivery. The trehalose as a disaccharide has shown dramatic 
impact on siRNA delivery in both step growth polymers and diblock copolymers as 
coating block. The polytrehalose coating has been examined to be an effective technique 
to preserve the formulation during freeze drying cycle, and can be a potential coating 
block for other pharmaceutical approach for drug delivery and other biomedical 
applications.    
In summary, the carbohydrate family plays an important role in search of 
biocompatible materials for siRNA delivery. The trehalose has been demonstrated to be 
effective component for developing coating materials for anti-aggregation, protection 
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from fierce environmental changes and essential to achieve quantitative siRNA delivery. 
The results from preliminary study in vitro tests suggest it is promising to further 
investigate on these carbohydrate based biomaterials.    
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